



# TO OUR STOCKHOLDERS

We started the 2023 year with a cyber-attack in January that shut down the operations at two of our facilities for several weeks, then rallied throughout the year to deliver our highest annual revenue and operating profit in fifteen years. From my perspective this performance is a testament to our dedicated employees, suppliers and customers who persevered through a difficult situation. We continue to provide our unique expertise and manufacturing capability to best service the increasing needs of our customers while supplying our unique products which provide the highest performance, safety, and reliability for critical applications. We provide our customers with localized support facilitating strong, lasting relationships, while leveraging our collective resources and capabilities to expedite global growth opportunities and diversifying our end markets.

Our performance for 2023 showcased these key capabilities. Our consolidated sales increased 20% to \$158.6 million with solid growth of 8% in commercial and 49% in government/defense sales resulting in a 64/36 split between these market sectors, respectively. We continued our aggressive pursuit of exciting new revenue opportunities, through market and sales-reach expansion, new product development and customer partnerships, and continued progress on our transformational new projects. Increasing gross margin was a key objective heading into 2023 and we reported a positive trend throughout 2023, despite allocating a great deal of our valuable resources to the recovery from the cyber-attack during much of the first half of the year. We improved gross margin by 240 basis points to 24.7% due primarily to better alignment of the timing of price realization with the impact of cost inflation on raw materials and key components. We extended the time horizon of our sales & operations planning process with both customers and suppliers while upgrading our internal resources responsible for the process to reduce the negative impact of production line start-ups, shutdowns and changeovers due to irregular component availability and lead time extensions. We launched concerted efforts to level-load production resulting in improved labor utilization efficiency and higher cost absorption, and improved our process for launching new products to reduce the cost and time of transitioning to high-volume manufacturing. The net result of our sales growth combined with the leverage provided by improved gross margin and controlled spending was operating profit of \$9.5 million, our highest level since 2008.

# **Battery & Energy Products (B&EP)**

B&EP sales increased 8% to \$130.0 million in 2023, reflecting solid growth of 8% in both commercial and government/defense sales. Commercial sales, which comprise 78% of 2023 segment sales, were propelled by the highest annual level of medical sales in our history as strong demand continued from our global medical device OEM customers as well as for our X-5 medical cart battery system. Government/Defense sales comprised 22% of total segment sales with growth resulting from higher domestic demand for our military core products. During 2023, we continued to advance several of our multi-year development new products, most notably our thin cell batteries in the rapidly growing medical wearables and product tracking markets, our 3-volt product line serving the IOT market, our Thionyl Chloride product line targeting industrial monitoring and telemetry applications, and our SEASAFE subsurface batteries for offshore projects, as well as our conformal wearable battery used to power advanced dismounted soldier equipment.

## **Communications Systems**

Communications Systems sales increased 142% to \$28.7 million in 2023, reflecting the fulfillment of long-lead time orders of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. During 2023, we remained embedded with our OEM and channel partners making progress on our advanced amplification and power products to support air, ground and sea communications primarily military in nature, as well as shipping our first substantial order of EL8000 server cases to several customers which provides the opportunity to diversify sales into commercial markets, thereby adding further scale to the segment.

# Going Forward

I firmly believe this is a very opportune time for the company, having spent over 30 years of my career in the battery business with Ultralife in design, development, testing, operations and sales functions. We have a strong base business with an exciting pipeline of new and diverse products in just the beginning of commercialization.

Sales funnel and commercial opportunity pipeline growth remain a top priority to keep our strong organic growth trajectory going while realizing the opportunities provided by our transformational new products. Through continued strong focus on lean and material deflation initiatives, we are targeting gross margin improvements for both of our businesses, which will further improve cash generation and allow us to continue to pay down our acquisition debt.

As a result, with a very strong finish to 2023, a backlog representing 65% of our 2023 sales and durable demand across our end markets, a positive trend of gross margin improvements, solid progress with our transformational new products, strengthened customer relationships and ongoing collaboration with partners on advanced cell prototypes, we are well positioned to deliver sustainable high-quality, profitable growth and shareholder value going forward.

In closing, I would like to thank our dedicated employees for their 2023 accomplishments and commitment toward executing our growth plans; our partners and customers for their continued collaboration with us; and our shareholders for their continued support in a very challenging environment.

Mike Manna,

1 Bell

**President and Chief Executive Officer** 

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

| (Mark 0  | One)  |                                |               |  |  |  |  |
|--|---|--------------------------------|---------------|--|--|--|--|
| $\boxtimes$  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |                                |               |  |  |  |  |
|  | 1934  |                                |               |  |  |  |  |
|  | For the   | fiscal year ended              | December      | 31, 2023   |  |  |  |
|  |   | OR                             |               |  |  |  |  |
|  | TRANSITION REPORT PURSUAN   | OF THE SECURITIES EXCHANGE ACT |               |  |  |  |  |
|  | OF 1934   |                                | ( )           |  |  |  |  |
|  |   | n period from                  | t             | 0  |  |  |  |
|  | Со  | mmission file nu               | mber: 0-208   | 352  |  |  |  |
|  | ULTRA   | ALIFE CO                       | RPOR          | ATION  |  |  |  |
| (Exact name of registrant as specified in its charter)   |   |                                |               |  |  |  |  |
|  | Dolowano  |                                |               | 16-1387013   |  |  |  |
| (Sta   | <b>Delaware</b> (State or other jurisdiction of incorporation of organization)  |                                |               | R.S. Employer Identification No.)  |  |  |  |
| 2  | 000 Tashualagu Dauluway Nawault N   | ov. Voul. 14512                |               | (215) 222 7100   |  |  |  |
| 2000 Technology Parkway Newark, New York 14513 (Address of principal executive offices) (Zip Code) |   |                                | (Registran    | (315) 332-7100<br>s's telephone number, including area code:)  |  |  |  |
|  | Securities reg  | istered pursuant to            | Section 12    | (b) of the Act   |  |  |  |
|  | _   | istored pursuant to            | o Section 12  | (b) of the rec.  |  |  |  |
| Comm   | on Stock, \$0.10 par value per<br>share   | ULBI                           |               | NASDAQ   |  |  |  |
|  | (Title of each class)   | (Trading Symb                  | ool)          | (Name of each exchange on which registered)  |  |  |  |
|  | Securities registe  | ered pursuant to S             | ection 12(g)  | of the Act: None   |  |  |  |
| Indicate Yes □   | -   | is a well-known so             | easoned issu  | er, as defined in Rule 405 of the Securities Act.  |  |  |  |
| Indicate Yes □   |   | required to file rep           | oorts pursuar | nt to Section 13 or Section 15(d) of the Act.  |  |  |  |
| Securiti   |   | eceding 12 month               | s (or for suc | hired to be filed by Section 13 or 15(d) of the a shorter period that the registrant was required the past 90 days. Yes $\boxtimes$ No $\square$ |  |  |  |
|  |   |                                |               | lly every Interactive Data file required to be c) during the preceding 12 months (or for such  |  |  |  |

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

shorter period that the registrant was required to submit such files). Yes  $\boxtimes$  No  $\square$ 

| Large accelerated filer □  | Accelerated filer □  |
|--|--|
| Non-accelerated filer <b>⊠</b>                                   | Smaller reporting company  |
|  | Emerging growth company $\square$  |
|  | e registrant has elected not to use the extended transition period<br>standards provided pursuant to Section 13(a) of the Exchange                       |
| •  | port on and attestation to its management's assessment of the under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. ed or issued its audit report. □ |
|  | ct, indicate by check mark whether the financial statements of n error to previously issued financial statements. Yes $\square$ No $\boxtimes$           |
| •  | are restatements that required a recovery analysis of incentive-<br>outive officers during the relevant recovery period pursuant to                      |
| Indicate by check mark whether the registrant is a shell con No⊠ | npany (as defined in Rule 12b-2 of the Exchange Act). Yes□   |

On June 30, 2023, the aggregate market value of the common stock held by non-affiliates as defined in Rule 405 under the Securities Act of 1933) of the registrant was approximately \$46,718,255 (in whole dollars) based upon the closing price for such common stock as reported on the NASDAQ Global Market on June 30, 2023.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of March 18, 2024, the registrant had 16,446,832 shares of common stock outstanding.

#### DOCUMENTS INCORPORATED BY REFERENCE

Certain portions of the registrant's definitive proxy statement relating to the Annual Meeting of Stockholders are specifically incorporated by reference in Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K, except for the equity plan information required by Item 12 as set forth herein.

# TABLE OF CONTENTS

|          | ITEM  | PAGE   |
|----------|---|--------|
| PART I   | 1 Business  | 1      |
|          | 1A Risk Factors   | 14     |
|          | 1B Unresolved Staff Comments  | 25     |
|          | 1C Cybersecurity  | 25     |
|          | 2 Properties  | 25     |
|          | 3 Legal Proceedings   | 26     |
|          | 4 Mine Safety Disclosures   | 26     |
| PART II  | 5 Market for Registrant's Common Equity, Related Stockholder<br>Matters and Issuer Purchases of Equity Securities | 27     |
|          | 6 Selected Financial Data   | 27     |
|          | 7 Management's Discussion and Analysis of Financial Condition and Results of Operations                           | 28     |
|          | 7A Quantitative and Qualitative Disclosures About Market Risk   | 40     |
|          | 8 Financial Statements and Supplementary Data   | 41     |
|          | 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                            | 65     |
|          | 9A Controls and Procedures  | 65     |
|          | 9B Other Information  | 65     |
| PART III | 10 Directors, Executive Officers and Corporate Governance   | 66     |
|          | 11 Executive Compensation   | 66     |
|          | 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                 |        |
|          | 13 Certain Relationships and Related Transactions, and Director Independent                                       | ence66 |
|          | 14 Principal Accountant Fees and Services   | 66     |
| PART IV  | 15 Exhibits, Financial Statement Schedules  | 67     |
|          | Signatures  | 70     |

#### **PART I**

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. This report contains certain forward-looking statements and information that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, changes in economic conditions including inflation and supply chain disruptions affecting our business, revenues and earnings adversely; our reliance on certain key customers; reductions or delays in U.S. and foreign military spending; our efforts to develop new products or new commercial applications for our products; potential disruptions in our supply of raw materials and components; breaches in information systems security and other disruptions in our information technology systems; our ability to recruit and retain top management and key personnel; our resources being overwhelmed by our growth; the continued impact of COVID-19 causing delays in the manufacture and delivery of our mission critical products to end customers; the unique risks associated with our China operations; fluctuations in the price of oil and the resulting impact on the demand for downhole drilling; possible future declines in demand for the products that use our batteries or communications systems; variability in our quarterly and annual results and the price of our common stock; safety risks, including the risk of fire; rising interest rates increasing the cost of our variable borrowings; purchases by our customers of product quantities not meeting the volume expectations in our supply agreements; potential costs attributable to the warranties we supply with our products and services; our inability to comply with changes to the regulations for the shipment of our products; our entrance into new end-markets which could lead to additional financial exposure; negative publicity concerning Lithium-ion batteries; our ability to utilize our net operating loss carryforwards; our exposure to foreign currency fluctuations; possible impairments of our goodwill and other intangible assets; the risk that we are unable to protect our proprietary and intellectual property; rules and procedures regarding contracting with the U.S. and foreign governments; exposure to possible violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act or other anti-corruption laws; known and unknown environmental matters; possible audits of our contracts by the U.S. and foreign governments and their respective defense agencies; our ability to comply with government regulations regarding the use of "conflict minerals"; and other risks and uncertainties, certain of which are beyond our control.

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and developments in the industries in which we operate may differ materially from those made in or suggested by the forward-looking statements contained herein. In addition, even if our results of operations, financial condition and liquidity and the development of the industries in which we operate are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements that we make herein speak only as of the date of those statements, and we undertake no obligation to update those statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data. When used in this report, the words "anticipate", "believe", "estimate", "plan", "intend", "foresee", "may", "could", "will", "likely" or "expect" or words of similar import are intended to identify some, but not all, such forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see "Risk Factors" in Item 1A and Management's Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of this Form 10-K Annual Report.

As used in this Form 10-K Annual Report, unless otherwise indicated, the terms the "Company", "we", "our" and "us" refer to Ultralife Corporation ("Ultralife") and its wholly owned subsidiaries ABLE New Energy Co., Limited and its wholly owned subsidiary ABLE New Energy Co., Ltd (collectively "ABLE"); Ultralife UK LTD and its wholly owned subsidiary Accutronics Ltd (collectively "Accutronics"); Ultralife Batteries (UK) Ltd.; Southwest Electronic Energy Corporation and its wholly owned subsidiary, CLB, Inc. (collectively "SWE"); Ultralife Excell Holding Corp. ("UEHC") and its wholly owned subsidiary Excell Battery Corporation USA (collectively "Excell Battery USA"), Ultralife Canada Holding Corp (wholly owned by UEHC, "UCHC") and its wholly owned subsidiary Excell Battery Canada ULC ("Excell Battery Canada"), and its majority-owned joint venture Ultralife Batteries India Private Limited ("Ultralife India").

Dollar amounts throughout this Form 10-K Annual Report are presented in thousands of dollars, except for per share amounts.

#### **ITEM 1. BUSINESS**

#### General

We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, expansion of our sales force to penetrate new markets and territories, as well as seeking opportunities to expand through acquisitions.

We sell our products worldwide through a variety of trade channels, including original equipment manufacturers ("OEMs"), industrial and defense supply distributors, and directly to U.S. and foreign defense departments. We enjoy strong name recognition in our markets under our Ultralife<sup>®</sup>, Ultralife HiRate<sup>®</sup>, Ultralife Thin Cell<sup>®</sup>, Ultralife Batteries Inc.<sup>®</sup>, Lithium Power<sup>®</sup>, McDowell Research<sup>®</sup>, AMTI<sup>TM</sup>, ABLE<sup>TM</sup>, ACCUTRONICS<sup>TM</sup>, ACCUPRO<sup>TM</sup>, ENTELLION<sup>TM</sup>, SWE Southwest Electronic Energy Group<sup>TM</sup>, SWE SEASAFE<sup>TM</sup>, Excell Battery Group<sup>TM</sup> and Criterion Gauge<sup>TM</sup> brands, among others. We have sales, operations and product development facilities in North America, Europe and Asia.

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. As such, we report segment performance at the gross profit level and operating expenses as Corporate charges. (See Note 9 in the notes to consolidated financial statements contained in Item 8 of this Form 10-K.)

Our website address is www.ultralifecorporation.com. We make available free of charge via a hyperlink on our website (see Investor Relations link on the website) our annual reports on Form 10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports and statements as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission ("SEC"). We will provide copies of these reports upon written request to the attention of Philip A. Fain, CFO, Treasurer and Secretary, Ultralife Corporation, 2000 Technology Parkway, Newark, New York, 14513. Our filings with the SEC are also available through the SEC website at www.sec.gov or at the SEC Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or by calling 1-800-SEC-0330.

# Battery & Energy Products

We manufacture and/or market a family of Lithium Manganese Dioxide (Li-MnO<sub>2</sub>), Lithium Manganese Dioxide Carbon Monofluoride (Li-CFx/MnO2) hybrid and Lithium Thionyl Chloride (Li-SOCl2) non-rechargeable batteries including 9-volt, Ultralife HiRate® cylindrical, Ultralife Thin Cell®, and other form factors. Applications for our 9-volt batteries include smoke alarms, wireless security systems and intensive care monitors, among many other devices. Our Ultralife HiRate® and Ultralife Thin Cell® Lithium non-rechargeable batteries are sold primarily to the military and to OEMs in industrial and medical markets for use in a variety of applications including radios, emergency radio beacons, search and rescue transponders, pipeline inspection gauges, portable medical devices, wearable medical products, Bluetooth tracking devices and other specialty applications. Military applications for our non-rechargeable Ultralife HiRate® batteries include manpack and survival radios, night vision devices, targeting devices, chemical agent monitors and thermal imaging equipment. Our Lithium Thionyl Chloride batteries, sold under our ABLE and Ultralife brands as well as a private label brand, are used in a variety of applications including utility meters, wireless security devices, electronic meters, automotive electronics and geothermal devices. We believe that the chemistry of Lithium batteries provides significant advantages over other currently available nonrechargeable battery technologies. These advantages include higher energy density, lighter weight, longer operating time, longer shelf life and a wider operating temperature range. Our non-rechargeable batteries also have relatively flat voltage profiles, which provide stable power. Conventional non-rechargeable batteries, such as alkaline batteries, have sloping voltage profiles that result in decreasing power output during discharge. While the price of our Lithium batteries is generally higher than alkaline batteries, the increased energy per unit of weight and volume of our Lithium batteries allow for longer operating times and less frequent battery replacements for our targeted applications.

We believe that our ability to design and produce lightweight, high-energy Lithium-ion and Nickel Metal Hydride (NiMH) rechargeable batteries and charging systems in a variety of custom sizes, shapes, and thicknesses offers substantial benefits to

our customers. We market Lithium-ion and Nickel Metal Hydride rechargeable batteries comprising cells manufactured by qualified cell manufacturers. Our rechargeable products can be used in a wide variety of applications including communications, medical and other portable electronic devices.

Within this segment, we also seek to fund the development of new products that we hope will advance our technologies through contracts with both government agencies and private sector third parties.

We continue to be awarded development contracts with public and private customers resulting in intellectual property that we believe will enhance our efforts to commercialize new products that we develop. Revenues in this segment that pertain to product development may vary widely each year, depending upon the quantity and size of contracts awarded.

Revenues for this segment for the year ended December 31, 2023 were \$129,953 and segment contribution (gross profit) was \$30,775.

#### Communications Systems

Under our McDowell Research and AMTI brands, we design and manufacture a line of communications systems and accessories to support military communications requirements and under our Ultralife brand we provide system integration products and services.

The military systems include RF amplifiers, power supplies, power cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems and integrated communication systems for fixed or vehicle applications such as vehicle amplifier-adaptors ("VAA") for multiple programs. These programs include Vehicle Installed Power Enhanced Rifleman Appliqué ("VIPER") systems, U.S. Army Leader Radio Program, U.S. Army's Security Force Assistance Brigades ("SFABs") and SATCOM systems. All systems are packaged to meet specific customer needs in rugged enclosures to allow for their use in extreme environments. We market these products to all branches of the U.S. military and to foreign defense organizations that we are permitted to sell our products to, as well as to U.S. and to international prime defense contractors.

Commercial products offered to date under the Ultralife brand integrate information technology equipment and power conversion capability into rugged cases, supporting use in various industries. We market these products to automotive, cellular carriers and manufacturing industries.

Revenues for this segment for the year ended December 31, 2023 were \$28,691 and segment contribution (gross profit) was \$8,425.

#### Corporate

We report revenues and cost of sales for the above operating segments. The balance of income and expense, including but not limited to research and development expenses, and selling, general and administrative expenses, are reported as Corporate operating expenses.

Corporate had no revenues for the year ended December 31, 2023 and our Corporate operating expenses for the year ended December 31, 2023 were \$29,725.

See Management's Discussion and Analysis of Financial Condition and Results of Operations and the 2023 Consolidated Financial Statements and Notes thereto contained in this Form 10-K Annual Report for additional information on the expenses referred to above. For information relating to total assets by segment, revenues for the last two years by segment, and contribution by segment for the last two years, see Note 9 in the notes to consolidated financial statements.

#### History

Ultralife was formed as a Delaware corporation in December 1990. In March 1991, we acquired certain technology and assets from Eastman Kodak Company ("Kodak") relating to its 9-volt Lithium Manganese Dioxide non-rechargeable battery. In December 1992, we completed our initial public offering and became listed on NASDAQ.

In May 2006, we acquired ABLE New Energy Co., Ltd. ("ABLE"), an established manufacturer of Lithium batteries located in Shenzhen, China, which broadened our product offering, including a wide range of Lithium Thionyl Chloride and Lithium Manganese batteries, and provided additional exposure to new consumer markets.

In July 2006, we finalized the acquisition of substantially all the assets of McDowell Research, Ltd. ("McDowell"), a manufacturer of military communications accessories. This acquisition expanded our product distribution channels into the military communications area and strengthened our presence in global defense markets. During the second half of 2007, the operations of the Waco, Texas facility of McDowell were relocated to our Newark, New York facility. In January 2012, we relocated these operations to our Virginia Beach, Virginia facility in order to gain operational efficiencies.

In March 2008, we formed a joint venture, named Ultralife Batteries India Private Limited ("India JV"), with our distributor partner in India. The India JV assembles Ultralife power solution products and manages local sales and marketing activities, serving commercial, government and defense customers throughout India. We have invested cash into the India JV, as consideration for our 51% ownership stake in the India JV.

In March 2009, we acquired the tactical communications products business of Science Applications International Corporation. The tactical communications products business designs, develops and manufactures tactical communications products including amplifiers, man-portable systems, cables, power solutions and ancillary communications equipment, which are sold by Ultralife under the brand name AMTI. The acquisition strengthened our communications systems business and provided us with direct entry into the handheld radio/amplifier market, complementing Ultralife's communications systems offerings.

In January 2016, we acquired Accutronics Limited ("Accutronics"), a U.K. corporation based in Newcastle-under-Lyme, U.K., a leading independent designer and manufacturer of smart batteries and charger systems for high-performance, feature-laden portable and handheld electronic devices. With a portfolio encompassing custom battery design, development and manufacturing for OEM's; standard smart batteries, chargers and accessories; and pre-engineered batteries and power solutions for specific applications, Accutronics primarily serves the portable medical device market throughout Europe. Medical applications include digital imaging, ventilators, anesthesia, endoscopy, patient monitoring, cardiopulmonary care, oxygen concentration and aspiration. With our acquisition of Accutronics we advanced our strategy of commercial revenue diversification, expanded our geographical penetration, and achieved revenue growth from new product development. We continue to experience sales synergies between Accutronics and our existing commercial battery business as we cross-sell our existing products and the acquired Accutronics' products to our respective customer bases.

On May 1, 2019, we acquired Southwest Electronic Energy Corporation, a Texas corporation ("SWE"), and a leading designer and manufacturer of high-performance smart battery systems and battery packs to customer specifications using Lithium cells. SWE serves a variety of industrial markets, including oil and gas, remote monitoring, process control and marine, which demand uncompromised safety, service, reliability and quality. We acquired SWE as a bolt-on acquisition which has further supported our strategy of commercial revenue diversification by providing entry to the oil and gas exploration and production, and subsea electrification markets, which were previously unserved by Ultralife. Another key benefit of our acquisition of SWE was obtaining a highly valuable technical team of battery pack and charger system engineers and technicians which has added to our new product development-based revenue growth initiatives in our commercial end-markets particularly asset tracking devices, smart metering for utilities and other industrial applications, as well as their contribution to the development of certain government and defense products.

On December 13, 2021, we acquired Excell Battery Canada Inc., a British Columbia corporation ("Excell Canada"), and 656700 B.C. Ltd., a British Columbia corporation ("656700") and its wholly owned subsidiary, Excell Battery Corporation USA, a Texas corporation ("Excell USA" and together with Excell Canada and 656700, collectively, "Excell"), which operate under the name Excell Battery Group. Based in Canada with U.S. operations, Excell Battery Group is a leading independent designer and manufacturer of high-performance smart battery systems, battery packs and monitoring systems to customer specifications. Excell serves a variety of industrial markets including downhole drilling, OEM industrial and medical devices, automated meter reading, ruggedized computers, and mining, marine and other mission critical applications which demand uncompromised safety, service, reliability and quality. Our acquisition of Excell has been an important component of our strategy to diversify commercial revenue and expand the end markets we serve. Acquiring Excell has allowed us to further scale our Battery & Energy Products business and drive the operating leverage of our

business model, expand into OEM device verticals that we do not presently serve, enhance our contributed value to both our customers and realize cost synergies. Furthermore, we utilize Excell experienced technical resources in our global new product initiatives and add a complementary line of highly engineered products, both existing and in development, that are costly for our customers to substitute with products of a competitor.

## **Products, Services and Technology**

#### Battery & Energy Products

A non-rechargeable battery is used until discharged and then replaced. The principal competing non-rechargeable battery technologies are Carbon Zinc, Alkaline and Lithium. We manufacture a range of non-rechargeable battery products based on Lithium Manganese Dioxide, Lithium Manganese Dioxide Carbon Monofluoride hybrid, and Lithium Thionyl Chloride technologies.

#### Non-Rechargeable Batteries

We believe that the chemistry of Lithium batteries provides significant advantages over currently available non-rechargeable battery technologies, which include lighter weight, longer operating time, longer shelf life, and a wider operating temperature range. Our non-rechargeable batteries also have relatively flat voltage profiles, which provide more stable power. Conventional non-rechargeable batteries, such as Alkaline batteries, have sloping voltage profiles that result in decreasing power during discharge. While the prices for our Lithium batteries are generally higher than commercially available Alkaline batteries produced by others, we believe that the increased energy per unit of weight and volume of our batteries will allow longer operating time and less frequent battery replacements for our targeted applications. As a result, we believe that our non-rechargeable batteries are priced competitively with other battery technologies on a price per unit of energy or volume basis.

Our non-rechargeable products include the following product configurations:

9-Volt Lithium Battery. Our 9-volt Lithium battery delivers a unique combination of the highest-available energy density and stable voltage, which results in a longer operating life for the battery and, accordingly, fewer battery replacements. While our 9-volt Lithium battery price is generally higher than conventional 9-volt Carbon Zinc and Alkaline batteries, we believe the enhanced operating performance and decreased costs associated with longer battery life make our 9-volt Lithium battery more cost effective than conventional batteries on a cost per unit of energy or volume basis when used in a variety of applications.

We market our 9-volt Lithium batteries to OEM, distributor and retail markets including industrial electronics, safety and security, and medical. Typical applications include smoke alarms, wireless alarm systems, bone growth stimulators, telemetry devices, blood analyzers, ambulatory infusion pumps and parking meters. A significant portion of the sales of our 9-volt Lithium battery is to major smoke alarm OEMs for use in their long-life smoke alarms. We also manufacture our 9-volt Lithium battery under private labels for a variety of companies. Additionally, we sell our 9-volt Lithium battery to the broader consumer market through national and regional retail chains and online retailers.

We believe our current 9-volt Lithium battery manufacturing capacity is adequate to meet forecasted customer demand over the next three years.

Cylindrical Batteries. Featuring high energy, wide temperature range, long shelf life and operating life, our cylindrical cells and batteries, based on Lithium Manganese Dioxide, Lithium Manganese Dioxide Carbon Monofluoride hybrid and Lithium Thionyl Chloride technologies, represent some of the most advanced Lithium power sources currently available. We market a wide range of cylindrical non-rechargeable Lithium cells and batteries in various sizes under both the Ultralife HiRate and ABLE brands. These include D, C, 5/4 C, 1/2 AA, 2/3 A, CR123A and other sizes, which are sold individually as well as packaged into multi-cell battery packs, including our leading BA-5390 military battery, an alternative to the competing Li-SO<sub>2</sub> BA-5590 battery, a widely used battery type in the U.S. armed forces for portable applications. Our BA-5390 battery provides 50% to 100% more energy (mission time) than the BA-5590, and it is used in approximately 60 military applications. With the introduction of our Lithium Carbon Monofluoride hybrid chemistry, we now offer a D-cell that has 100% more energy than the competing Li-SO<sub>2</sub> D-cell.

We market our line of Lithium cells and batteries to the OEM market for commercial, defense, medical, asset tracking and search and rescue applications, among others. Significant commercial applications include oil and gas, pipeline inspection equipment, automatic re-closers and oceanographic and subsea devices. Asset tracking applications include Radio Frequency Identification ("RFID"), cellular, and Bluetooth systems. Among the defense uses are manpack radios, night vision goggles, chemical agent monitors and thermal imaging equipment. Medical applications include Automated External Defibrillators (AEDs), infusion pumps, wearable patient monitoring and telemetry systems. Search and rescue applications

include Emergency Locator Transmitters (ELTs) for aircraft and Emergency Position Indicating Radio Beacons (EPIRBs) for ships. Oil and gas applications include battery packs for downhole and directional drilling applications such as Measurement While Drilling (MWD) and Logging While Drilling (LWD) and pipeline inspection and monitoring.

Thin Cell Batteries. We manufacture a range of thin Lithium Manganese Dioxide batteries under the Ultralife Thin Cell® brand. Thin Cell batteries are flat, lightweight batteries providing a unique combination of high energy, long shelf life, wide operating temperature range and very low profile. We are currently marketing these batteries to OEMs for applications such as displays, wearable medical devices, toll passes, theft detection systems, and RFID and Bluetooth tracking devices.

# Rechargeable Batteries

In contrast to non-rechargeable batteries, after a rechargeable battery is discharged, it can be recharged and reused many times. Generally, discharge and recharge cycles can be repeated hundreds or thousands of times in rechargeable batteries depending on the technology of the battery. The achievable number of cycles (cycle life) varies among technologies and is an important competitive factor. All rechargeable batteries experience a small, but measurable, loss in energy capacity with each cycle. The industry commonly reports cycle life in the number of cycles a battery can achieve until 80% of the battery's initial energy capacity remains. In the rechargeable battery market, the principal competing technologies are Nickel Metal Hydride and Lithium-ion (including Lithium polymer) batteries. Rechargeable batteries are used in many applications, such as military radios, laptop computers, mobile telephones, portable medical devices, wearable devices and many other commercial, defense and consumer products.

Three important performance characteristics of a rechargeable battery are design flexibility, energy density and cycle life. Design flexibility refers to the ability of rechargeable batteries to be designed to fit a variety of shapes and sizes of battery compartments. Thin profile batteries with prismatic geometry provide the design flexibility to fit the battery compartments of today's electronic devices. Energy density refers to the total amount of electrical energy stored in a battery divided by the battery's weight and volume as measured in watt-hours per kilogram and watt-hours per liter, respectively. High energy density batteries generally are longer lasting power sources providing longer operating time and necessitating fewer battery recharges. High energy density and long achievable cycle life are important characteristics for comparing rechargeable battery technologies. Greater energy density will permit the use of batteries of a given weight or volume for a longer time period. Accordingly, greater energy density will enable the use of smaller and lighter batteries with energy comparable to those currently marketed. Lithium-ion batteries, by the nature of their electrochemical properties, are capable of providing higher energy density than comparably sized batteries that utilize other chemistries and, therefore, tend to consume less volume and weight for a given energy content. Long achievable cycle life, particularly in combination with high energy density, is suitable for applications requiring frequent battery recharges, such as cellular telephones and notebook computers, and allows the user to charge and recharge many times before noticing a difference in performance. We believe that our Lithium-ion batteries generally have high energy density and a long cycle life.

Lithium-ion Cells and Batteries. We market a variety of Lithium-ion cells and rechargeable batteries comprised of cells manufactured by qualified cell manufacturers. These products are used in a wide variety of applications including communications, medical and other portable electronic devices.

Battery Charging Systems and Accessories. To provide our customers with complete power system solutions, we offer a wide range of rugged military and commercial battery charging systems and accessories including smart chargers, multi-bay charging systems and a variety of cables.

*Multi-Kilowatt Module.* Our Multi-Kilowatt Module Lithium-ion battery system is a large format battery utilizable for energy storage, battery back-up, and remote power applications. This product is a direct replacement of 1.25 kWh and larger capacity lead acid batteries in 24V or 48V applications. It can be connected in multiples to obtain higher-voltages and is capable of over 3,000 cycles while maintaining 80% of its capacity.

*Technology Contracts.* Our technology contract activities involve the development of new products or the enhancement of existing products through contracts with both government agencies and private sector third parties.

#### Communications Systems

Under our McDowell Research and AMTI brands, we design and manufacture a line of communications systems and accessories to support military communications systems, including RF amplifiers, power supplies, power cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems and integrated communication systems for fixed or vehicle applications such as vehicle amplifier-adaptors. We package all systems to

meet specific customer needs in rugged enclosures to allow their use in extreme environments and under our Ultralife Corporation brand provide system integration products and services for commercial requirements.

We offer a wide range of military communications systems and accessories designed to enhance and extend the operation of communications equipment such as vehicle-mounted, manpack and handheld transceivers. Our communications products include the following product configurations:

*RF Amplifiers*. These amplifiers are used to extend the range of manpack and handheld tactical transceivers, and our RF amplifiers include both mounted and dismounted versions and many related accessories and kits which can be used on mobile or fixed site applications.

Integrated Systems. Our integrated systems include vehicle mounted systems; SATCOM systems; rugged, deployable case systems; and multiband transceiver kits. These systems provide enhanced capabilities which enable communications operators to provide links to support Command, Control, Communications, Computers, Cyber and Intelligence, Surveillance and Reconnaissance (C5ISR).

*Power Systems.* Our power systems include AC/DC power supplies with battery backup for tactical manpack radios and power adaptors and chargers. We can provide power supplies for virtually all tactical communications devices.

Our commercial products integrate information technology capability into rugged cases, supporting use of high computing capability in various configurations. We market these products to automotive, cellular carriers and manufacturing industries.

Communications and Electronics. Our communications and electronics services include the design, integration, and deployment of portable, mobile and fixed-site communications systems.

#### Sales and Marketing

We employ a staff of sales and marketing personnel in North America, Europe and Asia. We sell our products and services directly to commercial customers, including OEMs, as well as government and defense agencies in the U.S. and abroad and have contractual arrangements with sales agents who market our products on a commission basis in defined territories. Every effort is made to adjust future prices when and if possible, but the ability to adjust prices is generally based on market conditions.

We also distribute some of our products through domestic and foreign distributors and retailers. Sales of these products are generated primarily from purchase orders issued by these customers. We have several long-term contracts with the U.S. government and other customers. These contracts do not commit the customers to specific purchase volumes, nor to specific timing of purchase order releases, and they include fixed price agreements over various periods of time. In general, we do not believe our sales are seasonal, although we may sometimes experience seasonality for some of our military products based on the timing of government fiscal budget expenditures.

A significant portion of our business comes from sales of products and services to U.S. and foreign governments through various contracts. These contracts are subject to procurement laws and regulations that specify policies and procedures for acquiring goods and services. The procurement laws and regulations also contain guidelines for managing contracts after they are awarded, including conditions under which contracts may be terminated, in whole or in part, at the government's convenience or for default. Failure to comply with applicable procurement laws or regulations can result in civil, criminal or administrative proceedings involving fines, penalties, suspension of payments, or suspension or debarment from government contracting or subcontracting for a period of time. Even if a contract is awarded to us there is no guarantee that the government will order any product under the contract.

We have one major customer, a large global defense primary contractor, which comprised 15% of our total revenues in 2023, and 17% of our total revenues in 2022. There were no other customers that comprised greater than 10% of our total revenues during these years.

In 2023, sales to U.S. and foreign customers were approximately \$81,396 and \$77,248, respectively. In 2022, sales to U.S. and foreign customers were approximately \$67,914 and \$63,926, respectively.

#### Battery & Energy Products

We target sales of our non-rechargeable products to manufacturers of security and safety equipment, medical devices, search and rescue equipment, specialty instruments, oil and gas downhole drilling and pipe inspection equipment, point of sale equipment and metering applications, as well as users of military equipment. Our strategy is to develop sales and marketing alliances with OEMs and governmental agencies that utilize our batteries in their products, commit to cooperative research and development or marketing programs, and recommend our products for design-in or replacement use in their products. We are addressing these markets through direct contact by our sales and technical personnel, use of sales agents and stocking distributors, manufacturing under private labels, and promotional activities.

We seek to capture a significant market share for our products within our targeted OEM markets, which we believe, if successful, will result in increased product awareness and sales at the end-user or consumer level. We are also selling our 9-volt battery to the consumer market through retail distribution channels. Most military procurements are done directly by the specific government organizations requiring products, based on a competitive bidding process. Additionally, we are typically required to successfully meet contractual specifications and to pass various qualifications testing for the products under contract by the military. Our inability to pass these tests for our new products in a timely fashion could have a material adverse effect on future growth prospects. When a government contract is awarded, there is a government procedure that permits unsuccessful companies to formally protest the award if they believe they were unjustly treated in the government's bid evaluation process. A prolonged delay in the resolution of a protest, or a reversal of an award resulting from such a protest, could have a material adverse effect on our business, financial condition and results of operations.

We market our products to defense organizations in the U.S. and other countries. In September 2019, we were awarded an indefinite-delivery/indefinite-quantity contract from the U.S. Government's Defense Logistics Agency for up to five years, with the potential to generate revenue of \$14,422, to provide our BA-5368 batteries. In May 2021 we were awarded an indefinite-delivery/indefinite-quantity contract from the U.S. Army for purchases of Conformal Wearable Batteries ("CWB") not to exceed \$168,000 during the three-year base award period with the potential for up to an additional \$350,000 should the six one-year options be exercised. Our development work on the CWB continues, and we have successfully completed UN/DOT shipment testing in 2023, a major milestone which allows us to now ship batteries to customers for initial testing and functional feedback. We are working on completing validation testing to enter U.S. Government First Article Testing, which is currently scheduled to start later in 2024. In December 2021, we were awarded an indefinite-delivery/indefinite-quantity contract not to exceed \$9,900 for the U.S. Government's Defense Logistics Agency for our Lithium Manganese Dioxide, non-rechargeable BA-5390 batteries. The award consists of a three-year base contract with two one-year option periods.

We target sales of our Lithium-ion rechargeable batteries and charging systems to OEM customers, as well as distributors and resellers focused on our target markets. We respond to Requests for Proposals ("RFPs") to design products for OEMs, and believe that our design capabilities, product characteristics and solution integration will encourage OEMs to incorporate our batteries into their product offerings, resulting in revenue growth opportunities for us.

We continue to expand our marketing activities as part of our strategic plan, a comprehensive forward-looking document which sets forth our strategic growth plans, tactical actions and financial projections over a rolling three-year period, to increase sales of our battery and energy products for commercial, standby, defense and communications applications, as well as hand-held devices, wearable devices and other electronic portable equipment. A key part of this expansion includes increasing our design and assembly capabilities as well as building our international network of distributors and value-added distributors.

At December 31, 2023 and 2022, our backlog related to Battery & Energy Products was approximately \$92,000 and \$88,600, respectively. The 4% year-over-year increase in our Battery & Energy Products backlog at December 31, 2023 primarily resulted from the demand for our medical, government and defense, and oil and gas batteries.

The 2023 year-end Battery & Energy Products backlog is primarily related to orders that are expected to ship throughout 2024 and does not include future shipments under the indefinite-delivery/indefinite-quantity awards with the U.S. Department of Defense.

#### Communications Systems

We target sales of our communications systems, which include power solutions and accessories to support communications systems such as RF amplifiers, power supplies, power cables, connector assemblies, amplified speakers, equipment mounts, case equipment and integrated communication systems, to military OEMs and U.S. and allied foreign militaries. We sell our

products directly and through authorized distributors to OEMs and directly to defense contractors and U.S. and foreign militaries. We market our products to defense organizations and OEMs in the U.S. and internationally.

Sales targets for commercial products include integrated systems for information technology equipment to support fixed, mobile and deployable locations. We sell our products directly to commercial businesses in the U.S.

At December 31, 2023 and 2022, our backlog related to Communications Systems orders was approximately \$11,500 and \$22,400, respectively. The 49% decrease in our Communications Systems backlog at December 31, 2023 is primarily a result of fulfillment in 2023 of purchase orders received in 2022 to supply a global defense prime with our Vehicle Amplifier-Adaptors for the U.S. Army's Leader Radio program and to supply an international defense contractor with our amplifiers and radio vehicle mounts for an ongoing allied country government/defense modernization program. The 2023 year-end Communications Systems backlog is related to orders that are expected to ship throughout 2024.

#### **Patents, Trade Secrets and Trademarks**

We use our patented and unpatented proprietary information, know-how and trade secrets to maintain and develop our competitive position. Despite our efforts to protect our proprietary information, there can be no assurance that others will neither develop the same or similar information independently nor unlawfully obtain access to our proprietary information, know-how and trade secrets. In addition, there can be no assurance that we would prevail if we asserted our intellectual property rights against third parties, or that third parties will not successfully assert infringement claims against us in the future. We believe, however, that our success depends more on the knowledge, ability, experience and technological expertise of our employees, than on the legal protection that our patents and other proprietary rights may or will afford.

We hold thirty-four patents issued in the U.S., six patents issued in the European Union member states, five patents issued in the European Union, five patents issued in the United Kingdom, five patents issued in Japan, four patents issued in India, four patents issued in South Korea, three patents issued in Canada, three patents issued in China, three patents issued in Taiwan, two patents issued in Norway, one patent issued in Australia, one patent issued in Hong Kong, one patent issued in Iceland, one patent issued in Mexico and one patent issued by the World Intellectual Property Organization. We believe our patents protect technology that makes automated production more cost-effective and protects important competitive features of our products. However, we do not consider our business to be dependent on patent protection.

As part of our employment commencement process, our employees are required to enter into agreements providing for confidentiality of certain information and the assignment of rights to inventions made by them while employed by us. These agreements also contain certain non-competition and non-solicitation provisions which are effective during the employment term and for varying periods thereafter depending on position and location. There can be no assurance that we will be able to enforce these agreements. All of our employees agree to abide by the terms of a Code of Ethics policy that provides for the confidentiality of certain information received during the course of their employment. Nevertheless, the enforceability of such agreements is subject to public policy limitations that vary from state to state and country by country so we cannot assure that they will be enforceable in accordance with their terms, if at all.

Trademarks are an important aspect of our business. We sell our products under a number of trademarks, that we own. Our trademarks include the following: Ultralife®, Ultralife Thin Cell®, Ultralife HiRate®, Ultralife & design®, LithiumPower®, LithiumPower & Design®, Smart Circuit®, Smart Circuit & design®, WE. ARE. POWER®, AMTI®, ABLE™, ACCUTRONICS™, ACCUPRO™, ENTELLION™, McDowell Research®, SWE Southwest Electronic Energy Group®, SWE DRILL-DATA®, SWE DRILL-DATA OBSERVER®, SWE SEASAFE®, SWE SEASAFE (& DESIGN)®, SWE SEASAFE + DIRECT®, SWE SOUTHWEST ELECTRONIC ENERGY GROUP ADVANCED BATTERY SOLUTIONS & DESIGN®, Excell Battery Group™ and Criterion Gauge™.

#### **Manufacturing and Raw Materials**

We manufacture our products from raw materials and component parts that we purchase. Our manufacturing facility in Newark, New York is ISO 9001 and ISO 13485 certified. Our Canadian manufacturing facilities in Calgary, Vancouver and Mississauga are ISO 9001 certified and ISO 13485 certified. Our manufacturing facility in Shenzhen, China is ISO 9001, ISO 14001 and ISO 13485 certified. Our manufacturing facility in Missouri City, Texas is ISO 9001 and ISO 13485 certified. Our manufacturing facilities in the United Kingdom are ISO 9001 and ISO 13485 certified. Our manufacturing facility in Virginia Beach, Virginia is ISO 9001 certified.

We expect our future raw material purchases to fluctuate based on global demand for our products, our knowledge regarding the timing of customer orders, the related need to build inventory in anticipation of orders and actual shipment dates. The prices and availability of some raw materials were impacted by COVID-19/supply chain disruptions in 2023 and may continue to be affected in 2024.

#### Battery & Energy Products

Our Newark, New York and Shenzhen, China facilities have the capacity to produce cylindrical cells, 9-volt Lithium batteries, 3-volt battery and thin cells. Capacity, however, is affected by demand for particular products, and product mix changes can produce bottlenecks in an individual operation, constraining overall capacity. We have acquired new machinery and equipment in areas where production bottlenecks have occurred in the past and we believe that we have sufficient capacity in most areas. We continually evaluate our requirements for additional capital equipment and direct labor resources, to help ensure that our planned increases will be adequate to meet foreseeable customer demand.

Certain materials used in our products, other than rechargeable battery cells, are available only from a single source or a limited number of sources. Additionally, we may elect to develop relationships with a single or limited number of sources for materials that are otherwise generally available. Although we believe that alternative sources may in some cases be available to supply materials that could replace materials we use and that, if necessary, we would be able to redesign our products to make use of an alternative material provided extensive customer testing and recertification are not required, any interruption in our supply from any supplier that serves currently as our sole source could delay product shipments and adversely affect our financial performance and relationships with our customers. Although we have experienced interruptions of product deliveries by sole source and other suppliers in 2023 resulting in the delay of some shipments to future periods, we cannot assure that these interruptions and delays will not have an adverse effect on us in the future.

Generally, the raw materials and components utilized for our rechargeable batteries are readily available from many sources. Although we believe that alternative sources are available to supply materials and components that could replace materials or components we use, any interruption in our supply from any supplier that serves currently as our sole source could delay product shipments and adversely affect our financial performance and relationships with our customers.

Our Newark, New York facility has the capacity to produce significant volumes of batteries and energy products. This operation generally manufacturers non-rechargeable battery cells, non-rechargeable and rechargeable battery packs, and chargers and is limited only by physical space and is not constrained by manufacturing equipment capacity which can accommodate significant additional volumes of product. Similarly, our China and United Kingdom facilities also have capacity to produce significant quantities of non-rechargeable batteries and rechargeable battery packs beyond current volumes and are not constrained by manufacturing equipment capacity. Our Missouri City, Texas facility has the capacity to produce significant quantities of rechargeable and non-rechargeable battery packs and is not constrained by manufacturing equipment capacity and the same is presently true for our Excell facilities in Calgary, Mississauga and Vancouver, Canada. We continue to access the capacity of our global facilities based on increased demand for our products, and to determine constraints associated with human capital resources and/or manufacturing equipment.

The total carrying value of our Battery & Energy Products inventory, including raw materials, work in process and finished goods, amounted to \$35,221 and \$32,771 as of December 31, 2023 and 2022, respectively. The year-over-year 7% increase primarily reflects an increase in materials, including rechargeable cells, required to fulfill the backlog for our batteries primarily used in the medical devices, government and defense, and oil and gas sectors. Management continuously monitors inventory levels in an effort to optimize such levels.

#### Communications Systems

In general, we believe that the raw materials and components utilized by us for our communications and commercial accessories and systems, including RF amplifiers, power supplies, cables, repeaters and integration kits and systems, are available from many sources. Although we believe that alternative sources are available to supply materials and components that could replace materials or components we use, any interruption in our supply from any supplier that serves currently as our sole source or any significant increase in lead times to provide components could delay product shipments and adversely affect our financial performance and relationships with our customers.

Our Virginia Beach, Virginia facility has the sufficient capacity to produce communications products and systems to meet current demand. This operation generally assembles products and is limited only by physical space and is not constrained by manufacturing equipment capacity.

The total carrying value of our Communications Systems inventory, including raw materials, work in process and finished goods, amounted to \$6,994 and \$8,421 as of December 31, 2023 and 2022, respectively. The year-over-year 17% decrease is due to the fulfillment of certain large purchase orders in 2023 that contained longer lead time components to meet the commitment dates. Management continuously monitors inventory levels in an effort to optimize such levels.

#### **Research and Development**

We devote significant resources to research and development activities to improve the technological capabilities of our products and to design new products for customers' applications. We conduct our research and development in Newark, New York; Virginia Beach, Virginia; Tallahassee, Florida; Missouri City, Texas; Newcastle-under-Lyme, United Kingdom; and Shenzhen, China. During 2023 and 2022, we expended \$8,587 and \$7,874, respectively, on research and development, including \$1,056 and \$793, respectively, on customer sponsored research and development activities, which are included in cost of products sold. The year-over-year increase in customer sponsored research and development is due to the timing of key projects, including the development of customer-driven new products.

We expect that research and development expenditures in the future, including 2024, could increase by 10% or more over 2023 levels, based on current initiatives. These current initiatives include the following: completing the development and testing of new battery and power solutions in our facilities in Newark, New York, Houston and Missouri City, Texas, Canada and Newcastle-under-Lyme, UK; our Thionyl Chloride battery project in China and new product initiatives for our Communications Systems business. We expect that new product development is one of the factors that will drive our growth. As in the past, we will continue to make funding decisions for our research and development efforts based upon demand for customer applications.

#### Battery & Energy Products

We continue to internally develop non-rechargeable cells and batteries with the goal of broadening our product offering to our customers.

We continue to internally develop our rechargeable product portfolio, including batteries, battery management systems, cables and charging systems, as our customers' needs for portable power continue to grow and new technologies become available.

The U.S. government sponsors research and development programs, which Ultralife participates in, designed to improve the performance and safety of existing battery systems and to develop new battery systems.

#### Communications Systems

We continue to internally develop a variety of communications accessories and systems for the global defense and commercial markets to meet the ever-changing demands of our customers.

#### Safety; Regulatory Matters; Environmental Considerations

Certain materials utilized in our batteries may pose safety problems if improperly used, stored, or handled. We have designed our batteries to minimize safety hazards both in manufacturing and in use. Our batteries are subject to the regulations noted below, among others.

The transportation of non-rechargeable and rechargeable Lithium batteries is regulated in the U.S. by the Department of Transportation's Pipeline and Hazardous Materials Safety Administration ("PHMSA"), and internationally by the International Civil Aviation Organization ("ICAO") and corresponding International Air Transport Association ("IATA"), Dangerous Goods Regulations and the International Maritime Dangerous Goods Code ("IMDG"), and other country specific regulations. These regulations are based on the United Nations Recommendations on the Transport of Dangerous Goods Model Regulations and the United Nations Manual of Tests and Criteria. We currently ship our products pursuant to PHMSA, ICAO, IATA, IMDG and other country specific hazardous goods regulations. These regulations require companies to meet certain testing, packaging, labeling, marking and shipping paper specifications for safety reasons. We have not incurred, and do not expect to incur, any significant costs in order to comply with these regulations. We believe we comply with all current U.S. and international regulations for the shipment of our products, and we intend and expect to comply with any new applicable

regulations that are imposed. We have established our own testing facilities to help ensure that we comply with these regulations. However, if we are unable to comply with any such new regulations, or if regulations are introduced that limit our or our customers' ability to transport our products in a cost-effective manner, this could have a material adverse effect on our business, financial condition and results of operations.

The European Union's Restriction of Hazardous Substances Directive (the "EU RoHS Directive") places restrictions on the use of certain hazardous substances in electrical and electronic equipment. All applicable products sold in the European Union market must pass EU RoHS Directive compliance. While this directive does not apply to batteries and does not currently affect our defense products, should any changes occur in the directive that would affect our products, we intend and expect to comply with any new applicable regulations that are imposed. However, we cannot ensure that the cost of complying with such new regulations would not have a material adverse effect on us. We believe our commercial chargers are in material compliance with the EU RoHS Directive.

The European Union's Battery Directive "on batteries and accumulators and waste batteries and accumulators" (the "EU Battery Directive") is intended to cover all types of batteries regardless of their shape, volume, weight, material composition or use. It is aimed at reducing mercury, cadmium, lead and other metals in the environment by minimizing the use of these substances in batteries and by treating and re-using old batteries. The EU Battery Directive applies to all types of batteries except those used to protect European Union member states' security, for military purposes, or sent into space. To achieve these objectives, the EU Battery Directive prohibits the marketing of some batteries containing hazardous substances. It establishes schemes aimed at high levels of collection and recycling of batteries with quantified collection and recycling targets. The EU Battery Directive sets out minimum rules for producer responsibility and provisions with regard to labeling of batteries and their removability from equipment. The EU Battery Directive requires product markings for batteries and accumulators to provide information on capacity and to facilitate reuse and safe disposal. We currently ship our products pursuant to the requirements of the EU Battery Directive.

The EU Battery Directive requires producers or importers of particular classes of electrical goods to be financially responsible for specified collection, recycling, treatment and disposal of past and future covered products. This directive assigns levels of responsibility to companies doing business in European Union markets based on their relative market share. This directive calls on each European Union member state to enact enabling legislation to implement the directive. As additional European Union member states pass enabling legislation, we believe our compliance system should be sufficient to meet such requirements. Our current estimated costs associated with our continued compliance with these directives based on our current market share are not significant. However, we continue to evaluate the impact of these directives as European Union member states implement guidance, and actual costs could differ from our current estimates.

China's "Management Methods for Restricted Use of Hazardous Substances in Electrical and Electronic Products" ("China RoHS 2") provides a regulatory framework including hazardous substance restrictions similar to those imposed by the EU RoHS Directive. China RoHS 2 applies to methods for the control and reduction of pollution and other public hazards to the environment caused during the production, sale, and import of electrical and electronic products ("EEP") in China. The regulatory framework of China RoHS 2 also now references the updated marking and labeling requirements under Standard SJ/T 11364-2014. The methods under China RoHS 2 only apply to EEP placed in the marketplace in China. We believe our compliance system is sufficient to meet our requirements under China RoHS 2. Our current estimated costs associated with our compliance with this regulation based on our current market share are not significant. However, we continue to evaluate the impact of this regulation, and actual costs could differ from our current estimates.

National, state and local laws impose various environmental controls on the manufacture, transportation, storage, use and disposal of batteries and of certain chemicals used in the manufacture of batteries. Although we believe that our operations are in material compliance with current environmental regulations, there can be no assurance that changes in such laws and regulations will not impose costly compliance requirements on us or otherwise subject us to future liabilities, costs and expenses. There can be no assurance that additional or modified regulations relating to the manufacture, transportation, storage, use and disposal of materials used to manufacture our batteries or restricting disposal of batteries will not be imposed or that such regulations will not have a material adverse effect on our business, financial condition and results of operations. In 2023 and 2022, we spent \$199 and \$264, respectively, on environmental compliance, including costs to properly dispose of potentially hazardous waste.

Since non-rechargeable and rechargeable Lithium battery chemistries react adversely with water and water vapor, certain of our manufacturing processes must be performed in a controlled environment with low relative humidity. Our Newark, New York and Shenzhen, China facilities contain dry rooms or glove box equipment, as well as specialized air-drying equipment.

In addition to the environmental regulations previously described, our products are subject to U.S. and international laws and regulations governing international trade and exports including but not limited to the International Traffic in Arms Regulations ("ITAR"), the Export Administration Regulations ("EAR") and trade sanctions against embargoed countries.

The ITAR is a set of U.S. government regulations that control the export and import of defense-related articles and services on the United States Munitions List. These regulations implement the provisions of the Arms Export Control Act, and are described in the Code of Federal Regulations. The Department of State Directorate of Defense Trade Controls interprets and enforces ITAR. Its goal is to safeguard U.S. national security and further U.S. foreign policy objectives.

The related EAR are enforced and interpreted by the Bureau of Industry and Security in the Commerce Department. The Department of Defense is also involved in the review and approval process. Inspections in support of import and export laws are performed at border crossings by Customs and Border Protection, an agency of the Department of Homeland Security.

Products and services developed and manufactured in our foreign locations are subject to the export and import controls of the nation in which the foreign location operates.

We believe we are in material compliance with these domestic and international export regulations. However, failure of compliance could have a material adverse effect on our business through possible fines, denial of export privileges, or loss of customers. Further, while we are not aware of any proposed changes to these regulations, any change in the scope or enforcement of export or import regulations or related legislation could have a material adverse effect on our business through increased costs of compliance or reduction in the international growth prospects available to us.

Based upon our current sales volumes, our future estimated costs associated with our compliance with ITAR, EAR, and the foreign export and import controls are not significant. However, we continue to evaluate the impact of these regulations, and actual costs could differ from our current estimates.

#### Battery & Energy Products

Our non-rechargeable battery products incorporate Lithium metal, which reacts with water and may cause fires if not handled properly. In the past, we have experienced fires that have temporarily interrupted certain manufacturing operations. We believe that we have adequate fire suppression systems and insurance, including business interruption insurance, to protect against the occurrence of fires and fire losses in our facilities.

Our 9-volt battery, among other sizes, is designed to conform to the dimensional and electrical standards of the American National Standards Institute. Authorized certification bodies such as Underwriters Laboratories, Intertek and SGS have certified several of our products.

#### Communications Systems

We are not currently aware of any regulatory requirements regarding the disposal of our communications products.

#### Corporate

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 Section 1502 (the "Dodd-Frank Act") requires public companies to disclose whether tantalum, tin, gold and tungsten, commonly known as "conflict minerals," are necessary to the functionality or production of a product manufactured by a public company and if those elements originated from armed groups in the Democratic Republic of Congo or adjoining countries. To comply with the Dodd-Frank Act, as implemented by SEC rules, we are required to perform due diligence inquiries of our suppliers to determine whether or not our products contain such minerals and from which countries and source (smelter) the minerals were obtained. Our annual report on Form SD was filed by the statutory due date of May 31, 2023 for the 2022 calendar year and we continue to utilize appropriate measures with our suppliers to better ascertain the origin of the conflict minerals in our products.

#### Competition

Competition in both the battery and communications systems markets is, and is expected to remain, intense. The competition ranges from development stage companies to major domestic and international companies, many of which have financial, technical, marketing, sales, manufacturing, distribution and other resources significantly greater than ours. We compete against companies producing batteries as well as companies producing communications systems. We compete on the basis of design flexibility, performance, price, reliability and customer support. There can be no assurance that our technologies and products will not be rendered obsolete by developments in competing technologies or services that are currently under development or that may be developed in the future or that our competitors will not market competing products and services that obtain market acceptance more rapidly than ours.

While we cannot assure that other entities will not attempt to take advantage of the growth of the battery market, the Lithium battery cell industry has certain technological and economic barriers to entry. The development of technology, equipment and manufacturing techniques and the operation of a facility for the automated production of Lithium battery cells require large capital expenditures, which may deter new competitors from commencing production. Through our experience in battery cell manufacturing, we have also developed significant production and design expertise in the non-rechargeable battery market, which we believe would be difficult for new competitors to reproduce without substantial time and expense.

#### **Employees**

As of December 31, 2023, we employed a total of 536 permanent and temporary employees: 412 in production, 75 in sales and administration, and 49 in research and development. None of our employees are represented by a labor union.

#### ITEM 1A. RISK FACTORS

Our business faces many risks. As such, prospective investors and stockholders should carefully consider and evaluate all of the risk factors described below as well as other factors discussed in this Form 10-K Annual Report, including without limitation, the Management's Discussion and Analysis of Financial Condition and Results of Operations, and in our other filings with the SEC. Any of these factors could adversely affect our business, financial condition and results of operations. Additional risks and uncertainties that are not currently known to us or that are not currently believed by us to be material may also harm our business operations and financial results. These risk factors may change from time to time and may be amended, supplemented, or superseded by updates to the risk factors and other information contained in periodic reports on Form 10-Q, Form 10-K, and current reports on Form 8-K that we file with the SEC in the future.

#### **Company Risk Factors**

Changes in economic conditions, including inflation, interest rates, and supply-chain disruptions have affected and may continue to affect our business, revenues and earnings adversely.

The disruptions resulting from supply chain and logistics complications hit a crescendo in 2022 in large part because of a sharp uptick for our more-advanced rechargeable battery packs which increased our need for highly sought-after components, including various electronic components, PC boards, chip sets and certain metals to name a few. The underlying factors pressuring our gross margins in this timeframe included rapid cost inflation on raw materials and key components not entirely aligned with the timing of customer price increases; incremental fees to source and expedite critical components in a timely manner, necessitating the one-time use of brokers at a much higher cost and with more complex logistics, and further complicating the timely matching of higher costs with customer price increases; and irregular component availability and lead time extensions causing continuous production-line start-ups, shut-downs and changeovers resulting in labor inefficiencies, higher scrap and decreased absorption of overhead. While these conditions persisted in 2023, although to a lesser extent, the negative impact was partially mitigated by our proactive actions including the following: closer alignment of cost increases with customer price increases, extending the time horizon of our sales & operations planning process ("S&OP") with both customers and suppliers to provide greater visibility in ordering components while upgrading our internal resources responsible for the process, and improving our process for launching new products to reduce the cost and time of transitioning to high-volume manufacturing.

While price increases, longer lead times and key component shortages are easing, they still exist. Despite our proactive actions to improve gross margins and to secure alternate vendors to minimize the disruptions experienced in the past, we may not be able to fully offset in a timely fashion the unfavorable impact these disruptions may continue to cause on our business and financial results going forward.

A significant portion of our revenues is derived from certain key customers.

We have one customer, L3Harris Technologies, a large global defense primary contractor, which comprised 15% of our total revenues in 2023 and 17% of our total revenues in 2022. There were no other customers that comprised greater than 10% of our total revenues during these years. While we consider our relationship with this major customer to be good, the reduction, delay or cancellation of orders from this customer or any delays in payments beyond their payment terms, for any reason, would reduce our revenues and operating income and could materially and adversely affect our business, operating results and financial condition in other ways.

Reductions or delays in U.S. and foreign military spending could have a material adverse effect on our business, financial condition and results of operations.

A significant portion of our revenues is derived from contracts with U.S. and foreign militaries or OEMs that supply U.S. and foreign militaries. In the years ended December 31, 2023 and 2022, \$57,802 or 36% and \$38,795 or 29%, respectively, of our revenues were comprised of sales made directly or indirectly to U.S. and foreign militaries.

While significant gains have been made in commercial markets with our business, we are still highly dependent on sales to U.S. Government customers. The amounts and percentages of our net revenue that were derived from sales to U.S. Government customers, including the Department of Defense, whether directly or through prime contractors, was approximately \$43,476 or 27% in 2023 and \$33,064 or 25% in 2022. Therefore, any significant disruption to or deterioration of our relationship with the U.S. Government or any prime defense contractor could significantly reduce our revenues. Our competitors continuously engage in efforts to expand their business relationships with the U.S. Government and will continue these efforts in the future, and the U.S. Government may choose to use other contractors or suppliers.

Budget and appropriations decisions made by the U.S. Government, including possible future sequestration periods or other similar formulaic reductions in federal expenditures, are outside of our control and have long-term consequences for our business. A decline in U.S. or foreign military expenditures could result in a reduction in the military demand for our products, which could have a material adverse effect on our business, financial condition and results of operations.

Our efforts to develop new products or new commercial applications for our products could be prolonged, not be profitable, not be accepted by our customers or could otherwise fail to achieve market share.

Although we develop certain products for new commercial applications, we cannot assure that these new products will be accepted due to the highly competitive nature of our industries. There are many new product and technology entrants into the markets we sell our products to. We must continually reassess the markets in which our products can be successful and seek to engage customers in those markets that will adopt our products for use in their products. In addition, these customers must be successful with their products in their markets for us to gain increased business. Increased competition, failure to gain customer acceptance of our products, the introduction of competitive technologies or failure of our customers to purchase our products in their markets all may have an adverse effect on our business and reduce our revenues and operating income.

Our supply of raw materials and components could be disrupted or delayed due to business conditions, global conflicts, weather, the continuing impact of COVID-19 or other factors not under our control, or the cost of those raw materials and components may materially increase.

Certain materials and components used in our products are available only from a single or a limited number of suppliers. Some materials and components have been and may continue to be in short supply resulting in limited availability and/or increased costs. Additionally, we may elect to develop relationships with a single or limited number of suppliers for materials and components that are otherwise generally available. Due to our supplying defense products to the U.S. Government, we could receive a government preference to continue to obtain critical supplies to meet military production needs. However, if the government did not provide us with a government preference in such circumstances or if the suppliers are not able to meet the necessary demand for the components, the difficulty in obtaining supplies on a timely basis could have a material adverse effect on our business, financial condition and results of operations. We believe that alternative suppliers are available to supply materials and components that could replace materials and components currently used and that, if necessary, we may be able to redesign our products to make use of such alternatives provided that the costs and timing of our customers recertifying the alternate materials and components where necessary is not deemed prohibitive to our customers or us. Nevertheless, any interruption in the supply from any supplier that serves as a

sole source could delay product shipments and have a material adverse effect on our business, financial condition and results of operations. We have experienced interruptions of product deliveries by sole source and other suppliers in the past, and we cannot guarantee that we will not experience a continuation of material interruption of deliveries from sole source or other suppliers in the future. Past supply chain disruptions and increased component lead times resulting from COVID-19 and its after-effects were exacerbated by the increased demand for Lithium-based cells from the electric vehicle manufacturers. While the latter has resulted in increased supply of such cells, meeting such electric vehicle demand could possibly result in delays or even the discontinuation of the cells required for our products. Accordingly, these circumstances require us to regularly monitor all aspects of our supply chain and share the updates with our customers, to ensure that any potential supply interruptions are understood with all efforts taken to minimize.

As we look forward to potential rising demand for electrification, our lead times for certain critical components from our suppliers could be extended even further, resulting in shipping delays causing us to miss contractual timelines. Our internal purchasing process is focused on the current economic environment, and lead times in the current environment are considered when placing orders from our vendors, but we cannot control the ability of our vendors or potential vendors to meet our delivery dates.

Additionally, we could continue to face prolonged, increasing pricing pressure from our suppliers due to rising costs incurred by these suppliers that could be passed on to us in higher prices for our raw materials. These increased prices could increase our cost of business, lower our margins and have other materially adverse effects on our business, financial condition and results of operations, particularly, if our pass through of these price increases is not accepted by our customers or if our lean manufacturing initiatives take longer than anticipated.

Breaches in security, whether cyber or physical, and related disruptions and/or our inability to prevent or respond to such breaches, has previously, and in the future could diminish our ability to generate revenues or contain costs, compromise our assets, and negatively impact our business in other ways.

We face certain security threats, including threats to our information technology infrastructure, attempts to gain access to our proprietary or classified information, and threats to cyber and physical security. Our information technology networks and related systems are critical to the operation of our business and essential to our ability to successfully perform day-today operations. The risks of a security breach, cyberattack, cyber intrusion, or disruption, particularly through actions taken by computer hackers, foreign governments and cyber terrorists, have increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Although we have acquired and developed systems and processes designed to protect our proprietary or classified information, they may not be sufficient to prevent security breach, cyberattack, cyber intrusion, or disruption, and the failure to prevent these types of events could disrupt our operations, require significant management attention and resources, and could negatively impact our reputation among our customers and the public, which could have a negative impact on our financial condition, operating results and liquidity. In 2017, we formed a cross-functional executive management Security Steering Committee focused on mitigating the risk of security breaches, cyberattacks, cyber intrusions, or disruptions. In 2018, with the assistance of outside security consultants, we completed a comprehensive Systems Security Plan ("SSP") and a Plan of Action & Milestones ("POAM") in compliance with the requirements of National Institute of Standards and Technology ("NIST") Special Publication 800-171, Protecting Controlled Unclassified Information in Nonfederal Information Systems and Organizations. In 2019, the Company made further progress in implementing many of the security measures in our SSP and POAM, including increasing the security awareness across our employee base. In 2020 through 2023, we continued to make progress towards achieving full implementation of all NIST 800-171 security standards, as well as the requirements under the Cybersecurity Maturity Model Certification ("CMMC") framework released by the Department of Defense in 2020. We continue to review all key aspects of cybersecurity utilizing our outside security consultants to ensure a robust plan is in place and provides timely updates to our Board. Despite these measures, we cannot eliminate the risk of such security breaches and the potential adverse impacts these breaches may have on our business and financial results. Accordingly, for several years, including 2023, we maintained our cybersecurity insurance policy to help mitigate the impact of a cybersecurity incident.

As reported on Form 8-K filed on March 2, 2023, during performance of their daily information technology security procedures on January 25, 2023, our Information Technology Team ("IT Team") discovered an unauthorized entry into our information technology systems for our Newark, New York and Virginia Beach, Virginia locations. The accounts in question were immediately disabled by our IT Team, and the Company's Security Steering Committee met promptly, taking swift action, including the immediate notification of our cybersecurity insurance carrier. Shortly thereafter, with assistance of recommendations from our cybersecurity carrier, we engaged external incident response professionals to assist with our assessment, recovery and response. On February 7, 2023, the Company received an electronic communication allegedly from a third-party, known for nefarious ransomware attacks, claiming responsibility for the incident, and discussions with that third party commenced through experienced cybersecurity professionals engaged by the Company.

This incident caused a partial disruption of our business operations at these locations, which resulted in production and shipping downtime of several weeks. With the efforts of internal resources supported by external expertise, the Company restored its information technology systems and production was resumed in both locations. Based on the recovery of our systems, review of the files affected, as well as the Company's prompt response to and assessment of the incident, no ransom or other amount has been paid to the third-party. Nevertheless, the cybersecurity event and the resulting restoration was costly to the Company, and a business interruption claim was filed with our cyber insurance underwriter. The claim remains in review and is not included in our 2023 financial results. The Company's deductible for its cyber insurance is \$100 which was recognized in our 2023 results.

We continue to monitor our information systems for any intrusions or other irregularities.

Our ability to recruit and retain experienced, competent management is critical to the success of the business, and the loss of top management and key personnel could significantly harm our business, and ability to implement our succession plan.

The continued service of our officers and executive team is key to the successful implementation of our business model and growth strategy designed to deliver sustainable, consistent profitability. A top management priority has been the development and implementation of a formal written succession plan to mitigate the risks associated with the loss of senior executives. This formal succession plan is updated annually and presented to our Board of Directors. There is no guarantee that we will be successful in our efforts to effectively implement our succession plan.

Because of the specialized, technical nature of our business, we are highly dependent on certain members of our management, sales, engineering and technical staffs. The loss of one or more of these employees could have a material adverse effect on our business, financial condition and results of operations. Our ability to effectively pursue our business strategy will depend upon, among other factors, the successful retention of our key personnel, recruitment of additional highly skilled and experienced managerial, sales, engineering and technical personnel, and the integration of such personnel obtained through business acquisitions. We cannot assure that we will be able to retain or recruit this type of personnel at reasonable costs, or at all. An inability to hire sufficient numbers of people or to find people with the desired skills could result in greater demands being placed on limited management resources which could delay or impede the execution of our business plans and have other material adverse effects on our business, financial condition and results of operations.

Our growth and expansion strategy could strain or overwhelm our resources.

Rapid growth of our business could significantly strain management, operations and technical resources. If we are successful in obtaining rapid market growth of our products, we may be required to deliver large volumes of products to customers on a timely basis at a reasonable cost. For example, demand for our new or existing products combined with our ability to penetrate new markets and geographies or secure a major project award, could strain the current capacity of our manufacturing facilities and require a substantial increase in our direct labor workforce in a tight job market, and require additional capital resources, equipment and time to meet the required demand. We cannot assure, however, that our business will grow rapidly or that our efforts to expand manufacturing and quality control activities will be successful or that we will be able to satisfy commercial scale production requirements on a timely and cost-effective basis. While our backlog remained at over \$100 million for the last five quarters, this does not mean that rapid growth and demand for our products in all cases will be met by our resources without delay. Although we have highly experienced technical and engineering employees, we cannot assure you that we will be able to fulfil the orders of our customers for our products, without delay. The failure to manage growth and expansion effectively could have a material adverse effect on our business, financial condition, and results of operations.

The COVID-19 pandemic and other related illnesses have caused and may continue to create significant economic and social disruption and uncertainty around the world, may impact the health of our employees, the employees of our customers, and the employees of our suppliers, causing delays in the manufacture and delivery of our mission critical products to end customers, and may disrupt business with our collaborative business partners and service providers, which may continue to adversely impact our business and operating results.

The novel coronavirus disease of 2019 (COVID-19) has created significant economic disruption and uncertainty around the world. As we enter the fourth year of the pandemic, our workforce, customers and vendors still face the risk of the emergence of new strains, availability of effective treatment, and potential regulatory and macroeconomic effects stemming from such impacts. Except for certain situations in China, lockdowns, shelter-in-place restrictions, and vaccine mandates,

prevalent during the initial stages of the pandemic, have now been lifted for most companies. While we have maintained normal business operations at virtually all our facilities throughout the pandemic, the related supply chain disruptions including increased lead times on key components experienced within our business and by our customers and vendors, continue to impact our work schedules and timing of shipments. The lingering impact of these conditions, potentially exacerbated by the emergence of new strains, on our business and financial results is uncertain and will depend on many evolving factors which we continue to monitor but cannot predict, including the resistance to treatments and current vaccinations, and the duration and scope of any new pandemic variants, the resulting actions taken by governments, businesses and individuals, and the flow-through impact on operations and supply chains.

Our operations in China are subject to unique risks and uncertainties, including political changes, tariffs and trade restrictions.

Our operating facility in China presents unique risks including, but not limited to, changes in local regulatory requirements, changes in labor laws, local wage laws, environmental regulations, taxes and operating licenses, compliance with U.S. regulatory requirements, including the Foreign Corrupt Practices Act, uncertainties as to the application and interpretation of local laws and enforcement of contract and intellectual property rights, currency restrictions, currency exchange controls, fluctuations in the value of currency to the U.S. dollar and currency revaluations, eminent domain claims, civil unrest, power outages, water shortages, labor shortages, labor disputes, increase in labor costs, rapid changes in government, economic and political policies, political or civil unrest, war, acts of terrorism, or the threat of boycotts, other civil disturbances, the impact of the imposition of tariffs by the U.S. Government on 9-volt batteries that we manufacture in China as well as any retaliating trade policies or restrictions, and an outbreak of a contagious disease variant, related to COVID-19 or not, which may cause us or our suppliers and/or customers to temporarily suspend operations in the affected city or region. Any such disruptions could depress our earnings and have other material adverse effects on our business, financial condition and results of operations.

Fluctuations in the demand, supply and price of oil and gas and the resulting volatility in the level of downhole drilling could have a material adverse effect on our business, financial condition and results of operations.

Fluctuations in the demand, supply and pricing encountered in the oil and gas industry, have placed financial strain on the producers and the companies that provide oilfield services and equipment to those producers. The volatility in this industry, whether driven by geopolitical developments; international tensions; supply and demand economics; the introduction of new global, national, and industry-specific regulations; U.S. administration policies; and technology, appears to be a trend. A significant downturn in the price of oil may result in a decrease in downhole drilling and adversely impact our financial results.

A decline in demand for products using our batteries or communications systems could reduce demand for our products and/or our products could become obsolete resulting in lower revenues and profitability.

A substantial portion of our business depends on the continued demand for products using our batteries and communications systems sold by our customers, including OEMs. Our success depends significantly upon the success of those customers' products in the marketplace. We are subject to many risks beyond our control that influence the success or failure of a particular product or service offered by a customer, including:

- competition faced by the customer in its particular industry,
- market acceptance of the customer's product or service,
- the engineering, sales, marketing and management capabilities of the customer,
- challenges unrelated to our technology or products faced by the customer in developing its products or services, and
- the financial and other resources of the customer.

The market for our products is characterized by rapidly changing technology and evolving industry standards, often resulting in product obsolescence or short product lifecycles. Although we believe that our products utilize state-of-the-art technology, there can be no assurance that competitors will not develop technologies or products that would render our technologies and products obsolete or less marketable. Many of the companies with which we compete have substantially greater resources than we do, and some have the capacity and volume of business to be able to produce their products more efficiently than we can. In addition, these companies are developing or have developed products using a variety of technologies that are expected to compete with our technologies. Furthermore, we have noted an increase in foreign competition, especially in Asia, over the last several years which tends to compete on price in the battery industry. If these

companies successfully market their products in a manner that renders our technologies obsolete, this may reduce our revenues and operating income and could have other material adverse effects on our business, financial condition and results of operations.

Our quarterly and annual results and the price of our common stock have and could in the future continue to fluctuate significantly.

Our future operating results and the price of our common stock may vary significantly from quarter-to-quarter and from year-to-year depending on factors such as the timing and shipment of significant orders, new product introductions, the transition of new products to higher-volume production, major project wins, U.S. and foreign government demand, delays in customer releases of purchase orders, delays in receiving raw materials from vendors and other supply-chain disruptions, the mix of distribution channels through which we sell our products and services and general economic conditions. Due to such variances in operating results, we have sometimes failed to meet, and in the future may not meet, market expectations regarding our future operating results.

In addition to the uncertainties of quarterly and annual operating results, future announcements concerning us or our competitors, including technological innovations or commercial products, litigation or public concerns as to the safety or commercial value of one or more of our products, or the impact of economic or geopolitical factors on any of the markets segments we participate in may cause the market price of our common stock to fluctuate substantially, all of which may be unrelated to our operating results.

We are subject to certain safety risks, including the risk of fire or explosion, inherent in the manufacture, use and transportation of Lithium batteries. These risks also create the potential for claims against the Company, which can have a negative impact on our financial results.

Due to the high energy inherent in Lithium batteries, our Lithium batteries can pose certain safety risks, including the risk of fire. We incorporate procedures in research, development, product design, manufacturing processes and the transportation of Lithium batteries that are intended to minimize safety risks, but we cannot assure that accidents will not occur or that our products will not be subject to recall for safety concerns. Although we currently carry insurance policies which cover loss of plant and machinery, leasehold improvements, inventory and business interruption, any accident, whether at the manufacturing facilities or from the use and transportation of the products, may result in significant production delays or claims for damages resulting from injuries or death. While we maintain what we believe to be sufficient casualty liability coverage to protect against such occurrences, these types of losses could reduce our available cash and our operating and net income and have other material adverse effects on our reputation, business, financial condition and results of operation.

Rising interest rates will increase the cost of our variable borrowing and will affect our earnings adversely.

The Company's Amended Credit Agreement, among other things, provides for a 5-year, \$10,000 senior secured term loan (the "Term Loan Facility") and extends the term of the \$30,000 senior secured revolving credit facility (the "Revolving Credit Facility", and together with the Term Loan Facility, the "Amended Credit Facilities") through May 30, 2025. Up to six months prior to May 30, 2025, the Revolving Credit Facility may be increased to \$50,000 with the Bank's concurrence.

Upon closing of the Excell Acquisition on December 13, 2021, the Company drew down the full amount of the Term Loan Facility and \$10,980 under the Revolving Credit Facility. As of December 31, 2023, the Company had \$6,167 outstanding principal on the Term Loan Facility, of which \$2,000 is due to be paid in 2024 and included in current portion of long-term debt on the balance sheet, and \$19,580 outstanding on the Revolving Credit Facility. The related interest rates on our borrowings are variable as disclosed in Note 2 to our consolidated financial statements. While it is in the best interests of the Company to reduce the amount of debt quickly, those funds in some cases have been diverted to purchase raw material and component inventory above historical levels in order satisfy commitments to our customers in light of the continuing increase in our backlog and lingering long lead times and other supply chain disruptions. Accordingly, any increase in interest rates will adversely impact the Company's reported financial results, perhaps materially.

Our customers may not meet the volume expectations in our supply agreements.

We sell most of our products and services through supply agreements and contracts. While supply agreements and contracts contain volume-based pricing based on expected volumes, we cannot assure that adjustments to reflect volume shortfalls will be made under current industry practices because pricing is rarely adjusted retroactively when contract volumes are not achieved. Every effort is made to adjust future prices accordingly, but our ability to adjust prices is generally based on market conditions and we may not be able to adjust prices in various circumstances. This could have an adverse impact in the form of reduced revenues or lower margins.

We may incur significant costs or liabilities to satisfy obligations under the terms of the warranties we supply and the contractual terms under which we sell our products and services.

We typically offer standard warranties against product defects that range from ninety (90) days to three (3) years from the date of purchase. We also offer separately priced extended warranty contracts on certain Communications Systems products. Warranty costs expected to be incurred are estimated based on the Company's experience and recorded as costs of products sold. There is no assurance that future warranty claims will be consistent with our estimates, and in the event we experience a significant increase in warranty claims, there is no assurance that our reserves will be sufficient to cover such increased warranty claims. Excessive warranty claims could have a material adverse effect on our business, financial condition and results of operations.

Any inability to comply with changes to the regulations for the shipment of our products could limit our ability to transport our products to customers in a cost-effective manner and reduce our operating income and margins.

The transportation of Lithium batteries is regulated by the International Civil Aviation Organization ("ICAO") and corresponding International Air Transport Association ("IATA") Dangerous Goods Regulations and the International Maritime Dangerous Goods Code ("IMDG") and in the U.S. by the Department of Transportation's Pipeline and Hazardous Materials Safety Administration ("PHMSA"). These regulations are based on the United Nations Recommendations on the Transport of Dangerous Goods Model Regulations and the United Nations Manual of Tests and Criteria. We currently ship our products pursuant to ICAO, IATA and PHMSA hazardous goods regulations. These regulations require companies to meet certain testing, packaging, labeling and shipping specifications for safety reasons. We have not incurred, and do not expect to incur, any significant costs in order to comply with these regulations. We believe we materially comply with all current U.S. and international regulations for the shipment of our products, and we intend and expect to comply with any new regulations that are imposed. We have established our own testing facilities to ensure that we materially comply with these regulations. If, however, we are unable to comply with any such new regulations, or if regulations are introduced that limit our ability to transport our products to customers in a cost-effective manner, this could reduce our operating income and margins, and have other material adverse effects on our business, financial condition and results of operations.

Our entrance into new markets could lead to additional exposure to financial risk or increased liability, and our failure to successfully enter into those markets could lead to negative customer perception or loss of business from existing customers.

Our new products supporting our commercial diversification strategy will likely result in the introduction of our products in new end markets that we have not participated in before. These new market opportunities may carry certain risks that we may not have experienced in the past or that we may not be fully aware of. While we perform extensive due diligence in the launch of our products in new end markets and attempt to mitigate our risks with our contracts and insurance coverage, we may not be fully aware of the risks that may exist until we gain more experience in these markets.

Negative publicity concerning Lithium-ion batteries may negatively impact the industries or markets we operate in.

We are unable to predict the impact, severity or duration of negative publicity related to fire/mishandling of Lithium-ion batteries or the environmental impact of their disposal, and how it may impact the industries or markets we serve. Ongoing negative attention regarding Lithium-ion batteries that are used in certain cellular phones or are integrated into the power systems of new commercial aircraft and electric motor vehicles may have an impact on the Lithium-ion battery industry as a whole, regardless of the design or usage of those batteries. The effects of such events could have an adverse effect on our business, financial condition, and results of operations.

Our ability to use our net operating loss and tax credit carryforwards in the future may be limited, which could increase our tax liabilities and reduce our cash flow and net income.

At December 31, 2023, we had approximately \$27,200 of U.S. net operating loss carryforwards and \$2,900 of U.S. tax credit carryforwards available to offset future taxable income. We continually assess the carrying value of these assets based on the relevant accounting standards. Based on our latest assessment at December 31, 2023, we believe it is more likely than not that our U.S. deferred tax assets will be fully realized. However, failure to achieve our business targets could result in future charges to our income tax provision if any of the net operating loss or tax credit carryforwards are not utilized. See discussion in Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 28.

We are subject to foreign currency fluctuations.

We maintain manufacturing operations in North America, the United Kingdom and China, and we export products to various countries. We purchase materials and sell our products in foreign currencies, and therefore currency fluctuations have and may in the future impact our pricing of products sold and materials purchased. Sales to non-U.S. customers make up a significant percentage of our total revenues. For example, the percentage of our business with customers outside of the U.S. was 49% in 2023 and 48% in 2022. A future strengthening of the U.S. dollar relative to our customers' currencies could make our products relatively more expensive and may adversely affect our sales levels and reduce profitability. In addition, our United Kingdom and China subsidiaries maintain their books in local currency and their translation to U.S. dollars for our consolidated financial statements have and may in the future have an adverse effect on our consolidated financial results due to changes in local currency values relative to the U.S. dollar. With the rapid pace of geopolitical events, it is difficult at this time to assess any future impact of currency fluctuation on the Company's financial results, despite our proactive efforts to minimize the short-term risks of currency fluctuations. Accordingly, currency fluctuations could have a material adverse effect on our business, financial condition and results of operations by increasing our expenses and reducing our income. Finally, we maintain certain domestic U.S. cash balances denominated in foreign currencies, and the U.S. dollar equivalent of these balances fluctuates with changes in the foreign exchange rates between these currencies and the U.S. dollar.

Any impairment of goodwill and/or other indefinite-lived intangible assets could adversely impact our results of operations.

Our goodwill and other indefinite-lived intangible assets are subject to impairment testing on an annual basis. Additionally, goodwill and other indefinite-lived intangible assets are assessed for impairment whenever events and circumstances indicate that impairment may exist. Any excess carrying value of goodwill and/or other intangible assets resulting from an impairment assessment must be written off in the period of determination. In addition, from time to time, we may acquire a business which will require us to record goodwill and/or other indefinite-lived intangible assets based on the allocation of the total consideration transferred to consummate the acquisition to the identified tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values. We may subsequently experience unforeseen circumstances related to past or future acquisitions which may adversely impact the forecasted cash flows or other assumptions used to value these assets. Future determinations that the estimated fair value of our goodwill and/or indefinite-lived intangible assets is less than their respective carrying values may result in significant (non-cash) impairment charges which could have a material adverse impact on our future results of operations.

A finding that our proprietary and intellectual property rights are not enforceable or invalid could allow our competitors and others to produce competing products based on our proprietary and intellectual property or limit our ability to continue to manufacture and market our products.

We believe our success depends more on the knowledge, ability, experience and technological expertise of our employees than on the legal protection of patents and other proprietary rights. However, we claim proprietary rights in various unpatented technologies, know-how, trade secrets and trademarks relating to our products and manufacturing processes. We cannot guarantee the degree of protection these various claims may or will afford, or that competitors will not independently develop, patent or license technologies that are substantially equivalent or superior to our technologies. We also protect our proprietary rights in our products and operations through contractual obligations, including nondisclosure agreements with certain employees, customers, consultants and strategic partners. There can be no assurance as to the degree of protection these contractual measures may or will afford. We have had patents issued and have patent applications pending in the U.S. and elsewhere. We cannot assure (1) that patents will be issued from any of these pending applications, or that the claims allowed under any issued patents will sufficiently protect our technology, (2) that any patents issued to us will not be challenged, invalidated or circumvented, or (3) as to the degree or adequacy of protection that any patents or patent applications may or will afford. Further, if we are found to be infringing upon third party patents, we cannot assure

that we will not be subjected to significant liability for damages or that we will be able to obtain licenses with respect to such patents on acceptable terms, if at all. In this event, the failure to obtain necessary licenses could delay product shipments or the introduction of new products, and costly attempts to design around such patents could foreclose the development, manufacture or sale of products, all of which could materially adversely affect our business and our results of operations.

We are subject to the contract rules and procedures of the U.S. and foreign governments. These rules and procedures create significant risks and uncertainties for us that are not usually present in contracts with private parties.

We continue to develop battery products and communications systems to meet the needs of the U.S. and foreign governments. We compete in solicitations for awards of contracts from these governments. The receipt of an award, however, does not always result in the immediate release of an order and does not guarantee in any way any given volume of orders. Any delay of solicitations or anticipated purchase orders by, or future failure of, the U.S. or foreign governments to purchase products manufactured by us could have a material adverse effect on our business, financial condition and results of operations. In these scenarios we are also typically required to successfully meet contractual specifications and to pass various qualification-testing for the products under contract. Our inability to pass these tests in a timely fashion, or to meet delivery schedules for orders released under contract, could have a material adverse effect on our business, financial condition and results of operations.

Additionally, when a U.S. government contract is awarded, there is a government procedure that permits unsuccessful companies to formally protest such award if they believe they were unjustly treated in the evaluation process. As a result of these protests, the government is precluded from proceeding under these contracts until the protests are resolved. A prolonged delay in the resolution of a protest, or a reversal of an award resulting from such a protest could have material adverse effects on our business, financial condition and results of operations.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act ("FCPA"), the U.K. Bribery Act or other anti-corruption laws.

The FCPA, U.K. Bribery Act and other anti-corruption laws generally prohibit companies and their intermediaries from making improper payments (to foreign officials and otherwise) and require companies to keep accurate books and records and maintain appropriate internal controls. Our training program and policies mandate compliance with such laws. We operate in some parts of the world that have experienced governmental corruption to some degree, and, in certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices. If we are found to be liable for violations of anti-corruption laws (either due to our own acts or our inadvertence, or due to the acts or inadvertence of others, including employees of our third-party partners or agents), we could suffer from civil and criminal penalties or other sanctions, incur significant internal investigation costs and suffer reputational harm. Such circumstances, if they occur, could have a material adverse impact on our results of operations.

We may incur significant costs because of known and unknown environmental matters.

National, state and local laws impose various environmental controls on the manufacture, transportation, storage, use and disposal of batteries and of certain chemicals used in the manufacture of batteries. We use and generate a variety of chemicals and other hazardous by-products in our manufacturing operations. These environmental laws govern, among other things, air emissions, wastewater discharges and the handling, storage and release of wastes and hazardous substances. Such laws and regulations can be complex and are subject to change. Although we believe that our operations are in substantial compliance with current environmental regulations and that there are no environmental conditions that will require material expenditures for clean up at our present or former facilities or at facilities to which we have sent waste for disposal, there can be no assurance that changes in such laws and regulations will not impose costly compliance requirements on us or otherwise subject us to future liabilities. There can be no assurance that additional or modified regulations relating to the manufacture, transportation, storage, use and disposal of materials used to manufacture our batteries or restricting disposal of batteries will not be imposed, or as to how these regulations will affect us or our customers. Such changes in regulations could reduce our operating income and margins and have other material adverse effects on our business, financial condition and results of operations. We could incur substantial costs as a result of violations of environmental laws, including clean-up costs, fines and sanctions and third-party property damage or personal injury claims. Failure to comply with environmental requirements could also result in enforcement actions that materially limit or otherwise affect the operations of the facilities involved. Under certain environmental laws, a current or previous owner or operator of an environmentally contaminated site may be held liable for the entire cost of investigation, removal

or remediation of hazardous materials at such property. This liability could result whether or not the owner or operator knew of, or was responsible for, the presence of any hazardous materials.

The EU RoHS Directive places restrictions on the use of certain hazardous substances in electrical and electronic equipment. All applicable products sold in the European Union market after July 1, 2006 must comply with EU RoHS Directive. While this directive does not apply to batteries and does not currently affect our defense products, should any changes occur in the directive that would affect our products, we intend and expect to comply with any new regulations that are imposed. Our commercial chargers comply with this directive. Additional European Union directives, entitled the Waste Electrical and Electronic Equipment ("WEEE") Directive and the Directive "on batteries and accumulators and waste batteries and accumulators", impose regulations affecting our non-defense products. These directives require producers or importers of particular classes of electrical goods to be financially responsible for specified collection, recycling, treatment and disposal of past and future covered products. These directives assign levels of responsibility to companies doing business in European Union markets based on their relative market share. These directives call on each European Union member state to enact enabling legislation to implement the directive. As additional European Union member states pass enabling legislation our compliance system should be sufficient to meet such requirements. Our current estimated costs associated with our compliance with these directives based on our current market share are not significant. However, we continue to evaluate the impact of these directives as European Union member states implement guidance, and actual costs could differ from our current estimates.

The EU Battery Directive is intended to cover all types of batteries regardless of their shape, volume, weight, material composition or use. It is aimed at reducing mercury, cadmium, lead and other metals in the environment by minimizing the use of these substances in batteries and by treating and re-using old batteries. This directive applies to all types of batteries except those used to protect European member states' security, for military purposes, or sent into space. To achieve these objectives, the EU Battery Directive prohibits the marketing of some batteries containing hazardous substances. It establishes processes aimed at high levels of collection and recycling of batteries with quantified collection and recycling targets. The directive sets out minimum rules for producer responsibility and provisions with regard to labeling of batteries and their removability from equipment. Product markings are required for batteries and accumulators to provide information on capacity and to facilitate reuse and safe disposal. We currently ship our products pursuant to the requirements of the directive. Our current estimated costs associated with our compliance with these directives based on our current market share are not significant. However, we continue to evaluate the impact of these directives as European Union member states implement guidance, and actual costs could differ from our current estimates.

The China RoHS 2 directive provides a regulatory framework, including hazardous substance restrictions which are similar to those imposed by the EU RoHS Directive, and applies to methods for the control and reduction of pollution and other public hazards to the environment caused during the production, sale, and import of EEP in China affecting a broad range of electronic products and parts. The regulatory framework of China RoHS 2 also now references the updated marking and labeling requirements under Standard SJ/T 11364-2014. The methods required by China RoHS 2 only apply to EEP placed in the marketplace in China. We believe our compliance system is sufficient to meet our requirements under China RoHS 2. Our current estimated costs associated with our compliance with this regulation based on our current market share are not significant. However, we continue to evaluate the impact of this regulation, and actual costs could differ from our current estimates.

A number of domestic and international communities are prohibiting the landfill disposal of batteries and requiring companies to make provisions for product recycling. Of particular note are the EU Batteries Directive and the New York State Rechargeable Battery Recycling Law. We are committed to responsible product stewardship and ongoing compliance with these and future statutes and regulations. The compliance costs associated with current recycling statutes and regulations are not expected to be significant at this time. However, we continue to evaluate the impact of these regulations, and actual costs could differ from our current estimates and additional laws could be enacted by these and other states which entail greater costs of compliance.

The U.S. and foreign governments can audit our contracts with their respective defense and government agencies and, under certain circumstances, can adjust the economic terms, delivery schedule or other terms of those contracts.

A portion of our business comes from sales of products and services to the U.S. and foreign governments through various contracts. These contracts are subject to procurement laws and regulations that lay out policies and procedures for acquiring goods and services. The procurement laws and regulations also contain guidelines for managing contracts after they are awarded, including conditions under which contracts may be terminated, in whole or in part, at the government's convenience or for default. Failure to comply with the procurement laws or regulations can result in civil, criminal or

administrative proceedings involving fines, penalties, suspension of payments, or suspension or disbarment from government contracting or subcontracting for a period of time, which could have a material adverse effect on the Company.

Compliance with government regulations regarding the use of "conflict minerals" may result in increased costs and risks to the Company.

As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Act"), the SEC has promulgated disclosure requirements regarding the use of certain minerals, which are mined from the Democratic Republic of Congo and adjoining countries, known as conflict minerals. We are required to perform due diligence inquiries of our supply chain and publicly disclose whether we manufacture (as defined in the Act) any products that contain conflict minerals and could incur significant costs related to implementing a process that will meet the mandates of the Act. Additionally, customers typically rely on us to provide critical data regarding the parts they purchase, including conflict mineral information. Our material sourcing is broad-based and multi-tiered, and we may not be able to easily verify the origins for conflict minerals used in the products we sell. We have many suppliers, and each provides conflict mineral information in a different manner, if at all. Accordingly, because our supply chain is complex, we may face reputational challenges if we are unable to sufficiently verify the origins of conflict minerals used in our products. Additionally, customers may demand that the products they purchase be free of conflict minerals. Such demands may limit the number of suppliers that can provide products in sufficient quantities to meet customer demand or at competitive prices. Any of these consequences may increase our costs of operations, increase or margins and harm our business.

#### ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

#### ITEM 1C. CYBERSECURITY

Securing the Company's IT systems is integral and foundational to its everyday operations. The Company's Security Steering Committee is comprised of cross-functional executive management team members that collectively possess an extensive level of security and technology operations expertise. The mission of our Security Steering Committee is to focus on defining and deploying its information security strategy, sustaining a robust employee cyber awareness and training program, executing security engineering, providing continuous monitoring of its operations, responding and coordinating the response and investigation of cyber threats, building and testing its disaster recovery plans in support of its businesses' continuity plan requirements, and developing its cyber and information security policies.

The Company's cybersecurity strategy is based on recognized best practices, standards, and frameworks for cybersecurity and information technology, including the Center for Information Security ("CIS") Controls and National Institute of Standards and Technology ("NIST"). The strategy focuses on implementing technologies, controls, and processes to constantly monitor, identify, assess, and manage cybersecurity risks.

The Company's cybersecurity program includes exercises and trainings designed to sustain a high level of cybersecurity awareness and readiness across our employee base. The Company also has a cybersecurity incident response plan that is designed to provide a framework across all functions for a coordinated identification and response to security incidents.

The Company engages leading cybersecurity firms to assist with its security engineering and operations; provide independent evaluations of its security posture through regular assessments; and to audit and provide advice on how to make its security processes and controls more effective.

Furthermore, the Company utilizes third-party service providers to perform a variety of functions to assist in operating the business. The cybersecurity risks associated with the use of certain providers are covered under a vendor management process. Depending on the nature of the services provided, the sensitivity and/or quantity of information processed, the vendor management process may include reviewing cybersecurity practices of these providers, contractually imposing obligations on the provider, inspecting independently audited reports, and/or conducting its own security assessments of their services.

The Company's Board of Directors has ultimate oversight of the Company's cybersecurity risk. Management updates the Board of Directors on the Company's cybersecurity and information security posture at least quarterly at the Company's board meetings, or more frequently as determined to be necessary or advisable. These updates include a review of cybersecurity incidents determined to have a moderate to high business impact, even if immaterial to the Company as a whole. The Audit Committee has responsibility for assisting the Board in the review and oversight of risks affecting the Company, and oversees the enterprise risk management process, which includes, with the assistance of senior management, assessing the Company's exposure to cybersecurity risk and the effectiveness of the Company's processes and controls to address and respond to those risks. Management is responsible for hiring appropriate personnel, integrating cybersecurity considerations into the Company's overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.

Notwithstanding the focus and emphasis on cybersecurity, the Company has experienced and will continue to experience cybersecurity incidents, and there can be no guarantee that future incidents will not have a material adverse effect on its business. See "Risk Factors - Breaches in security, whether cyber or physical, and related disruptions and/or our inability to prevent or respond to such breaches, could diminish our ability to generate revenues or contain costs, compromise our assets, and negatively impact our business in other ways" for more information on the Company's cybersecurity risks.

# **ITEM 2. PROPERTIES**

As of December 31, 2023, we own two buildings in Newark, New York comprising approximately 250,000 square feet, which serve operations primarily in the Battery & Energy Products operating segment. Our corporate headquarters are located in our Newark, New York facility. We own one building in Missouri City, Texas comprising 69,000 square feet, which houses our SWE and Excell USA operations, and lease approximately 97,000 square feet in two buildings on one campus in Shenzhen,

China, including a dormitory facility, approximately 25,000 square feet in six buildings in a contiguous area in Newcastle-under-Lyme, United Kingdom, and approximately 24,000 square feet in three facilities for our Excell Canada operations located in Calgary, Mississauga and Vancouver, Canada, all which serve operations in the Battery & Energy Products operating segment. We lease approximately 32,500 square feet in a facility in Virginia Beach, Virginia, which serves operations in the Communications Systems operating segment. We also lease sales and administrative offices, as well as manufacturing and production facilities, in India, which serve operations in the Battery & Energy Products operating segment. Our research and development efforts for Battery & Energy Products are conducted at our Newark, New York; Missouri City, Texas; Newcastle-under-Lyme, United Kingdom; Shenzhen, China; and our Canada facilities, while our research and development efforts for our Communications Systems products are conducted in our leased facilities in Tallahassee, Florida and in Virginia Beach, Virginia. We believe that our facilities are adequate and suitable for our current needs and provide sufficient capacity to produce our products to meet current demand.

#### ITEM 3. LEGAL PROCEEDINGS

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company's financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company's financial position, results of operations or cash flows. We are not aware of any such situations at this time.

#### ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

#### **PART II**

# ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

#### **Market Information**

Ultralife's common stock is listed on the NASDAQ Global Market under the symbol "ULBI."

#### Holders

As of March 1, 2024, there were approximately 4,300 registered holders of record of our common stock.

#### **Purchases of Equity Securities by the Issuer**

There were no purchases of our common stock by the Company during the years ended December 31, 2023 and December 31, 2022.

#### **Dividends**

We have never declared or paid any cash dividends on our capital stock. Pursuant to our current credit facility, we are precluded from paying any dividends. We intend to retain earnings, if any, to finance future operations and expansion and, therefore, do not anticipate paying any cash dividends in the foreseeable future. Any future payment of dividends will depend upon our financial condition, capital requirements and earnings, as well as upon other factors that our Board of Directors may deem relevant.

# ITEM 6. [RESERVED]

# ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the accompanying consolidated financial statements and notes thereto appearing in Item 8 of this Form 10-K.

The financial information in this Management's Discussion and Analysis of Financial Condition and Results of Operations is presented in thousands of dollars, except for share and per share amounts. All figures presented below represent results from continuing operations, unless otherwise specified.

#### General

We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design, manufacture, install and maintain power and communications systems including rechargeable and non-rechargeable batteries, communications and electronics systems and accessories and custom engineered systems. We sell our products internationally through a variety of trade channels, including original equipment manufacturers ("OEMs"), industrial and defense supply distributors and directly to U.S. and international defense departments.

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. As such, we report segment performance at the gross profit level and operating expenses as Corporate charges.

We continually evaluate ways to grow, including opportunities to expand through mergers, acquisitions and joint ventures, which we believe can broaden the scope of our products and services, expand operating and market opportunities and provide the ability to enter new lines of business synergistic with our portfolio of product offerings.

In January 2016, we acquired Accutronics Limited ("Accutronics"), a U.K. corporation based in Newcastle-under-Lyme, U.K., a leading independent designer and manufacturer of smart batteries and charger systems for high-performance, feature-laden portable and handheld electronic devices. Our acquisition of Accutronics advanced our strategy of commercial revenue diversification, expanded our geographic penetration, and achieved revenue growth from new product development.

On May 1, 2019, we acquired Southwest Electronic Energy Corporation, a Texas corporation ("SWE"), and a leading designer and manufacturer of high-performance smart battery systems and battery packs to customer specifications using Lithium cells. SWE serves a variety of industrial markets, including oil and gas, remote monitoring, process control and marine, which demand uncompromised safety, service, reliability and quality. We acquired SWE as a bolt-on acquisition which has supported our strategy of commercial revenue diversification by providing entry to the oil and gas exploration and production, and subsea electrification markets, which were previously unserved by us. Another key benefit has been obtaining a highly valuable technical team of battery pack and charger system engineers and technicians which has added to our new product development-based revenue growth initiatives in our commercial end-markets particularly asset tracking, smart metering and other industrial applications.

On December 13, 2021, we acquired Excell Battery Canada Inc., a British Columbia corporation ("Excell Canada") and 656700 B.C. Ltd., a British Columbia corporation ("656700") and its wholly owned subsidiary, Excell Battery Corporation USA, a Texas corporation ("Excell USA" together with Excell Canada and 656700, collectively, "Excell"), which operate under the name Excell Battery Group. Based in Canada with U.S. operations, the Excell Battery Group is a leading independent designer and manufacturer of high-performance smart battery systems, battery packs and monitoring systems to customer specifications. Excell serves a variety of industrial markets including downhole drilling, OEM industrial and medical devices, automated meter reading, and mining, marine and other mission critical applications which demand uncompromised safety, service, reliability and quality. We acquired Excell as an important component of our strategy to diversify commercial revenue and expand the end markets we serve. Acquiring Excell has allowed us to further scale our Battery & Energy Products business and drive the operating leverage of our business model, expand into OEM device verticals that we do not presently serve, enhance our contributed value to both our customers and realize cost synergies. Furthermore, we utilize Excell experienced technical resources in our global new product initiatives and add a

complementary line of highly engineered products, both existing and in development, that are costly for our customers to substitute with products of a competitor.

Currently, we do not experience significant seasonal sales trends in either of our operating segments, although sales to the U.S. Department of Defense and other international defense organizations can be sporadic based on the needs of those particular customers and allocated funding levels.

The COVID-19 pandemic has created significant economic disruption and uncertainty around the world. The Company continues to closely monitor the developments surrounding COVID-19 and its related strains and take actions to mitigate the business risks involved. We remain focused on ensuring the health and safety of our employees by implementing the material protocols established by public health officials. We continue to strive to ensure an uninterrupted flow of our mission critical products serving medical device, first responder, public safety, energy and national security customers.

Consolidated revenues increased by \$26,804 or 20.3% to \$158,644 for the year ended December 31, 2023 compared to \$131,840 for the year ended December 31, 2022. During 2023, we experienced revenue growth of 8.3% for our Battery & Energy Products business and 142.2% for our Communications Systems business. This 2023 performance reflected a \$7,797 or 8.4% increase in sales to our commercial customers and a \$19,007 or 49.0% increase in sales to government and defense customers. The increase in our commercial business was due to medical sales of \$36,945 which increased \$9,624 or 35.2% due primarily to higher demand from a large global medical device OEM and the successful launch of our X-5 medical cart battery system. The increase in government and defense sales reflects growth in Battery & Energy Products sales of \$2,161 or 8.0% representing higher demand from prime defense contractors and growth in Communications Systems of \$16,846 or 142.2% primarily attributable to fulfilling long-lead time orders of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. Demand for our products remains strong with our 2023 year-end backlog of \$103,535.

Gross margin increased to 24.7% for the year ended December 31, 2023 from 22.3% for the year ended December 31, 2022. The 240-basis point improvement was due primarily to the following: better alignment of the timing of our customer price increases with the impact of cost inflation on raw materials and key components; extending the time horizon of our sales & operations planning process ("S&OP") with both customers and suppliers while upgrading our internal resources responsible for the process to reduce the negative impact of production line start-ups, shutdowns and changeovers due to irregular component availability and lead time extensions; concerted efforts to level-load production resulting in improved labor utilization efficiency and higher cost absorption; and improving our process for launching new products to reduce the cost and time of transitioning to high-volume manufacturing.

Operating expenses increased by \$454 or 1.6% to \$29,725 during the year ended December 31, 2023, compared to \$29,271 during the year ended December 31, 2022. The increase is primarily attributable to increased new product development investments, the recording of the \$100 deductible on our cybersecurity insurance policy for expenses incurred associated with the January 2023 cyberattack and higher variable compensation, including Officer and Executive Team bonuses and salesforce commissions, and insurance costs. Both periods reflected continued tight control over discretionary spending. Operating expenses as a percentage of revenue was 18.7% for 2023 compared to 22.2% for 2022, a 350-basis point improvement reflecting the sales leverage of our business model.

Other expenses totaled \$358 for the year-ended December 31, 2023 compared to \$575 for the year ended December 31, 2022. Other expenses for the 2023 period includes an Employee Retention Credit ("ERC") of \$1,544 under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during the second quarter of 2023. Interest and financing expense increased \$1,065, or 112.0%, from \$951 for 2022 to \$2,016 for the comparable period in 2023. The increase is primarily due to the financing of our acquisition of Excell in December 2021, working capital funding resulting from our January 2023 cyberattack and rising interest rates. Excluding the ERC gain in the 2023 period, miscellaneous income amounted to \$114 for the 2023 period compared to \$376 for the 2022 period, primarily attributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange rates.

Income tax provision was \$1,951 for the year ended December 31, 2023, compared to an income tax benefit of \$326 for the year ended December 31, 2022. Our effective tax rate decreased to 21.4% for the 2023 period as compared to 73.1% for the 2022 period, primarily attributable to the year over year increase in income before income taxes. The income tax provision for 2023 is comprised of a \$650 current provision for taxes expected to be paid on income primarily in foreign jurisdictions, representing a cash-based effective tax rate of 7.1%, and a \$1,301 deferred tax provision which primarily represents non-cash charges for U.S. taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. For the comparable 2022 period, the income tax benefit was comprised of a \$636

current tax provision and a \$962 deferred tax benefit primarily for U.S. pre-tax losses and temporary tax differences expected to offset future U.S. taxable income.

Net income attributable to Ultralife Corporation was \$7,197, or \$0.44 per share – basic and diluted on a GAAP basis for the year ended December 31, 2023, compared to a net loss of \$119, or \$0.01 per share – basic and diluted for the year ended December 31, 2022. Adjusted EPS was \$0.52 per share on a diluted basis for 2023, compared to a \$0.07 loss per share for 2022. Adjusted EPS for 2023 excludes the provision for deferred income taxes of \$1,301 which represents non-cash charges primarily for U.S. income taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. Adjusted EPS for 2022 excludes the benefit for deferred income taxes of \$962 which represents a non-cash benefit primarily for U.S. net operating losses and temporary tax differences which are expected to offset future U.S. taxable income. See section "Adjusted EPS" on page 36 for a reconciliation of adjusted EPS to EPS.

Adjusted EBITDA, defined as net income (loss) attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, plus/minus income/expense that we do not consider reflective of our continuing operations, amounted to \$15,703 for the year ended December 31, 2023, compared to \$6,575 for the prior year. See the section "Adjusted EBITDA" beginning on page 34 for a reconciliation of adjusted EBITDA to net income attributable to Ultralife.

The Company's liquidity remains solid, with cash on hand of \$10,278, working capital of \$66,473 and a current ratio (current assets divided by current liabilities) of 3.8. To protect our ability to service our substantial backlog while considering the longer lead times and unreliable delivery dates for critical components, during 2023 we increased inventory by \$1,023 or 2.5%. As of December 31, 2022, the Company had cash on hand of \$5,713, working capital of \$50,075 and a current ratio of 2.7.

As we look ahead, we believe our backlog, durable customer relationships, diversified end markets, new product initiatives, and ongoing actions to improve our gross margins and further strengthen our balance sheet position us to deliver high-quality, sustainable profitable growth.

#### **Results of Operations**

Year ended December 31, 2023 compared with the year ended December 31, 2022:

|   | Year ended December 31, |            | Increase/  |
|---|-------------------------|------------|------------|
|   | 2023                    | 2022       | (decrease) |
| Revenues:   |                         |            |            |
| Battery & Energy Products                                 | \$129,953               | \$119,995  | \$9,958    |
| Communications Systems                                    | 28,691                  | 11,845     | 16,846     |
| Total   | 158,644                 | 131,840    | 26,804     |
| Cost of products sold:                                    |                         |            |            |
| Battery & Energy Products                                 | 99,178                  | 93,841     | 5,337      |
| Communications Systems                                    | 20,266                  | 8,599      | 11,667     |
| Total   | 119,444                 | 102,440    | 17,004     |
| Gross profit:   |                         |            |            |
| Battery & Energy Products                                 | 30,775                  | 26,154     | 4,621      |
| Communications Systems                                    | 8,425                   | 3,246      | 5,179      |
| Total   | 39,200                  | 29,400     | 9,800      |
| Operating expenses  | 29,725                  | 29,271     | 454        |
| Operating income  | 9,475                   | 129        | 9,346      |
| Other expense, net  | 358                     | 575        | (217)      |
| Income (loss) before income taxes                         | 9,117                   | (446)      | 9,563      |
| Income tax provision (benefit)                            | 1,951                   | (326)      | 2,277      |
| Net income (loss)   | 7,166                   | (120)      | 7,286      |
| Net loss attributable to non-controlling interest         | (31)                    | (1)        | (30)       |
| Net income (loss) attributable to Ultralife Corporation   | \$7,197                 | (\$119)    | \$7,316    |
| Net income (loss) attributable to Ultralife common shares |                         |            |            |
| - basic   | \$0.44                  | (\$0.01)   | \$0.45     |
| Net income (loss) attributable to Ultralife common shares |                         |            |            |
| - diluted   | \$0.44                  | (\$0.01)   | \$0.45     |
|   |                         |            |            |
| Weighted average shares outstanding – basic               | 16,213,746              | 16,125,239 | 88,507     |
| Weighted average shares outstanding - diluted             | 16,226,407              | 16,125,239 | 101,168    |
|   |                         |            |            |

*Revenues*. Total revenues for the year ended December 31, 2023 amounted to \$158,644, an increase of \$26,804, or 20.3% from the \$131,840 reported for the year ended December 31, 2022.

Battery & Energy Products revenues increased \$9,958, or 8.3%, for the year ended December 31, 2023 as compared to the prior year. Commercial revenues of this business increased \$7,797 or 8.4% from 2022 and now comprise 77.6% of total segment sales versus 77.5% last year. The increase in our commercial business was due to medical sales of \$36,945 which increased \$9,624 or 35.2% due primarily to the high demand for our batteries used in ventilators, respirators, infusion pumps and other medical devices and the successful launch of our X-5 medical cart battery system, and oil and gas sales of \$40,562 which increased \$2,235 or 5.8% due to continuing high demand for our down-hole drilling batteries. Industrial and other commercial sales of \$23,335 decreased \$4,062 or 14.8% primarily due to timing of demand for 9-Volt and our new Thionyl Chloride and thin cell battery cells which are expected to rebound in future periods. Government and defense sales of this business increased \$2,161 or 8.0% from 2022 and now comprise 22.4% of total segment sales versus 22.5% last year. The increase primarily reflects higher U.S. demand resulting in year-over-growth of 9.3%. This was partially offset by a 2.3% decrease in sales to allied countries.

Communications Systems revenues increased \$16,846 or 142.2% for the year ended December 31, 2023 as compared to the prior year. The increase is primarily attributable to fulfilling long-lead time orders of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program.

Our order backlog at December 31, 2023 was \$103,535, a decrease of \$7,459 or 6.7% from the backlog at December 31, 2022 which was \$110,994. For our Battery & Energy Products business, the backlog increased \$3,365 or 3.8% to \$91,997 from \$88,632. The year-over-year increase is primarily driven by higher demand across the major markets that we serve including government and defense, medical, oil and gas and industrial. The 2023 year-end backlog is primarily related to

orders expected to ship in the next year and does not include future shipments under any of the indefinite delivery/indefinite quantity U.S. Department of Defense awards.

For our Communications Systems business, the backlog decreased \$10,824 or 48.4% to \$11,538 from \$22,362. The year-over-year decrease is primarily a result of fulfilling a July 2022 purchase order valued at approximately \$4,600 to supply a global defense prime with our Vehicle Amplifier-Adaptors for the U.S. Army's Leader radio program, a September 2022 contract valued at approximately \$7,500 to supply its integrated system of A-320 amplifiers and A-320HVA radio vehicle mounts to a major international defense contractor for an ongoing government/defense modernization program, and an October 2022 purchase order for \$5,500 to supply its vehicle communications systems to a global prime defense contractor for the U.S. Army. We expect additional orders for Leader Radio and Vehicle Amplifier-Adaptors in 2024. The 2023 year-end backlog is related to orders that are expected to ship throughout 2024.

Cost of Products Sold and Gross Profit. Cost of products sold for the year ended December 31, 2023 increased \$17,004 or 16.6% from the year ended December 31, 2022. Consolidated cost of products sold as a percentage of total revenue decreased from 77.7% for the year ended December 31, 2022 to 75.3% for the year ended December 31, 2023. Correspondingly, consolidated gross margin was 24.7% for the year ended December 31, 2023, compared with 22.3% for the year ended December 31, 2022. The 240-basis point improvement in gross margin is due primarily to better alignment of the timing of our customer price increases with the impact of cost inflation on raw materials and key components; extending the time horizon of our sales & operations planning process ("S&OP") with both customers and suppliers while upgrading our internal resources responsible for the process to reduce the negative impact of production line start-ups, shutdowns and changeovers due to irregular component availability and lead time extensions; concerted efforts to level-load production resulting in improved labor utilization efficiency and higher cost absorption; and improving our process for launching new products to reduce the cost and time of transitioning to high-volume manufacturing.

For our Battery & Energy Products segment, the cost of products sold increased \$5,337 or 5.7%, from the year ended December 31, 2022. Battery & Energy Products' gross profit for 2023 was \$30,775 or 23.7% of revenues, an increase of \$4,621 or 17.7% from gross profit of \$26,154, or 21.8% of revenues, for 2022. Battery & Energy Products' gross margin increased for the year ended December 31, 2023 by 190 basis points from the prior year to 23.7% primarily due to improved price realization as well as our concerted effort to level-load production more evenly resulting in labor utilization efficiencies and higher cost absorption.

For our Communications Systems segment, the cost of products sold increased by \$11,667 or 135.7% from the year ended December 31, 2022. Communications Systems' gross profit for the year ended December 31, 2023 was \$8,425 or 29.4% of revenues, an increase of \$5,179 or 159.6% from gross profit of \$3,246 or 27.4% of revenues for the year ended December 31, 2022. The 200 basis points increase in gross margin during 2022 to 29.4% is primarily due to higher factory throughput resulting in higher cost absorption.

Operating Expenses. Total operating expenses for the year ended December 31, 2023 increased \$454 or 1.6% from the year ended December 31, 2022. The increase in operating expense is primarily attributable to increased new product development investments, the recording of the \$100 deductible on our cybersecurity insurance policy for expenses associated with the January 2023 cyberattack and higher variable compensation, including officer and executive team bonuses and salesforce commissions, and insurance costs. Both periods reflected our continued tight control over discretionary spending.

Overall, operating expenses as a percentage of revenues was 18.7% for the year ended December 31, 2023 compared to 22.2% for the comparable 2022 period. Amortization expense associated with intangible assets related to our acquisitions decreased to \$889 for the year-ended December 31, 2023 (\$792 in selling, general and administrative expenses and \$97 in research and development costs) from \$1,282 for the year ended December 31, 2022 (\$1,185 in selling, general and administrative expenses and \$97 in research and development costs) as a result of the amortization periods of certain intangible assets associated with our acquisition of Excell in December 2021. Research and development costs were \$7,531 in 2023, an increase of \$450 or 6.4%, from \$7,081 reported in 2022. This increase is largely attributable to investments in new product development. Selling, general, and administrative expenses increased \$4 to \$22,194 for the year ended December 31, 2023 from \$22,190 for the year ended December 31, 2022. We continued tight control over discretionary spending across the Company.

Other Expense. Other expense totaled \$358 for the year ended December 31, 2023 compared to \$575 for the year ended December 31, 2022. Other expenses for 2023 includes an ERC of \$1,544 under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during the second quarter of 2023. Interest and financing expense increased \$1,065, or 112.0%, from \$951 for 2022 to \$2,016 for the comparable period in 2023. The increase is primarily due to the financing of our acquisition of Excell in December 2021, working capital funding

resulting from our January 2023 cyberattack and rising interest rates. Excluding the ERC gain in the 2023 period, miscellaneous income amounted to \$114 for the 2023 period compared to \$376 for the 2022 period, primarily attributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange rates.

Income Tax (Benefit) Provision. The income tax provision for 2023 was \$1,951, compared to an income tax benefit of \$326 for 2022. Our effective tax rate decreased to 21.4% for the 2023 period as compared to 73.1% for the 2022 period, primarily attributable to the year over year increase in income before income taxes. The income tax provision for 2023 is comprised of a \$650 current provision for taxes expected to be paid on income primarily in foreign jurisdictions, representing a cash-based effective tax rate of 7.1%, and a \$1,301 deferred tax provision which primarily represents non-cash charges for U.S. taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. For the comparable 2022 period, the income tax benefit was comprised of a \$636 current tax provision and a \$962 deferred tax benefit primarily for U.S. net operating losses and temporary tax differences expected to offset future U.S. taxable income.

Net income attributable to Ultralife Corporation was \$7,197 for 2023, as compared to a net loss of \$119 for 2022. Net income attributable to Ultralife Corporation common stockholders per diluted share was \$0.44 for 2023 and a net loss of \$0.01 for 2022. Adjusted EPS was \$0.52 per share on a diluted basis for 2023, compared to a \$0.07 loss per share for 2022. Adjusted EPS for 2023 excludes the provision for deferred income taxes of \$1,301 which represents non-cash charges primarily for U.S. income taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. Adjusted EPS for 2022 excludes the benefit for deferred income taxes of \$962 which represents a non-cash benefit primarily for U.S. net operating losses and temporary tax differences which are expected to offset future U.S. taxable income. See section "Adjusted EPS" on page 36 for a reconciliation of adjusted EPS to EPS.

Weighted average common shares outstanding used to compute diluted earnings per share increased from 16,125,239 for the 2022 period to 16,226,407 for the 2023 period, primarily due to the issuance of common stock upon the exercise of stock options and the vesting of restricted stock in 2023.

#### Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define adjusted EBITDA as net income (loss) attributable to Ultralife before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We also use adjusted EBITDA as a supplemental measure to review and assess our operating performance and to enhance comparability between periods. We also believe the use of adjusted EBITDA facilitates investors' understanding of operating performance from period to period by backing out potential differences caused by variations in such items as capital structures (affecting relative interest expense and stock-based compensation expense), the amortization of intangible assets acquired through our business acquisitions (affecting relative amortization expense and provision (benefit) for income taxes), the age and book value of facilities and equipment (affecting relative depreciation expense) and one-time charges/benefits relating to income taxes. We also present adjusted EBITDA from operations because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife, the most comparable financial measure under GAAP.

We use adjusted EBITDA in our decision-making processes relating to the operation of our business together with GAAP financial measures such as operating income. We believe that adjusted EBITDA permits a comparative assessment of our operating performance, relative to our performance based on our GAAP results, while isolating the effects of depreciation and amortization, which may vary from period to period without any correlation to underlying operating performance, and of stock-based compensation, which is a non-cash expense that varies widely among companies. We believe that by presenting adjusted EBITDA, we assist investors in gaining a better understanding of our business on a going forward basis. We provide information relating to our adjusted EBITDA so that securities analysts, investors and other interested parties have the same data that we employ in assessing our overall operations. We believe that trends in our adjusted EBITDA are a valuable indicator of our operating performance on a consolidated basis and of our ability to produce operating cash flows to fund working capital needs, to service debt obligations and to fund capital expenditures.

The term adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Our adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, adjusted EBITDA should not be considered in isolation or as a substitute for net income attributable to Ultralife or other consolidated statement of operations data prepared in accordance with GAAP. Some of these limitations include, but are not limited to, the following:

- a. Adjusted EBITDA does not reflect (1) our cash expenditures or future requirements for capital expenditures or contractual commitments; (2) changes in, or cash requirements for, our working capital needs; (3) the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; (4) income taxes or the cash requirements for any tax payments; and (5) all of the costs associated with operating our business;
- b. Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and adjusted EBITDA from continuing operations does not reflect any cash requirements for such replacements;
- c. While stock-based compensation is a component of cost of products sold and operating expenses, the impact on our consolidated financial statements compared to other companies can vary significantly due to such factors as assumed life of the stock-based awards and assumed volatility of our common stock; and
- d. Other companies may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

We compensate for these limitations by relying primarily on our GAAP results and using adjusted EBITDA only on a supplemental basis. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife.

|   | Year ended I | December 31, |
|---|--------------|--------------|
|   | 2023         | 2022         |
| Net income (loss) attributable to Ultralife Corporation | \$7,197      | (\$119)      |
| Adjustments:  |              |              |
| Interest expense, net                                   | 2,016        | 951          |
| Income tax provision (benefit)                          | 1,951        | (326)        |
| Depreciation expense                                    | 3,022        | 3,177        |
| Amortization of intangible assets                       | 889          | 1,282        |
| Stock-based compensation expense                        | 528          | 776          |
| Cyber insurance policy deductible                       | 100          | -            |
| Non-cash purchase accounting adjustments                | -            | 55           |
| Severance to former President & CEO                     | -            | 779          |
| Adjusted EBIDTA   | \$15,703     | \$6,575      |

#### Adjusted Earnings Per Share

In evaluating our business, we consider and use adjusted earnings per share ("EPS"), a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income (loss) attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

Adjusted EPS is calculated as follows for the periods presented:

|   | December 31, 2023 |                    |                         | December 31, 2022 |                    |                         |  |
|---|-------------------|--------------------|-------------------------|-------------------|--------------------|-------------------------|--|
|   | Amount            | Per basic<br>share | Per<br>diluted<br>share | Amount            | Per basic<br>share | Per<br>diluted<br>share |  |
| Net income (loss) attributable to Ultralife |                   |                    |                         |                   |                    |                         |  |
| Corporation                                 | \$2,873           | \$.18              | \$.17                   | (\$224)           | (\$.01)            | (\$.01)                 |  |
| Deferred tax provision (benefit)            | 56                | -                  | .01                     | (279)             | (.02)              | (.02)                   |  |
| Adjusted net income (loss)                  | \$2,929           | \$.18              | \$.18                   | (\$503)           | (\$.03)            | (\$.03)                 |  |
| Weighted average shares outstanding         |                   | 16,338             | 16,479                  |                   | 16,135             | 16,135                  |  |

| Year e | nded |
|--------|------|
|--------|------|

|   | December 31, 2023 |                    |                         | December 31, 2022 |                    |                         |  |
|---|-------------------|--------------------|-------------------------|-------------------|--------------------|-------------------------|--|
|   | Amount            | Per basic<br>share | Per<br>diluted<br>share | Amount            | Per basic<br>share | Per<br>diluted<br>share |  |
| Net income (loss) attributable to Ultralife |                   |                    |                         |                   |                    |                         |  |
| Corporation                                 | \$7,197           | \$.44              | \$.44                   | (\$119)           | (\$.01)            | (\$.01)                 |  |
| Deferred tax provision                      |                   |                    |                         |                   |                    |                         |  |
| (benefit)                                   | 1,301             | .08                | .08                     | (962)             | (.06)              | (.06)                   |  |
| Adjusted net income (loss)                  | \$8,498           | \$.52              | \$.52                   | (\$1,081)         | (\$.07)            | (\$.07)                 |  |
| Weighted average shares                     |                   |                    |                         |                   |                    |                         |  |
| outstanding                                 |                   | 16,214             | 16,226                  |                   | 16,125             | 16,125                  |  |

#### **Liquidity and Capital Resources**

Cash Flows and General Business Matters

As of December 31, 2023, cash totaled \$10,278 (including restricted cash of \$82), an increase of \$4,565 from the \$5,713 as of December 31, 2022, primarily attributable to our profitable operations in 2023.

During the year ended December 31, 2023, cash generated from operations was \$1,929, as compared to \$1,263 used in operations for the year ended December 31, 2022. For the 2023 period, cash provided by our operations was comprised of net income of \$7,166 plus non-cash items totaling \$5,804 for depreciation, amortization, stock-based compensation, and deferred taxes, partially offset by \$11,041 attributable to increased working capital. The increase in working capital was driven by \$3,890 attributable to increased accounts receivable reflecting the 23.4% year-over year increase in fourth quarter sales, \$3,098 attributable to increased prepaid expenses and other current assets including a \$1,544 receivable resulting from our ERC under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during the second quarter of 2023, \$943 attributable to increased inventory to secure key components for timely shipments in 2024, and \$3,110 attributable to decreased accounts payable and other liabilities reflective of the Company's improved cash flow in 2023.

Cash used in investing activities for the year ended December 31, 2023 was \$2,552 for capital expenditures, reflecting investments in equipment for new products transitioning to high-volume manufacturing, as compared to \$1,679 capital spending for the year ended December 31, 2022.

Cash provided by financing activities for the year ended December 31, 2023 was \$5,490, largely attributable to draws on our credit facility driven by advance purchases of certain critical raw materials, partially offset by principle payments on our term loan during the period, plus cash proceeds of \$1,248 on stock option exercises under our stock-based compensation plans.

We continue to have significant U.S. net operating loss carryforwards available to utilize as an offset to taxable income. As of December 31, 2023, none of our U.S. net operating loss carryforwards have expired. See Note 6 to the consolidated financial statements included in Item 8 of this Form 10-K for additional information.

Going forward, we expect positive operating cash flow and the availability under our credit facilities will be sufficient to meet our obligations for both financing and investing.

#### Commitments

As of December 31, 2023, the Company had \$6,167 outstanding principal on the Term Loan Facility, of which \$2,000 is due to be paid in 2024, and \$19,580 outstanding principal on the Revolving Credit Facility. The Company is in full compliance with its debt covenants under the Credit Facilities.

As of December 31, 2023, we had made commitments to purchase approximately \$890 of production machinery and equipment.

We typically offer standard warranties against product defects that range from ninety (90) days to three (3) years from the date of purchase. We also offer separately priced extended warranty contracts on certain Communications Systems products. Warranty costs expected to be incurred are estimated based on the Company's experience and recorded as costs of products sold. There is no assurance that future warranty claims will be consistent with our estimates, and in the event we experience a significant increase in warranty claims, there is no assurance that our reserves will be sufficient. Excessive warranty claims could have a material adverse effect on our business, financial condition and results of operations.

#### **Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements.

#### **Critical Accounting Policies and Estimates**

The above discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, included in Item 8 of this Form 10-K, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements requires the application of accounting policies and the use of estimates. The accounting policies most important to the preparation of the consolidated financial statements and estimates that require management's most difficult, subjective or complex judgments are described below.

#### Revenue Recognition:

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer's location, revenue is recognized on the date of delivery. For products shipped under vendor managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

Separately priced extended warranty contracts are offered on certain products. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet.

For customer contracts with an original expected duration of less than one year, we apply the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

#### Valuation of Inventory:

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out ("FIFO") method. Our inventory includes raw materials, work in process and finished goods. We recognize provisions for excess, obsolete or slow-moving inventory. Inherent in our estimates of net realizable value in determining inventory valuation are assumptions related to expectations of future demand for our products, product lifecycles, product support, technical obsolescence, regulatory requirements, and economic and market conditions. Estimates related to the valuation of inventory are susceptible to changes as the underlying assumptions are continuously evaluated. If our assumptions are adversely different from those estimated by management, inventory adjustments to reduce inventory values would result in an increase in inventory write-offs and a decrease in gross margins.

#### Goodwill and Other Indefinite Lived Intangible Assets:

Under the acquisition method of accounting, the total consideration transferred to consummate the acquisition is allocated to the identified tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values as of the acquisition date with the residual amount recorded to goodwill. We do not amortize goodwill and other intangible assets with indefinite lives, but instead evaluate these assets for impairment at least annually and whenever events or circumstances indicate that impairment may exist.

The annual impairment test for goodwill consists of a comparison of the estimated fair value for each reporting unit to which goodwill is assigned to the carrying value of the respective reporting unit. The annual impairment test for the other intangible assets with an indefinite life consists of a comparison of the estimated fair value of each asset to the carrying value of the respective asset. If the estimated fair value of a reporting unit or other indefinite-lived intangible asset exceeds its respective carrying value, the goodwill or indefinite-lived intangible asset is considered not impaired. If carrying value of a reporting unit or indefinite-lived intangible asset exceeds its estimated fair value, the excess carrying value of the respective goodwill or indefinite-lived intangible asset is recognized as an impairment loss.

We conducted our annual impairment test for goodwill and other indefinite-lived intangible assets as of October 1, 2023. We identified two (2) goodwill reporting units and five (5) indefinite-lived intangible assets. We performed a quantitative impairment assessment of each goodwill reporting unit and indefinite-lived intangible asset. The estimated fair value of each reporting unit was determined using a discounted cash flow model. The estimated fair value of each indefinite-lived intangible asset was determined using other income-based valuation models. Significant estimates and assumptions were used to estimate fair value, including our internal operating and cash flow forecasts, excess working capital requirements, and inputs to the weighted-average cost of capital used to discount future cash flows. Other key assumptions used to value the trademarks

and customer relationships included royalty rates and attrition rates, respectively. The significant estimates and assumptions used in these valuations are subject to judgment based on sources utilized and the assessment of risks related to our internal forecasts. Based on the results of our impairment test, and consideration of qualitative factors, no impairments were identified. There is a possibility that our goodwill and other intangible assets could be impaired in the future should there be a significant change in the significant estimates and assumptions used in our impairment assessment.

#### Impairment of Long-Lived Assets:

We assess our long-lived assets for impairment whenever events or circumstances indicate their carrying amounts may not be recoverable. This is accomplished by comparing the expected undiscounted future cash flows of the assets with the respective carrying amount as of the date of assessment. Should aggregate undiscounted future cash flows be less than the carrying value, a write-down would be required, measured as the difference between the carrying value and the fair value of the asset. Fair value is estimated either through the assistance of an independent valuation or as the present value of expected discounted future cash flows. The discount rate used by us in our evaluation is an industry-based weighted average cost of capital. If the expected undiscounted future cash flows exceed the respective carrying amount as of the date of assessment, no impairment charge is recognized.

#### **Income Taxes:**

We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Pursuant to ASC 740, a valuation allowance is recognized when the realizability of deferred tax assets is not more likely than not, based all available evidence, both positive and negative, weighted based on objective verifiability.

As of December 31, 2023, we concluded that it is more likely than not that our U.S. deferred tax assets will be fully realized based on management's assessment. In evaluating the realizability of our U.S. deferred tax assets, management considered all available evidence, both positive and negative, weighted based on objective verifiability. Our assessment also considered our ability to fully utilize before expiration our domestic net operating loss carryforwards, which expire 2031 thru 2035, and our general business tax credit carryforwards, which expire 2028 thru 2043. As of December 31, 2023, our domestic net operating loss carryforwards and general business tax credits were approximately \$27,200 and \$2,900, respectively.

As of December 31, 2023, for certain past operations in the U.K., we continue to report a valuation allowance for net operating loss carryforwards of approximately \$9,800, nearly all of which can be carried forward indefinitely. Management has concluded that utilization of the U.K. net operating losses may be limited due to the change in the past U.K. operation, and that they cannot currently be used to reduce taxable income of our other U.K. subsidiary, Accutronics Ltd. As of December 31, 2023, we have not recognized a valuation allowance against our other foreign deferred tax assets, including net operating loss carryforwards of \$1,300 which expire 2028 thru 2033, as we believe that it is more likely than not that they will be fully realized. We will continue to evaluate the realizability of our deferred tax assets in future periods.

#### Stock-Based Compensation:

We recognize compensation cost relating to share-based payment transactions in our financial statements. The cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity award). We calculate implied volatility for stock options based on an average of historical volatility over the expected life of the awards. The computation of expected term is determined based on historical experience of similar awards, giving consideration to the contractual terms of the awards and the vesting period. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury yield in effect at the time of grant. Our awards are generally valued using the Black-Scholes method. If required, our market-based awards are valued using a Monte Carlo simulation.

#### **Business Combinations:**

We account for businesses acquired using the acquisition method of accounting. Under this method, all acquisition-related costs are expensed as incurred, and the total consideration transferred to consummate the acquisition is allocated to the identified tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values as of the acquisition date with the residual amount recorded to goodwill. As part of this process, we identify and attribute values and estimated lives to property and equipment and intangible assets acquired. These determinations involve significant estimates and assumptions, including those with respect to future cash flows, discount rates and asset lives, and therefore require considerable judgment. These determinations affect the amount of depreciation and amortization expense recognized in future

periods. The results of operations of acquired businesses are included in the consolidated statements of income and comprehensive income beginning on the respective acquisition date.

#### Warranties:

We typically offer standard warranties against product defects that range from ninety (90) days to three (3) years from the date of purchase. We also offer separately priced extended warranty contracts on certain products. Warranty costs expected to be incurred are estimated based on the Company's experience and recorded as costs of products sold. Standard warranty costs are recognized upon product sale. Extended warranty costs are recognized over the term of the contract. Provision for warranty costs is recorded in accrued expenses and other current liabilities and other noncurrent liabilities on our consolidated balance sheet based on the duration of the warranty.

#### Environmental Issues:

Environmental expenditures, if any, that relate to current operations, are generally expensed. Remediation costs that relate to an existing condition caused by past operations are accrued when it is probable that these costs will be incurred and can be reasonably estimated.

#### ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide this information.

#### ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements and schedules listed in Item 15(a)(1) are included in this Report beginning on page 44.

| Report of Independent Registered Public Accounting Firm   | <u>Page</u><br>42 |
|---|-------------------|
| Consolidated Financial Statements:  |                   |
| Consolidated Balance Sheets as of December 31, 2023 and 2022  | 44                |
| Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the years ended December 31, 2023 and 2022 | 45                |
| Consolidated Statements of Changes in Stockholders' Equity for the years ended December 31, 2023 and 2022               | 46                |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022                                    | 47                |
| Notes to Consolidated Financial Statements  | 48                |

#### Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Ultralife Corporation

#### **Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Ultralife Corporation and its subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of income (loss) and comprehensive income (loss), changes in stockholders' equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

#### **Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

#### **Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

#### Estimate for excess, obsolete, and slow-moving inventory reserve

As discussed in Notes 1 and 3 to the financial statements, inventories are stated at the lower of cost or net realizable value with cost determined under the first-in, first-out method. The Company records provisions for excess, obsolete, and slow-moving inventory based on changes in customer demand, technology developments or other economic factors. The excess, obsolete, and slow-moving inventory reserve serves to reduce the Company's inventory balance through a charge to cost of products sold.

The Company's reserve for excess, obsolete, and slow-moving inventory is based upon assumptions related to expectations of future demand, product lifecycles, product support, technical obsolescence, regulatory requirements, and economic and market conditions. If the actual realization of excess, obsolete, and slow-moving inventory does not meet the Company's assumptions, future inventory adjustments would result in a decrease in gross margin. Due to the magnitude of the inventory and the subjectivity involved in estimating the reserve, we identified the evaluation of the reserve as a critical audit matter, which required a high degree of auditor judgment.

Addressing the matter involved performing subjective procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. The primary procedures we performed include obtaining an understanding

of the process and assumptions used by management to develop the reserve for excess, obsolete, and slow-moving inventory; testing management's calculation of the reserve for excess, obsolete, and slow-moving inventory by: testing the completeness and accuracy of the source information used, testing the mathematical accuracy of management's calculations, evaluating the reasonableness and consistency of methodology and assumptions applied by management, and performing a retrospective review of the prior-year estimates used to identify potential bias of management judgements.

#### **Goodwill Impairment Analysis**

As discussed in Notes 1 and 3 to the financial statements, the Company performs its goodwill impairment test on an annual basis as of October 1st or whenever events and changes in circumstances indicate that the carrying value of a reporting unit might exceed its fair value. For each reporting unit the Company performed a quantitative test, which compares the fair value of the reporting unit to the carrying value of the respective reporting unit. The Company has identified two goodwill reporting units.

Management determines fair value of the respective reporting units using a discounted cash flow model. Significant estimates and judgements used in this model include internal operating and cash flow forecasts, excess working capital requirements, and inputs to the weighted-average cost of capital used to discount future cash flows. Future revenue and operating cash flow forecasts, the development of the weighted average cost of capital used to discount the future cash flows, and excess working capital requirements are subject to judgment based on sources utilized and the assessment of risks related to the cash flows. Due to the subjectivity involved with the assumptions used to determine the fair value of the reporting units, we identified the goodwill impairment test as a critical audit matter, which required a high degree of auditor judgment.

Addressing the matter involved performing subjective procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. The primary procedures we performed include: obtaining an understanding of the process and assumptions used by management to perform the impairment test; and testing management's impairment calculation by: testing the completeness and accuracy of the source information used, testing the mathematical accuracy of management's calculations, evaluating the reasonableness and consistency of methodology and assumptions applied by management, performing a retrospective review of the prior-year estimates used to identify potential bias of management judgements, and verifying certain third party data used by the Company in building their assumptions. Professionals with specialized skills and knowledge were used to assist in evaluating certain methodologies and assumptions used in the model and performing sensitivity analysis on various inputs.

/s/ Freed Maxick CPAs, P.C.

We have served as the Company's auditor since 2016.

Rochester, NY March 21, 2024

#### ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)

#### ASSETS

| Trade accounts receivable, net of allowance for expected credit losses of \$300 and \$303, respectively  Inventories, net  Prepaid expenses and other current assets  Total current assets  Property, plant and equipment, net  Goodwill  Other intangible assets, net  Deferred income taxes, net  Other noncurrent assets  Total assets  **Total assets**  **LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities:  Accounts payable  Current portion of long-term debt   | December 31. 2023  10,278 81,761 42,215 5,949  00,203 21,117 87,571 15,107 10,567 | \$5,713<br>27,779<br>41,192<br>4,304<br>78,988<br>21,716 |
|--|---|--|
| Cash Trade accounts receivable, net of allowance for expected credit losses of \$300 and \$303, respectively Inventories, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets Total assets  Total assets  S  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | 10,278<br>81,761<br>42,215<br>5,949<br>90,203<br>21,117<br>87,571                 | \$5,713<br>27,779<br>41,192<br>4,304<br>78,988<br>21,716 |
| Cash Trade accounts receivable, net of allowance for expected credit losses of \$300 and \$303, respectively Inventories, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets Total assets  Total assets  S  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | 81,761<br>42,215<br>5,949<br>90,203<br>21,117<br>87,571<br>15,107                 | 27,779<br>41,192<br>4,304<br>78,988<br>21,716            |
| Trade accounts receivable, net of allowance for expected credit losses of \$300 and \$303, respectively Inventories, net Prepaid expenses and other current assets  Total current assets  Property, plant and equipment, net Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets  Total assets  S  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | 81,761<br>42,215<br>5,949<br>90,203<br>21,117<br>87,571<br>15,107                 | 27,779<br>41,192<br>4,304<br>78,988<br>21,716            |
| Inventories, net Prepaid expenses and other current assets  Total current assets  Property, plant and equipment, net  Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | 5,949<br>00,203<br>21,117<br>37,571<br>15,107                                     | 41,192<br>4,304<br>78,988<br>21,716                      |
| Prepaid expenses and other current assets  Total current assets  Property, plant and equipment, net  Goodwill  Other intangible assets, net  Deferred income taxes, net  Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities:  Accounts payable  Current portion of long-term debt  | 00,203<br>21,117<br>37,571<br>15,107  | 4,304<br>78,988<br>21,716                                |
| Total current assets  Property, plant and equipment, net  Goodwill  Other intangible assets, net  Deferred income taxes, net  Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities:  Accounts payable  Current portion of long-term debt   | 21,117<br>37,571<br>15,107  | 78,988<br>21,716   |
| Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | 37,571<br>15,107  | 21,716   |
| Goodwill Other intangible assets, net Deferred income taxes, net Other noncurrent assets Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt   | 15,107  |  |
| Deferred income taxes, net Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities: Accounts payable Current portion of long-term debt  | Ť.  | 37,428   |
| Deferred income taxes, net  Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities:  Accounts payable  Current portion of long-term debt   | 0,567   | 15,921   |
| Other noncurrent assets  Total assets  LIABILITIES AND STOCKHOLDERS' EQUITY  Current Liabilities:  Accounts payable  Current portion of long-term debt   |   | 12,069   |
| Current Liabilities:  Accounts payable Current portion of long-term debt   | 3,711   | 2,308  |
| Current Liabilities:  Accounts payable  Current portion of long-term debt  | 178,276   | \$168,430  |
| Accounts payable  Current portion of long-term debt  |   |  |
| Current portion of long-term debt  |   |  |
| Current portion of long-term deof  | 11,336  | \$16,074   |
| Accompany at the company of the comp | 2,000   | 2,000  |
| Accraca compensation and relaced ocherits  | 3,115   | 2,890  |
| Accruce expenses and other current habitutes   | 7,279   | 7,949  |
| Total cultent natimics   | 23,730  | 28,913   |
| Long-term debt, net  | 23,624  | 19,310   |
| Deterred income taxes  | 1,714   | 1,917  |
| Other noncurrent liabilities   | 3,781   | 1,887  |
| Total liabilities  | 52,849  | 52,027   |
| Commitments and contingencies (Note 4)   |   |  |
| Stockholders' Equity:  |   |  |
| Preferred stock – par value \$.10 per share; authorized 1,000,000 shares; none issued  | -   | -  |
| Common stock – par value \$.10 per share; authorized 40,000,000 shares;  |   |  |
| issued – 20,783,607 shares and 20,570,710 shares, respectively;  |   |  |
| outstanding - 16,347,493 shares and 16,135,358 shares, respectively  | 2,078   | 2,057  |
| Capital in excess of par value   | 89,160  | 187,405  |
| Accumulated deficit  | 40,754)   | (47,951)   |
| Accumulated other comprehensive loss   | (3,660)   | (3,750)  |
|  | 21,492)   | (21,484)   |
|  |   | 116,277  |
| Non-controlling interest   | 25,332  |  |
| Total stockholders' equity1  | 95  | 126  |
| Total liabilities and stockholders' equity   |   | 126<br>116,403   |

# ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (Dollars in Thousands, Except Per Share Amounts)

| Revenues         \$158,644         \$131,840           Cost of products sold         119,444         102,440           Gross profit         39,200         29,400           Operating expenses:           Research and development         7,531         7,081           Selling, general and administrative         22,194         22,190           Total operating expenses         29,725         29,271           Other expense (income):           Interest and financing expense         2,016         951           Miscellaneous income         (1,658)         (376)           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income (loss) peror income taxes         9,117         (446)           Income tax provision (benefit)         1,951         (326)           Net income (loss)         7,166         (120)           Net income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss)         2         (5,2216)           Foreign currency translation adjustments         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation common stockholders - Basic  |   | Year ended December 31, |           |  |
|--|---|-------------------------|-----------|--|
| Cost of products sold<br>Gross profit         119,444         102,440           Gross profit         39,200         29,400           Operating expenses:             Research and development         7,531         7,081           Selling, general and administrative         22,194         22,190           Total operating expenses         29,725         29,271           Operating income         9,475         129           Other expense (income):             Interest and financing expense         2,016         951           Miscellancous income         (1,658)         376           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income (loss) before income taxes         9,117         (446)           Income (loss)         7,166         (120)           Net income (loss)         7,166         (120)           Net income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss)          (5,216)           Foreign currency translation adjustments         90         (2,097)           Comprehensive income (loss) attributable to Ultrali  |   |                         |           |  |
| Gross profit         39,200         29,400           Operating expenses:   | Revenues  | \$158,644               | \$131,840 |  |
| Operating expenses:           Research and development         7,531         7,081           Selling, general and administrative         22,194         22,190           Total operating expenses         29,725         29,271           Operating income         9,475         129           Other expense (income):   | Cost of products sold   | 119,444                 | 102,440   |  |
| Research and development         7,531         7,081           Selling, general and administrative         22,194         22,190           Total operating expenses         29,725         29,271           Operating income         9,475         129           Other expense (income):         Interest and financing expense         2,016         951           Miscellaneous income         (1,658)         (376)           Total other expense, net         358         375           Income (loss) before income taxes         9,117         (446)           Income tax provision (benefit)         1,951         (326)           Net income (loss)         7,166         (120)           Net loss attributable to non-controlling interest         (31)         (1)           Income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss):         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation         \$7,287         (\$2,216)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic         \$.44         (\$.01)           Weighted average shares outstanding – Basic         16,214         16,125  | -   | 39,200                  | 29,400    |  |
| Selling, general and administrative   22,194   22,190     Total operating expenses   29,725   29,271     Operating income   9,475   129     Other expense (income):  |   |                         |           |  |
| Total operating expenses         29,275         29,271           Operating income         9,475         129           Other expense (income):         300         300           Interest and financing expense         2,016         951           Miscellaneous income         (1,658)         376           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income (loss)         7,166         (120)           Net income (loss)         7,166         (120)           Net loss attributable to non-controlling interest         (31)         (1)           Income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss):         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation         \$7,287         (\$2,216)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic         \$.44         (\$.01)           Weighted average shares outstanding – Basic         16,214         16,212  | *   | 7,531                   | 7,081     |  |
| Operating income         9,475         129           Other expense (income):         Interest and financing expense         2,016         951           Miscellaneous income         (1,658)         (376)           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income tax provision (benefit)         1,951         (326)           Net income (loss)         7,166         (120)           Net loss attributable to non-controlling interest         (31)         (1)           Income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss):         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation         \$7,287         (\$2,216)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic         \$.44         (\$.01)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted         \$.44         (\$.01)  |   |                         | 22,190    |  |
| Other expense (income):           Interest and financing expense         2,016         951           Miscellaneous income         (1,658)         (376)           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income tax provision (benefit)         1,951         (326)           Net income (loss)         7,166         (120)           Net loss attributable to non-controlling interest         (31)         (1)           Income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss):         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation         \$7,287         (\$2,216)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic         \$.44         (\$.01)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted         \$.44         (\$.01)   | Total operating expenses  | 29,725                  | 29,271    |  |
| Interest and financing expense   2,016   951     Miscellaneous income   (1,658)   (376)     Total other expense, net   358   575     Income (loss) before income taxes   9,117   (446)     Income (loss) before income taxes   9,117   (326)     Income (loss)   7,166   (120)     Net income (loss)   7,166   (120)     Net loss attributable to non-controlling interest   (31)   (1)     Income (loss) attributable to Ultralife Corporation   7,197   (119)     Other comprehensive income (loss):   Foreign currency translation adjustments   90   (2,097)     Comprehensive income (loss) attributable to Ultralife Corporation   \$7,287   (\$2,216)     Net income (loss) per share attributable to Ultralife Corporation   \$.44   (\$.01)     Net income (loss) per share attributable to Ultralife Corporation common stockholders - Basic   \$.44   (\$.01)   | Operating income  | 9,475                   | 129       |  |
| Miscellaneous income         (1,658)         (376)           Total other expense, net         358         575           Income (loss) before income taxes         9,117         (446)           Income tax provision (benefit)         1,951         (326)           Net income (loss)         7,166         (120)           Net loss attributable to non-controlling interest         (31)         (1)           Income (loss) attributable to Ultralife Corporation         7,197         (119)           Other comprehensive income (loss):         90         (2,097)           Comprehensive income (loss) attributable to Ultralife Corporation         \$7,287         (\$2,216)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic         \$.44         (\$.01)           Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted         \$.44         (\$.01)  | Other expense (income):   |                         |           |  |
| Total other expense, net  358 575  Income (loss) before income taxes Income (loss) before income taxes Income (loss) before income taxes Income (loss)  Net income (loss)  Net income (loss)  Net income (loss)  Total other expense, net  358 575  (446) (120)  Net income (loss)  7,166 (120)  Net income (loss)  Total other expense, net  (31) (1)  Income (loss) attributable to non-controlling interest (31) (1)  Income (loss) attributable to Ultralife Corporation Total other comprehensive income (loss):  Foreign currency translation adjustments 90 (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation Social components of the components of | Interest and financing expense                                    | 2,016                   | 951       |  |
| Income (loss) before income taxes Income (loss) before income taxes Income (loss) per share attributable to Ultralife Corporation Common stockholders – Diluted  Political part of the part of the political part of the pol | Miscellaneous income  | (1,658)                 |           |  |
| Income tax provision (benefit)  Net income (loss)  7,166  (120)  Net loss attributable to non-controlling interest  (31)  (1)  Income (loss) attributable to Ultralife Corporation  7,197  (119)  Other comprehensive income (loss): Foreign currency translation adjustments  90  (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation  \$7,287  (\$2,216)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic  Net income (loss) per share attributable to Ultralife Corporation  \$44  (\$.01)  Weighted average shares outstanding – Basic  | Total other expense, net  | 358                     | 575       |  |
| Net income (loss)       7,166       (120)         Net loss attributable to non-controlling interest       (31)       (1)         Income (loss) attributable to Ultralife Corporation       7,197       (119)         Other comprehensive income (loss):       390       (2,097)         Foreign currency translation adjustments       90       (2,097)         Comprehensive income (loss) attributable to Ultralife Corporation       \$7,287       (\$2,216)         Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic       \$.44       (\$.01)         Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted       \$.44       (\$.01)         Weighted average shares outstanding – Basic       16,214       16,125  | Income (loss) before income taxes                                 | 9,117                   | (446)     |  |
| Net loss attributable to non-controlling interest  (31) (1)  Income (loss) attributable to Ultralife Corporation  7,197 (119)  Other comprehensive income (loss): Foreign currency translation adjustments  90 (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation \$7,287 (\$2,216)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic  Net income (loss) per share attributable to Ultralife Corporation \$44 (\$.01)  Weighted average shares outstanding – Basic  16,214 16,125   | Income tax provision (benefit)                                    | 1,951                   | (326)     |  |
| Income (loss) attributable to Ultralife Corporation 7,197 (119)  Other comprehensive income (loss): Foreign currency translation adjustments 90 (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation \$7,287 (\$2,216)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic \$.44 (\$.01)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted \$.44 (\$.01)   | Net income (loss)   | 7,166                   | (120)     |  |
| Other comprehensive income (loss): Foreign currency translation adjustments  90 (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted  S.44 (\$.01)  Weighted average shares outstanding – Basic  16,214 16,125   | Net loss attributable to non-controlling interest                 | (31)                    | (1)       |  |
| Foreign currency translation adjustments 90 (2,097)  Comprehensive income (loss) attributable to Ultralife Corporation \$7,287 (\$2,216)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic \$.44 (\$.01)  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted \$.44 (\$.01)  Weighted average shares outstanding – Basic 16,214 16,125  | Income (loss) attributable to Ultralife Corporation               | 7,197                   | (119)     |  |
| Comprehensive income (loss) attributable to Ultralife Corporation  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted  S.44  (\$.01)  Weighted average shares outstanding – Basic  16,214  16,125  | Other comprehensive income (loss):                                |                         |           |  |
| Net income (loss) per share attributable to Ultralife Corporation common stockholders – Basic  Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted  \$.44 (\$.01)  Weighted average shares outstanding – Basic  16,214 16,125  | Foreign currency translation adjustments                          | 90                      | (2,097)   |  |
| Net income (loss) per share attributable to Ultralife Corporation common stockholders – Diluted  S.44  (\$.01)  Weighted average shares outstanding – Basic  16,214  16,125  | Comprehensive income (loss) attributable to Ultralife Corporation | \$7,287                 | (\$2,216) |  |
| common stockholders – Diluted 5.44 (5.01)  Weighted average shares outstanding – Basic 16,214 16,125   |   | \$.44                   | (\$.01)   |  |
|  |   | \$.44                   | (\$.01)   |  |
| Weighted average shares outstanding – Diluted 16,226 16,125  | Weighted average shares outstanding – Basic                       | 16,214                  | 16,125    |  |
|  | Weighted average shares outstanding – Diluted                     | 16,226                  | 16,125    |  |

## ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Dollars in Thousands)

|   | Common           | stock   |                                |   |                     |                |                                 |                |
|---|------------------|---------|--------------------------------|---|---------------------|----------------|---------------------------------|----------------|
|   | Number of shares | Amount  | Capital in excess of par value | Accumulated other comprehensive income (loss) | Accumulated deficit | Treasury stock | Non-<br>controlling<br>interest | Total          |
| Balance –<br>December 31, 2021  | 20,522,427       | \$2,052 | \$186,518                      | \$(1,653)                                     | \$(47,832)          | \$(21,469)     | \$127                           | \$117,743      |
| Net loss<br>Stock option exercises<br>Stock-based compensation -          | 39,119           | 4       | 112                            |   | (119)               | (7)            | (1)                             | (120)<br>109   |
| stock-based compensation -<br>stock-based compensation -                  |                  |         | 761                            |   |                     |                |                                 | 761            |
| restricted stock Vesting of restricted stock Foreign currency translation | 9,164            | 1       | 15<br>(1)                      |   |                     | (8)            |                                 | 15<br>(8)      |
| adjustments   |                  |         |                                | (2,097)                                       |                     |                |                                 | (2,097)        |
| Balance –<br>December 31, 2022  | 20,570,710       | \$2,057 | \$187,405                      | \$(3,750)                                     | \$(47,951)          | \$(21,484)     | \$126                           | \$116,403      |
| Net income<br>Stock option exercises                                      | 210,397          | 21      | 1,227                          |   | 7,197               | -              | (31)                            | 7,166<br>1,248 |
| Stock-based compensation -<br>stock options<br>Stock-based compensation - |                  |         | 522                            |   |                     |                |                                 | 522            |
| restricted stock Vesting of restricted stock                              | 2,500            | -       | 6 -                            |   |                     | (8)            |                                 | 6<br>(8)       |
| Foreign currency translation adjustments                                  |                  |         |                                | 90  |                     |                |                                 | 90             |
| Balance –<br>December 31, 2023  | 20,783,607       | \$2,078 | \$189,160                      | \$(3,660)                                     | \$(40,754)          | \$(21,492)     | \$95                            | \$125,427      |

#### ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands)

|  | Year ended December 31 |         |
|--|------------------------|---------|
|  | 2023                   | 2022    |
| OPERATING ACTIVITIES:  |                        |         |
| Net income (loss)  | \$7,166                | (\$120) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |                        |         |
| Depreciation   | 3,022                  | 3,177   |
| Amortization of intangible assets  | 889                    | 1,282   |
| Amortization of financing fees   | 64                     | 36      |
| Stock-based compensation   | 528                    | 776     |
| Deferred income tax expense (benefit)  | 1,301                  | (962)   |
| Changes in operating assets and liabilities:   |                        |         |
| Accounts receivable  | (3,890)                | (7,881) |
| Inventories  | (943)                  | (8,747) |
| Prepaid expenses and other assets  | (3,098)                | 911     |
| Income taxes receivable and payable  | (142)                  | 180     |
| Accounts payable and other liabilities   | (2,968)                | 10,085  |
| Net cash provided by (used in) operating activities  | 1,929                  | (1,263) |
| INVESTING ACTIVITIES:  |                        |         |
| Purchases of property, plant and equipment   | (2,552)                | (1,679) |
| Net cash used in investing activities  | (2,552)                | (1,679) |
| FINANCING ACTIVITIES:  |                        |         |
| Borrowings on credit facility  | 7,250                  | 3,350   |
| Payment of credit facilities   | (3,000)                | (2,833) |
| Proceeds from exercise of stock options  | 1,248                  | 116     |
| Payment of debt issuance costs   | <del>-</del>           | (100)   |
| Tax withholdings on stock-based awards   | (8)                    | (15)    |
| Net cash provided by financing activities  | 5,490                  | 518     |
| Effect of exchange rate changes on cash  | (302)                  | (276)   |
| INCREASE (DECREASE) IN CASH  | 4,565                  | (2,700) |
| Cash - Beginning of year   | 5,713                  | 8,413   |
| Cash - End of year   | \$10,278               | \$5,713 |
| Supplemental cash flow information:  |                        |         |
| Construction in process in accounts payable  | \$347                  | \$339   |
| Income taxes paid  | \$769                  | \$354   |
| Interest paid  | \$1,961                | \$930   |

## ULTRALIFE CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Thousands, Except Per Share Amounts)

#### Note 1 - Summary of Operations and Significant Accounting Policies

#### a. Description of Business

As used in this annual report, unless otherwise indicated, the terms the "Company", "we", "our" and "us" refer to Ultralife Corporation ("Ultralife") and its wholly owned subsidiaries ABLE New Energy Co., Limited and its wholly owned subsidiary ABLE New Energy Co., Ltd (collectively "ABLE"); Ultralife UK LTD and its wholly owned subsidiary Accutronics Ltd (collectively "Accutronics"); Ultralife Batteries (UK) Ltd.; Southwest Electronic Energy Corporation and its wholly owned subsidiary, CLB, Inc. (collectively "SWE"); Ultralife Excell Holding Corp. ("UEHC") and its wholly owned subsidiary Excell Battery Corporation USA (collectively "Excell USA"), Ultralife Canada Holding Corp (wholly owned by UEHC, "UCHC") and its wholly owned subsidiary Excell Battery Canada ULC ("Excell Canada," and collectively "Excell"); and its majority-owned joint venture Ultralife Batteries India Private Limited ("Ultralife India").

We offer products and services ranging from power solutions to communications and electronics systems. Through our engineering and collaborative approach to problem solving, we serve government, defense and commercial customers across the globe. We design, manufacture, install and maintain power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems. We sell our products worldwide through a variety of trade channels, including original equipment manufacturers ("OEMs"), industrial and defense supply distributors, and directly to U.S. and international defense departments.

#### b. Principles of Consolidation

The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and include the accounts of Ultralife Corporation and its wholly owned subsidiaries ABLE, Accutronics, Ultralife Batteries (UK) Ltd., SWE, Excell, and its majority-owned joint venture Ultralife India. Intercompany accounts and transactions have been eliminated in consolidation.

#### c. Management's Use of Judgment and Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at year end and the reported amounts of revenues and expenses during the reporting period. Key areas affected by estimates include: (a) carrying value of goodwill and intangible assets; (b) reserves for excess and obsolete inventory, deferred tax assets, warranties, and bad debts; (c) valuation of assets acquired and liabilities assumed in business combinations; (d) various expense accruals; and (e) stock-based compensation. Our actual results could differ from these estimates.

#### d. Reclassifications

Certain items previously reported in specific financial statement captions are reclassified to conform to the current presentation. There were no material reclassifications for the years ended December 31, 2023 and 2022.

#### e. Cash

Our cash balances may at times exceed federally insured limits. We have not experienced any losses in these accounts and believe we are not exposed to any significant risk with respect to cash.

#### f. Accounts Receivable and Allowance for Expected Credit Losses

We extend credit to our customers in the normal course of business. We perform ongoing credit evaluations and generally do not require collateral. Payment terms are generally thirty (30) to sixty (60) days. Trade accounts receivable are recorded at their invoiced amounts, net of allowance for expected credit losses. We evaluate the adequacy of our allowance for doubtful accounts quarterly. Accounts outstanding for longer than contractual payment terms are considered past due and are reviewed for collectability. We maintain reserves for potential credit losses based upon our historical experience, aging profile and general market conditions. Receivable balances are written off when collection is deemed unlikely.

#### g. Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined under the first-in, first-out (FIFO) method. We record provisions for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors.

#### h. Property, Plant and Equipment

Property, plant and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives. Estimated useful lives are as follows (in years):

| Buildings                      | 10 - 40 |
|--------------------------------|---------|
| Machinery and Equipment        | 5 - 10  |
| Furniture and Fixtures         | 3 - 10  |
| Computer Hardware and Software | 2 - 5   |

Leasehold Improvements Lesser of useful life or lease term

Betterments, renewals and extraordinary repairs that extend the life of the assets are capitalized. Other repairs and maintenance costs are expensed when incurred. When disposed, the cost and accumulated depreciation applicable to assets retired are removed from the accounts and the gain or loss on disposition is recognized in operating income.

#### i. Long-Lived Assets, Goodwill and Intangibles

We assess our long-lived assets for impairment whenever events or circumstances indicate that their carrying amounts may not be recoverable. For property, plant and equipment and amortizable intangible assets, this is accomplished by comparing the expected undiscounted future cash flows of the assets with the respective carrying amount as of the date of assessment. If the expected undiscounted future cash flows exceed the respective carrying amount as of the date of assessment, no impairment is recognized. Should aggregate undiscounted future cash flows be less than the carrying value, a write-down would be required, measured as the difference between the carrying value and the fair value of the asset. Fair value is estimated as the present value of expected discounted future cash flows. The discount rate used in our evaluation is an industry-based weighted average cost of capital.

Under the acquisition method of accounting, the purchase price paid, or the total consideration transferred, to consummate the acquisition is allocated to the identified tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values as of the acquisition date with the residual amount recorded to goodwill. We do not amortize goodwill and intangible assets with indefinite lives, but instead evaluate these assets for impairment at least annually, or whenever events or circumstances indicate that impairment may exist. We amortize intangible assets that have definite lives so that the economic benefits of the intangible assets are being recognized over their estimated useful life.

The annual impairment test for goodwill consists of a comparison of the estimated fair value for each reporting unit to which goodwill is assigned to the carrying value of the respective reporting unit. The annual impairment test for other indefinite-lived intangible assets consists of a comparison of the estimated fair value of each asset to the carrying value of the respective asset. If the estimated fair value of a reporting unit or other indefinite-lived intangible asset exceeds its respective carrying value, the goodwill or indefinite-lived intangible asset is considered not impaired. If carrying value of a reporting unit or indefinite-lived intangible asset exceeds its estimated fair value, the excess carrying value of the respective goodwill or indefinite-lived intangible asset is recognized as an impairment loss.

#### j. Translation of Foreign Currency

The financial statements of our foreign subsidiaries are translated from the functional currency into U.S. dollar equivalents, with translation adjustments recorded as the sole component of accumulated other comprehensive income (loss). Exchange gains and losses related to foreign currency transactions and balances denominated in currencies other than the functional currency are recognized in net income (loss).

#### k. Revenue Recognition

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer's location, revenue is recognized on the date of delivery. For products shipped under vendor managed inventory

arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet.

As of December 31, 2023, there was deferred revenue on extended warranty contracts of \$1,407, comprised of \$287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and \$1,120 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

As of December 31, 2023 and 2022, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

#### 1. Warranty Reserves

We typically offer standard warranties against product defects that range from ninety (90) days to three (3) years from the date of purchase. We also offer separately priced extended warranty contracts on certain products. Warranty costs expected to be incurred are estimated based on the Company's experience and recorded as costs of products sold. Standard warranty costs are recognized upon product sale. Extended warranty costs are recognized over the term of the contract. Provision for warranty costs is recorded in accrued expenses and other current liabilities and other noncurrent liabilities on our consolidated balance sheet based on the duration of the warranty.

#### m. Shipping and Handling Costs

Costs incurred by us related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue.

#### n. Sales Commissions

Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of December 31, 2023 and 2022.

#### o. Research and Development

Research and development expenditures are charged to operations as incurred. The majority of research and development expenses pertain to salaries and benefits, developmental supplies, depreciation and other contracted services. For the years ended December 31, 2023 and 2022, we expended \$8,587 and \$7,874, respectively, on research and development, including costs of \$1,056 and \$793, respectively, on customer sponsored research and development activities, which are included in cost of products sold.

#### p. Environmental Costs

Environmental expenditures that relate to current operations are expensed. Remediation costs that relate to an existing condition caused by past operations are accrued when it is probable that these costs will be incurred and can be reasonably estimated.

#### q. Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Pursuant to ASC 740, a valuation allowance is recognized when the realizability of deferred tax assets is not more likely than not, based all available evidence, both positive and negative, weighted based on objective verifiability.

#### r. Concentration Related to Customers and Suppliers

One of our customers, a large global defense primary contractor, comprised 15% and 17% of our total consolidated revenues for 2023 and 2022, respectively. Revenues for this customer represented 18% and 19% of our total Battery & Energy Products segment revenues for 2023 and 2022, respectively. There were no other customers that comprised greater than 10% of our total consolidated revenues during these years.

#### s. Fair Value Measurements and Disclosures

Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1: Quoted prices in active markets for identical assets or liabilities.
- Level 2: Observable inputs, other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or that we corroborate with observable market data for substantially the full term of the related assets or liabilities.
- Level 3: Unobservable inputs supported by little or no market activity that are significant to the fair value of the assets or liabilities.

The fair value of financial instruments approximated their carrying values at December 31, 2023 and 2022. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments. The carrying value of long-term debt approximates fair value, as the variable interest rates approximate current market rates.

#### t. Earnings Per Share

Basic earnings per share ("EPS") is computed by dividing net income (loss) attributable to Ultralife Corporation by the weighted average shares of common stock outstanding for the period. Diluted EPS reflects the assumed exercise and conversion of dilutive outstanding stock options and unvested restricted stock, if any, applying the treasury stock method.

For the year ended December 31, 2023, there were 111,247 outstanding stock options and 4,029 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 12,661 potential common shares included in the calculation of diluted EPS. There were 1,139,348 outstanding stock options for the year ended December 31, 2023 not included in EPS as the effect would be antidilutive.

For the comparable year ended December 31, 2022, there were no potential common shares included in the calculation of diluted weighted average shares outstanding and diluted EPS, as no outstanding securities were dilutive. There were 1,425,693 outstanding stock options and 2,500 unvested restricted stock awards not included in the calculation of diluted EPS for the year ended December 31, 2022, as the effect would be antidilutive.

#### u. Stock-Based Compensation

We have various stock-based employee compensation plans that are described more fully in Note 5. The compensation cost relating to share-based payment transactions is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the employee's requisite service period (generally the vesting period of the equity award).

#### v. Segment Reporting

We have two operating segments – Battery & Energy Products and Communications Systems. The basis for determining our operating segments is the manner in which financial information is used in monitoring our operations. Management operates and organizes itself according to business units that comprise unique products and services across geographic locations.

#### w. Business Combinations

We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values on the acquisition date. Any excess of the purchase price over the net fair value of the separately identifiable assets acquired and liabilities assumed is allocated to goodwill. Management determines the fair values of identifiable intangible assets acquired based on historical data, estimated discounted future cash flows, expected royalty rates for trademarks and trade names, as well as certain other information. The valuation of assets acquired and liabilities assumed requires a number of judgments and is subject to change as additional information about the fair value of assets and liabilities becomes available. Additional information, which existed as of the acquisition date but unknown to us at that time, may become known during the remainder of the measurement period. This measurement period may not exceed twelve months from the acquisition date. We will recognize any adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustments are determined. Additionally, in the same period in which adjustments are recognized, we will record the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of any change to the provisional amounts, calculated as if the accounting adjustment had been completed at the acquisition date. Acquisition costs are expensed as incurred. The results of operations and cash flows of acquired businesses are included in our consolidated financial statements from the date of acquisition.

#### x. Leases

At contract inception, the Company determines whether the arrangement is or contains a lease and determines the lease classification. The lease term is determined based on the non-cancellable term of the lease adjusted to the extent optional renewal terms and termination rights are reasonably certain. Lease expense for operating leases is recognized evenly over the lease term. Variable lease payments are recognized as period costs. The present value of remaining lease payments is recognized as a liability on the balance sheet with a corresponding right-of-use asset adjusted for prepaid or accrued lease payments. The Company uses its incremental borrowing rate for the discount rate, unless the interest rate implicit in the lease contract is readily determinable. The Company has adopted the practical expedients to not separate non-lease components from lease components and to not present short-term leases on the balance sheet. See Note 7 for further disclosure regarding lease accounting.

#### y. Recent Accounting Pronouncements

#### Recently Adopted Accounting Guidance

In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-13, "Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments", which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance was effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The adoption of this new accounting standard did not have a material impact on our consolidated financial statements.

#### Recent Accounting Guidance Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

#### Note 2 - Debt

#### Credit Facilities

On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife ("SWE"), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE ("CLB"), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC ("UCHC"), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC ("Excell USA"), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association ("KeyBank" or the "Bank"), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the "Credit Agreement"). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC ("Excell Canada"), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with SOFR (the "Third Amendment Agreement"), and together with the Second Amendment Agreement and the Credit Agreement, the "Amended Credit Agreement").

The Amended Credit Agreement, among other things, provides for a 5-year, \$10,000 senior secured term loan (the "Term Loan Facility") and extends the term of the \$30,000 senior secured revolving credit facility (the "Revolving Credit Facility", and together with the Term Loan Facility, the "Amended Credit Facilities") through May 30, 2025. Up to six months prior to May 30, 2025, the Revolving Credit Facility may be increased to \$50,000 with the Bank's concurrence.

As of December 31, 2023, the Company had \$6,167 outstanding principal on the Term Loan Facility, \$2,000 of which is included in current portion of long-term debt on the balance sheet, and \$19,580 outstanding on the Revolving Credit Facility. As of December 31, 2023, total unamortized debt issuance costs of \$123, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.

The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.

The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2025. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of December 31, 2023.

Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.

Upon the effectiveness of the Third Amendment Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the Daily Simple SOFR Rate, plus an index spread adjustment of 0.10%, plus the applicable margin. The applicable margin ranges from 185 to 215 basis points and is determined based on the Company's senior leverage ratio.

The Company must pay a fee of 0.15% to 0.25% based on the average daily unused availability under the Revolving Credit Facility.

Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

Future minimum principal repayment obligations on our Amended Credit Facilities as of December 31, 2023 are as follows:

| 2024       | \$2,000  |
|------------|----------|
| 2025       | 21,580   |
| 2026       | 2,000    |
| 2027       | 167      |
| Thereafter | 0        |
| Total      | \$25,747 |

#### **Note 3 - Supplemental Balance Sheet Information**

#### a. Cash and Restricted Cash

The Company had cash and restricted cash totaling \$10,278 and \$5,713 as of December 31, 2023 and 2022, respectively.

|                 | December 31, |         |  |
|-----------------|--------------|---------|--|
|                 | 2023         | 2022    |  |
| Cash            | \$10,196     | \$5,634 |  |
| Restricted cash | 82           | 79      |  |
| Total           | \$10,278     | \$5,713 |  |

As of December 31, 2023 and December 31, 2022, restricted cash included \$82 and \$79, respectively, of euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. Restricted cash is included as a component of the cash balance for purposes of the consolidated statements of cash flows.

#### b. Inventory, Net

Inventories are stated at the lower of cost or net realizable value with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

|                   | December 31, |          |  |
|-------------------|--------------|----------|--|
|                   | 2023         | 2022     |  |
| Raw materials     | \$29,098     | \$29,200 |  |
| Work in process   | 3,187        | 2,757    |  |
| Finished products | 9,930        | 9,235    |  |
| Total             | \$42,215     | \$41,192 |  |

#### c. Property, Plant and Equipment

Major classes of property, plant and equipment consisted of the following:

|                                      | December 31, |          |
|--------------------------------------|--------------|----------|
|                                      | 2023         | 2022     |
| Land                                 | \$1,273      | \$1,273  |
| Buildings and leasehold improvements | 15,998       | 15,572   |
| Machinery and equipment              | 57,584       | 63,981   |
| Furniture and fixtures               | 2,845        | 2,845    |
| Computer hardware and software       | 7,868        | 7,744    |
| Construction in progress             | 2,033        | 1,245    |
|                                      | 87,601       | 92,660   |
| Less: Accumulated depreciation       | (66,484)     | (70,944) |
| Total                                | \$21,117     | \$21,716 |

Depreciation expense was \$3,022 and \$3,177 for the years ended December 31, 2023 and 2022, respectively.

#### d. Goodwill and Other Intangible Assets

The Company conducted its annual impairment test for goodwill and other indefinite-lived intangible assets as of October 1, 2023. We identified two (2) goodwill reporting units and five (5) indefinite-lived intangible assets. We performed a quantitative impairment assessment of each goodwill reporting unit and indefinite-lived intangible asset. Based on the results of our quantitative impairment tests, and consideration of qualitative factors as of our test date and December 31, 2023, no impairment was identified.

The following table summarizes the goodwill activity by segment for the years ended December 31, 2023 and 2022:

|  | Battery &       |                |          |
|--|-----------------|----------------|----------|
|  | Energy          | Communications |          |
|  | <b>Products</b> | Systems        | Total    |
| Balance – January 1, 2023              | \$25,935        | \$11,493       | \$37,428 |
| Effect of foreign currency translation | 143             | -              | 143      |
| Balance – December 31, 2023            | \$26,078        | \$11,493       | \$37,571 |

The composition of intangible assets was:

|                               | December 31, 2023 |                          |          |
|-------------------------------|-------------------|--------------------------|----------|
|                               | Cost              | Accumulated amortization | Net      |
| Customer relationships        | \$13,092          | \$6,656                  | \$6,436  |
| Patents and technology        | 5,606             | 5,322                    | 284      |
| Trade names                   | 4,647             | 647                      | 4,000    |
| Trademarks                    | 3,402             | -                        | 3,402    |
| Other                         | 1,500             | 515                      | 985      |
| Total other intangible assets | \$28,247          | \$13,140                 | \$15,107 |

|                               | <b>December 31, 2022</b> |                          |          |
|-------------------------------|--------------------------|--------------------------|----------|
|                               | Cost                     | Accumulated amortization | Net      |
| Customer relationships        | \$12,970                 | \$5,992                  | \$6,978  |
| Patents and technology        | 5,557                    | 5,171                    | 386      |
| Trade names                   | 4,629                    | 522                      | 4,107    |
| Trademarks                    | 3,404                    | -                        | 3,404    |
| Other                         | 1,500                    | 454                      | 1,046    |
| Total other intangible assets | \$28,060                 | \$12,139                 | \$15,921 |

The change in the cost value of other intangible assets is attributable to the effect of foreign currency translations.

Amortization of other intangible assets was included in the following financial statement captions:

|   | Year ended December 31, |         |
|---|-------------------------|---------|
|   | 2023                    | 2022    |
| Research and development expense            | \$97                    | \$97    |
| Selling, general and administrative expense | 792                     | 1,185   |
| Total                                       | \$889                   | \$1,282 |

Future amortization expense of amortizable intangible assets will be approximately \$912, \$912, \$775, \$775 and \$774 for the five fiscal years ending December 31, 2024 through 2028, respectively.

#### **Note 4 - Commitments and Contingencies**

#### a. Legal Matters

We are subject to legal proceedings and claims that arise from time to time in the ordinary course of business. We believe that the final disposition of any such matters of which we are currently aware will not have a material adverse effect on the Company's financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of current or future legal matters could have a material adverse impact on the Company's financial position, results of operations or cash flows. We are not aware of any such situations at this time.

#### b. *Indemnity*

Our organizational documents provide that our directors or officers will be reimbursed for all expenses, to the fullest extent permitted by law arising out of their performance.

#### c. Purchase Commitments

As of December 31, 2023, we have made commitments to purchase approximately \$890 of production machinery and equipment.

#### d. China

Our operating facility in China presents risks including, but not limited to, changes in local regulatory requirements, changes in labor laws, local wage laws, environmental regulations, taxes and operating licenses, compliance with U.S. regulatory requirements, including the Foreign Corrupt Practices Act, uncertainties as to application and interpretation of local laws and enforcement of contract and intellectual property rights, currency restrictions, currency exchange controls, fluctuations of currency, and currency revaluations, eminent domain claims, civil unrest, power outages, water shortages, labor shortages, labor disputes, increase in labor costs, rapid changes in government, economic and political policies, political or civil unrest, acts of terrorism, or the threat of boycotts, other civil disturbances and the possible impact of the imposition of tariffs by the U.S. Government on 9 Volt batteries that we manufacture in China as well as any retaliating trade policies or restrictions. Any such disruptions could depress our earnings and have other material adverse effects on our business, financial condition and results of operations.

#### e. Product Warranties

We typically offer standard warranties against product defects that range from ninety (90) days to three (3) years from the date of purchase. We also offer separately priced extended warranty contracts on certain products. Warranty costs expected to be incurred are estimated based on the Company's experience and recorded as costs of products sold. Standard warranty costs are recognized upon product sale. Extended warranty costs are recognized over the term of the contract.

|  | 2023  | 2022  |
|--|-------|-------|
| Accrued warranty obligations – beginning | \$323 | \$133 |
| Accruals for warranties issued           | 458   | 287   |
| Settlements made                         | (234) | (97)  |
| Accrued warranty obligations - ending    | \$547 | \$323 |

#### Note 5 – Stock-Based Compensation

We recorded non-cash stock compensation expense in each period as follows:

|                  | Year ended December 31, |       |  |
|------------------|-------------------------|-------|--|
|                  | 2023                    | 2022  |  |
| Stock options    | \$522                   | \$761 |  |
| Restricted stock | 6                       | 15    |  |
| Total            | \$528                   | \$776 |  |

We have various stock-based employee compensation plans, for which compensation cost is recognized in the financial statements. The cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity award).

Our stockholders have approved various equity-based plans that permit the grant of stock options, restricted stock and other equity-based awards. In addition, our stockholders have approved the grant of stock options outside of these plans.

In June 2014, our stockholders approved the 2014 Long-Term Incentive Plan ("2014 LTIP") as the successor plan to the 2004 Long-Term Incentive Plan ("2004 LTIP") that expired on June 10, 2014. Under the 2014 LTIP, a total of 1,750,000 shares of common stock were made available for grant of awards. In July 2021, our stockholders approved an amendment to the 2014 LTIP to increase the total number shares of our common stock authorized to be issued pursuant to the 2014 LTIP to 2,750,000. Of the total number of shares of common stock available for awards under the 2014 LTIP, no more than 800,000 shares of common stock may be used for awards other than stock options and stock appreciation rights. Grants under the 2014 LTIP may be awarded through June 2, 2024.

Stock options granted under the 2014 LTIP are either Incentive Stock Options ("ISOs") or Non-Qualified Stock Options ("NQSOs"). Key employees are eligible to receive ISOs and NQSOs; however, directors and consultants are eligible to receive only NQSOs. Stock options vest in equal installments on the first, second and third anniversaries of the grant date and expire on the seventh anniversary of the grant date. As of December 31, 2023, there were 1,250,595 stock options outstanding under the 2014 LTIP. There were no stock options outstanding under the 2004 LTIP.

As of December 31, 2023, there was \$844 of total unrecognized compensation costs related to outstanding stock options, which we expect to recognize over a weighted average period of 1.5 years.

We use the Black-Scholes option-pricing model to estimate fair value of stock-based awards. The following weighted average assumptions were used to value options granted during the years ended December 31, 2023 and 2022:

|  | Year ended December 31, |       |
|--|-------------------------|-------|
|  | 2023                    | 2022  |
| Risk-free interest rate                | 4.1%                    | 4.2%  |
| Volatility factor                      | 57%                     | 50%   |
| Weighted average expected life (years) | 4.9                     | 4.8   |
| Forfeiture rate                        | 10.0%                   | 10.0% |
| Dividends                              | 0.0%                    | 0.0%  |

We used a Monte Carlo simulation option-pricing model to estimate the fair value of market performance stock-based awards, of which there were no new awards for the years ended December 31, 2023 and 2022.

We calculate expected volatility for stock options by taking an average of historical volatility over the expected term. The computation of expected term was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards and vesting schedules. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury yield in effect at the time of grant. Forfeiture rates are calculated by dividing unvested shares forfeited by beginning shares outstanding. The pre-vesting forfeiture rate is calculated yearly and is determined based on historical experience.

The following tables summarize data for the stock options issued by us:

|                                   | Year ended Dece     | mber 31, 2023   |   |                                 |
|-----------------------------------|---------------------|---|---|---------------------------------|
|                                   | Number<br>of shares | Weighted<br>average<br>exercise<br>price<br>per share | Weighted<br>average<br>remaining<br>contractual<br>term | Aggregate<br>intrinsic<br>value |
| Shares under option – January 1   | 1,425,693           | \$6.72  |   |                                 |
| Options granted                   | 231,650             | 6.69  |   |                                 |
| Options exercised                 | (254,393)           | 5.83  |   |                                 |
| Options forfeited or expired      | (152,355)           | 5.06  |   |                                 |
| Shares under option – December 31 | 1,250,595           | \$7.10  | 3.97  | \$515                           |
| Vested and expected to vest -     |                     |   |   |                                 |

| December 31                       | 1,151,228 | \$7.17 | 3.79 | \$452 |
|-----------------------------------|-----------|--------|------|-------|
| Options exercisable – December 31 | 789,209   | \$7.56 | 2.69 | \$241 |

Year ended December 31, 2022

|                                   | Number<br>of shares | Weighted<br>average<br>exercise<br>price<br>per share |
|-----------------------------------|---------------------|---|
| Shares under option – January 1   | 1,306,824           | \$6.87  |
| Options granted                   | 289,950             | 5.42  |
| Options exercised                 | (59,500)            | 3.82  |
| Options forfeited or expired      | (111,581)           | 6.56  |
| Shares under option – December 31 | 1,425,693           | \$6.72  |
| Options exercisable – December 31 | 881,804             | \$7.13  |

The following table represents additional information about stock options outstanding at December 31, 2023:

|                 |                       | Option outstanding                               |                                  | Options ex        | xercisable                       |
|-----------------|-----------------------|--|----------------------------------|-------------------|----------------------------------|
| Range of        | Number of outstanding | Weighted-<br>average<br>remaining<br>contractual | Weighted-<br>average<br>exercise | Number of options | Weighted-<br>average<br>exercise |
| exercise prices | options               | life   | price                            | exercisable       | price                            |
| \$4.07 - \$6.36 | 338,364               | 4.79   | \$5.42                           | 156,099           | \$5.54                           |
| \$6.51 - \$6.84 | 353,733               | 5.54   | 6.71                             | 134,583           | 6.51                             |
| \$6.97 - \$8.25 | 334,165               | 2.89   | 7.64                             | 290,355           | 7.74                             |
| \$8.45 - \$9.96 | 224,333               | 1.88   | 9.44                             | 208,172           | 9.51                             |
| \$4.07 - \$9.96 | 1,250,595             | 3.97   | \$7.10                           | 789,209           | \$7.56                           |

The weighted average fair value of options granted during the years ended December 31, 2023 and 2022 was \$3.48 and \$2.55, respectively. The total intrinsic value of options (which is the amount by which the stock price exceeded the exercise price of the options on the date of exercise) exercised during the years ended December 31, 2023 and 2022 was \$556 and \$88, respectively.

Cash received from stock option exercises under our stock-based compensation plans for the years ended December 31, 2023 and 2022 was \$1,248 and \$116, respectively.

Restricted shares vest in equal annual installments over three years. In November 2023, we granted 4,029 shares of restricted stock awards. As of December 31, 2023, there was \$27 of total unrecognized compensation costs related to outstanding restricted shares.

There were 632,593 shares of common stock available for future issuance under equity compensation plans as of December 31, 2023.

#### **Note 6 - Income Taxes**

For the years ended December 31, 2023 and 2022, we recognized an income tax provision (benefit) of \$1,951 and (\$326), respectively.

|                                      | Year ended December 31, |         |
|--------------------------------------|-------------------------|---------|
|                                      | 2023                    | 2022    |
| Current:                             |                         |         |
| State                                | \$27                    | \$19    |
| Foreign                              | 623                     | 617     |
|                                      | 650                     | 636     |
| Deferred:                            |                         |         |
| Federal                              | 1,466                   | (661)   |
| Foreign                              | (165)                   | (301)   |
|                                      | 1,301                   | (962)   |
| Total income tax (benefit) provision | \$1,951                 | (\$326) |

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:

|   | December 31, |          |
|---|--------------|----------|
|   | 2023         | 2022     |
| Deferred tax assets:                        |              |          |
| Net operating loss carryforwards            | \$8,515      | \$11,460 |
| Research and development                    | 3,536        | 2,812    |
| Tax credit carryforwards                    | 2,898        | 2,600    |
| Accrued expenses, reserves and other        | 2,909        | 2,419    |
| Intangible assets                           | 1,596        | 1,521    |
| Total deferred tax assets                   | 19,454       | 20,812   |
| Valuation allowance for deferred tax assets | (2,441)      | (2,416)  |
| Net deferred tax assets                     | 17,013       | 18,396   |
| Deferred tax liabilities:                   |              |          |
| Intangible assets                           | (8,095)      | (8,176)  |
| Accrued expenses, reserves and other        | (65)         | (68)     |
| Total deferred tax liabilities              | (8,160)      | (8,244)  |
| Net deferred tax assets                     | \$8,853      | \$10,152 |

Net deferred tax assets (liabilities) are comprised of the following balance sheet amounts:

|                          | Decem    | December 31, |  |
|--------------------------|----------|--------------|--|
|                          | 2023     | 2022         |  |
| Deferred tax assets, net | \$10,567 | \$12,069     |  |
| Deferred tax liabilities | (1,714)  | (1,917)      |  |
|                          | \$8,853  | \$10,152     |  |

For financial reporting purposes, net income (loss) from continuing operations before income taxes is as follows:

|               | Year ended l | Year ended December 31, |  |
|---------------|--------------|-------------------------|--|
|               | 2023         | 2022                    |  |
| United States | \$7,294      | (\$2,771)               |  |
| Foreign       | 1,823        | 2,325                   |  |
| -             | \$9,117      | (\$446)                 |  |

The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to income from continuing operations before income taxes as follows:

|  | Year ended December 31, |        |
|--|-------------------------|--------|
|  | 2023                    | 2022   |
| Statutory income tax rate                            | 21%                     | 21%    |
| Increase (decrease) in tax provision resulting from: |                         |        |
| Equity compensation                                  | 0.4                     | (29.7) |
| Global intangible low-taxed income                   | 1.4                     | (73.1) |
| China R&D deduction                                  | (1.0)                   | 20.6   |
| Income tax credits                                   | (3.3)                   | 81.0   |
| Foreign tax rate change                              | -                       | 18.3   |
| Foreign tax rates                                    | 1.7                     | 11.5   |
| States taxes   | 0.8                     | (3.4)  |
| Other  | 0.4                     | 26.9   |
| Effective income tax rate                            | 21.4%                   | 73.1%  |

As of December 31, 2023, it was concluded that it is more likely than not that our U.S. deferred tax assets will be fully realized on the basis of management's assessment. In evaluating the realizability of our U.S. deferred tax assets, management considered all available evidence, both positive and negative, weighted based on objective verifiability. Our assessment also considered our ability to fully utilize before expiration our domestic net operating loss carryforwards, which expire 2031 thru 2035, and our general business tax credit carryforwards, which expire 2028 thru 2043. As of December 31, 2023, our domestic net operating loss carryforwards and general business tax credits were \$27,200 and \$2,900, respectively.

As of December 31, 2023, for certain past operations in the U.K., we continue to report a valuation allowance for net operating loss carryforwards of approximately \$9,800, nearly all of which can be carried forward indefinitely. Management has concluded that utilization of the U.K. net operating losses may be limited due to the change in the past U.K. operation, and that they cannot currently be used to reduce taxable income of our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

As of December 31, 2023, we have not recognized a valuation allowance against our other foreign deferred tax assets, including net operating loss carryforwards of \$1,300 which expire 2028 thru 2033, as we believe that it is more likely than not that they will be fully realized.

There were no unrecognized tax benefits related to uncertain tax positions at December 31, 2023 and 2022.

As of December 31, 2023, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2020 thru 2022 remain subject to IRS examination. Our U.S. tax matters for 2001-2002, 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2013 thru 2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2013 thru 2022 remain subject to examination by the respective foreign tax jurisdiction authorities.

#### Note 7 – Operating Leases

The Company has operating leases predominantly for operating facilities. As of December 31, 2023, the remaining lease terms on our operating leases range from approximately one (1) year to nine (9) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

The components of lease expense for the current and prior-year comparative periods were as follows:

|                      | Year ended December 31, |       |
|----------------------|-------------------------|-------|
|                      | 2023                    | 2022  |
| Operating lease cost | \$1,016                 | \$894 |
| Variable lease cost  | 114                     | 95    |
| Total lease cost     | \$1,130                 | \$989 |

Supplemental cash flow information related to leases was as follows:

|   | Year ended December 31, |       |
|---|-------------------------|-------|
|   | 2023                    | 2022  |
| Cash paid for amounts included in the measurement of lease liabilities: |                         |       |
| Operating cash flows from operating leases                              | \$1,036                 | \$908 |
| Right-of-use assets obtained in exchange for lease liabilities:         | \$2,192                 | \$476 |

Supplemental balance sheet information related to leases was as follows:

|   |  | Decem   | ber 31, |
|---|--|---------|---------|
|   | <b>Balance Sheet Classification</b>            | 2023    | 2022    |
| Assets:   |  |         |         |
| Operating lease right-of-use asset                | Other noncurrent assets                        | \$3,589 | \$2,187 |
| Liabilities:                                      |  |         |         |
| Current operating lease liability                 | Accrued expenses and other current liabilities | \$894   | \$895   |
| Operating lease liability, net of current portion | Other noncurrent liabilities                   | 2,644   | 1,307   |
| Total operating lease liability                   |  | \$3,538 | \$2,202 |
| Weighted-average remaining lease term (years)     |  | 5.3     | 4.7     |
| Weighted-average discount rate                    |  | 4.5%    | 4.5%    |

Future minimum lease payments as of December 31, 2023 are as follows:

| Maturity of Operating Lease Liabilities   |         |
|---|---------|
| 2024                                      | \$894   |
| 2025                                      | 698     |
| 2026                                      | 624     |
| 2027                                      | 644     |
| 2028                                      | 648     |
| Thereafter                                | 463     |
| Total lease payments                      | \$3,971 |
| Less: Imputed interest                    | (433)   |
| Present value of remaining lease payments | \$3,538 |

#### Note 8 - 401(k) Retirement Benefit Plan

We maintain a defined contribution 401(k) plan covering substantially all employees. Employees can contribute a portion of their salary or wages as prescribed under Section 401(k) of the Internal Revenue Code and, subject to certain limitations, we may, at the discretion of our Board of Directors, authorize an employer contribution based on a portion of the employees' contributions. For the years ended December 31, 2023 and 2022, the Company matched 100% on the first 3% and 50% on the next 2% contributed by the employee, or a maximum of 4% of the employee's income. For 2023 and 2022, we contributed \$678 and \$600, respectively, to the 401(k) plan.

#### **Note 9 - Business Segment Information**

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance.

#### 2023:

|  | Battery &<br>Energy<br>Products | Communications<br>Systems | Corporate | Total     |
|--|---------------------------------|---------------------------|-----------|-----------|
| Revenue  | \$129,953                       | \$28,691                  | \$-       | \$158,644 |
| Segment contribution                               | 30,775                          | 8,425                     | (29,725)  | 9,475     |
| Other expense, net                                 |                                 |                           | 358       | 358       |
| Income tax provision                               |                                 |                           | 1,951     | 1,951     |
| Non-controlling interest                           |                                 |                           | (31)      | (31)      |
| Net loss attributable to Ultralife                 |                                 |                           |           | \$7,197   |
| Total assets                                       | \$124,411                       | \$28,873                  | \$24,992  | \$178,276 |
| Capital expenditures                               | \$2,064                         | \$118                     | \$370     | \$2,552   |
| Goodwill   | \$26,078                        | \$11,493                  | \$-       | \$37,571  |
| Depreciation and amortization of intangible assets | \$3,336                         | \$183                     | \$392     | \$3,911   |
| Stock-based compensation                           | \$336                           | \$74                      | \$118     | \$528     |

#### 2022:

|  | Battery &<br>Energy<br>Products | Communications<br>Systems | Corporate | Total     |
|--|---------------------------------|---------------------------|-----------|-----------|
| Revenue  | \$119,995                       | \$11,845                  | <u> </u>  | \$131,840 |
| Segment contribution                               | 26,154                          | 3,246                     | (29,271)  | 129       |
| Other expense, net                                 |                                 |                           | 575       | 575       |
| Income tax benefit                                 |                                 |                           | (326)     | (326)     |
| Non-controlling interest                           |                                 |                           | (1)       | (1)       |
| Net loss attributable to Ultralife                 |                                 |                           |           | (\$119)   |
| Total assets                                       | \$117,017                       | \$29,424                  | \$21,989  | \$168,430 |
| Capital expenditures                               | \$1,371                         | \$81                      | \$227     | \$1,679   |
| Goodwill   | \$25,935                        | \$11,493                  | \$-       | \$37,428  |
| Depreciation and amortization of intangible assets | \$3,761                         | \$261                     | \$437     | \$4,459   |
| Stock-based compensation                           | \$396                           | \$82                      | \$298     | \$776     |

Long-lived assets (comprised of property, plant and equipment; goodwill; and other intangible assets) held outside the U.S., principally in Canada, United Kingdom and China, were \$23,709 and \$24,405 as of December 31, 2023 and 2022, respectively.

The following tables disaggregate our business segment revenues by major source and geography.

#### Commercial and Government/Defense Revenue Information:

#### Year ended December 31, 2023:

| Teal chucu December 31, 2023.   |           |            |             |
|---|-----------|------------|-------------|
|   | Total     |            | Government/ |
|   | Revenue   | Commercial | Defense     |
| Battery & Energy Products   | \$129,953 | \$100,842  | \$29,111    |
| Communications Systems  | 28,691    | -          | 28,691      |
| Total   | \$158,644 | \$100,842  | \$57,802    |
|   |           | 64%        | 36%         |
| Year ended December 31, 2022:   |           |            |             |
|   | Total     |            | Government/ |
|   | Revenue   | Commercial | Defense     |
| Battery & Energy Products   | \$119,995 | \$93,045   | \$26,950    |
| Communications Systems  | 11,845    | -<br>-     | 11,845      |
| Total   | \$131,840 | \$93,045   | \$38,795    |
|   |           | 71%        | 29%         |
| U.S. and Non-U.S. Revenue Information <sup>1</sup> :  Year ended December 31, 2023: |           |            |             |
| Teal chaca December 51, 2025.   | Total     | United     | Non-United  |
|   | Revenue   | States     | States      |
| Battery & Energy Products   | \$129,953 | \$64,120   | \$65,833    |
| Communications Systems  | 28,691    | 17,276     | 11,415      |
| Total   | \$158,644 | \$81,396   | \$77,248    |
|   | <u> </u>  | 51%        | 49%         |
| Year ended December 31, 2022:   |           |            |             |
| ,   | Total     | United     | Non-United  |
|   | Revenue   | States     | States      |
| Battery & Energy Products   | \$119,995 | \$58,820   | \$61,175    |
| Communications Systems  | 11,845    | 9,094      | 2,751       |
| Total   | \$131,840 | \$67,914   | \$63,926    |
|   |           |            |             |

<sup>&</sup>lt;sup>1</sup> Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

52%

48%

## ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

#### ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures – Our president and chief executive officer (principal executive officer) and our chief financial officer and treasurer (principal financial officer) have evaluated our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the period covered by this annual report. Based on this evaluation, our president and chief executive officer and chief financial officer and treasurer concluded that our disclosure controls and procedures were effective as of such date.

<u>Changes in Internal Controls Over Financial Reporting</u> –There has been no change in our internal control over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) that occurred during the fourth quarter of the fiscal year covered by this annual report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Management's Report on Internal Control Over Financial Reporting — Our management team is responsible for establishing and maintaining adequate internal control over our financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of the inherent limitations of internal control systems, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control-Integrated Framework (2013). Based on our assessment, we concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on those criteria.

| 1 | TEEN LOD | OTHE | DIMEGI | ALC MICANI |
|---|----------|------|--------|------------|
|   | ITEM 9B. | OTHE | KINKUI | RMATION    |

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

#### PART III

The information required by Part III, other than as set forth in Item 12, and each of the following items is omitted from this report and will be presented in our definitive proxy statement ("Proxy Statement") to be filed pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this report, in connection with our 2024 Annual Meeting of Stockholders, which information included therein is incorporated herein by reference.

## ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The sections entitled "Election of Directors", "Executive Officers", "Delinquent Section 16(a) Reports Compliance" and "Corporate Governance" in the Proxy Statement are incorporated herein by reference.

#### ITEM 11. EXECUTIVE COMPENSATION

The sections entitled "Executive Compensation", "Directors Compensation", "Employment Arrangements" and "Compensation and Management Committee" in the Proxy Statement are incorporated herein by reference.

# ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The section entitled "Security Ownership of Certain Beneficial Owners" and "Security Ownership of Management" in the Proxy Statement is incorporated herein by reference.

#### **Equity Compensation Plan Information**

| Plan Category  | Number of securities to<br>be issued upon exercise<br>of outstanding options,<br>warrants and rights  (a) | Weighted-average exercise price of outstanding options, warrants and rights  (b) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))  (c) |
|--|---|--|--|
| Equity compensation plans approved by security holders     | 1,250,595   | \$7.10   | 632,593  |
| Equity compensation plans not approved by security holders | <u> </u>  | <u> </u>   | <u>-</u>   |
| Total  | 1,250,595   | \$7.10   | 632,593  |

See Note 5 in the notes to consolidated financial statements for additional information.

# ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The section entitled "Corporate Governance – General" in the Proxy Statement is incorporated herein by reference.

#### ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The section entitled "Proposal to Ratify the Selection of Independent Registered Accounting Firm - Principal Accountant Fees and Services" in the Proxy Statement is incorporated herein by reference.

## **PART IV**

## ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

## (a) <u>Documents filed as part of this report:</u>

## 1. Financial Statements

The financial statements and schedules required by this Item 15 are set forth in Part II, Item 8 of this Form 10-K.

Auditor information: Freed Maxick CPAs, P.C. Rochester, New York PCAOB ID 317

## (b) <u>Exhibits</u>. The following exhibits are filed as a part of this report:

| Exhibit |   | Filed Herewith or Incorporated by   |
|---------|---|---|
| Index   | Description of Document   | Reference from:   |
| 2.1     | Share Purchase Agreement, dated December 13, 2021, by and among 1336889 B.C. Unlimited Liability Company, Mark Kroeker, Randolph Peters, Brian Larsen, M. & W. Holdings Ltd., Karen Kroeker, Heather                            | Exhibit 2.1 of the Form 8-K filed on December 16, 2021                                    |
|         | Peterson, Michael Kroeker, Nicholas<br>Kroeker, Brentley Peters, Craig Peters,<br>Kurtis Peters, Heather Larsen, Ian Kane,<br>Carol Peters, 0835205 B.C. LTD, and Excell<br>Battery Canada Inc.                                 |   |
| 2.2     | Share Purchase Agreement, dated December 13, 2021, by and among 1336902 B.C. Unlimited Liability Company, M. & W. Holdings Ltd., Ian Kane, Sanford Capital Ltd., Arcee Enterprises Inc., 0835205 B.C. Ltd., and 656700 B.C. LTD | Exhibit 2.2 of the Form 8-K filed on December 16, 2021                                    |
| 2.3     | Stock Purchase Agreement, dated May 1, 2019, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, Southwest Electronic Energy Medical Research Institute, and Claude Leonard Benckenstein               | Exhibit 10.1 of the Form 8-K filed on May 2, 2019   |
| 2.4     | Stock Purchase Agreement Relating to Accutronics Limited by and between Robert Andrew Phillips and Others and Ultralife Corporation   | Exhibit 2.2 of the Form 10-K for the year ended December 31, 2015, filed March 2, 2016    |
| 3.1     | Restated Certificate of Incorporation   | Exhibit 3.1 of the Form 10-K for the year ended December 31, 2008, filed March 13, 2009   |
| 3.2     | Amended and Restated By-laws  | Exhibit 3.2 of the Form 8-K filed December 9, 2011  |
| 4.1     | Specimen Stock Certificate  | Exhibit 4.1 of the Form 10-K for the year ended December 31, 2008, filed March 13, 2009   |
| 4.2     | Description of Registrant's Securities  | Exhibit 4.2 of the Form 10-K/A for the year ended December 31, 2019, filed April 28, 2020 |

| 10.1*       | Amendment to the Agreement relating to rechargeable batteries  | Exhibit 10.24 of our Form 10-K for the fiscal year ended June 30, 1996 (this Exhibit may be found in SEC File No. 0-20852) |
|-------------|--|--|
| 10.3†       | Ultralife Corporation Amended 2014 Long-<br>Term Incentive Plan  | Appendix B of Form DEF 14A filed on June 1, 2021   |
| 10.4        | Credit and Security Agreement between<br>Ultralife Corporation and KeyBank National<br>Association dated May 31, 2017  | Exhibit 10.1 of the Form 8-K filed on June 6, 2017   |
| 10.5        | First Amendment Agreement, dated May 1, 2019, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, Inc., and KeyBank National Association   | Exhibit 10.1 of the Form 8-K filed on May 2, 2019  |
| 10.6†       | Amendment No. 1 to Ultralife Corporation<br>Amended 2014 Long-Term Incentive Plan  | Appendix A of Form DEF 14A filed on June 1, 2021   |
| 10.7        | Second Amendment Agreement, dated<br>December 13, 2021, by and among Ultralife<br>Corporation, Southwest Electronic Energy<br>Corporation, CLB, Inc., Ultralife Excell<br>Holding Corp., Ultralife Canada Holding<br>Corp., Excell Battery Corporation USA, and<br>KeyBank National Association        | Exhibit 10.1 of the Form 8-K filed on December 16, 2021  |
| 10.8        | Third Amendment Agreement, dated November 28, 2022, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, Inc., Ultralife Excell Holding Corp., Ultralife Canada Holding Corp., Excell Battery Corporation USA, Excell Battery Canada ULC and KeyBank National Association | Exhibit 10.8 of the Form 10-K for the year ended December 31, 2022, filed March 31, 2013                                   |
| 21          | Subsidiaries   | Filed herewith   |
| 23.1        | Consent of Freed Maxick CPAs, P.C.   | Filed herewith   |
| 31.1        | Rule 13a-14(a) / 15d-14(a) CEO<br>Certifications   | Filed herewith   |
| 31.2        | Rule 13a-14(a) / 15d-14(a) CFO<br>Certifications   | Filed herewith   |
| 32          | Section 1350 Certifications  | Filed herewith   |
| 97.1        | Ultralife Corporation Policy for the Recovery of Erroneously Awarded Compensation  | Filed herewith   |
| 101.IN<br>S | Inline XBRL Instance Document  | Filed herewith   |
| 101.SC<br>H | Inline XBRL Taxonomy Extension Schema Document   | Filed herewith   |
| 101.CA<br>L | Inline XBRL Taxonomy Extension Calculation Linkbase Document   | Filed herewith   |
| 101.LA<br>B | Inline XBRL Taxonomy Extension Label Linkbase Document   | Filed herewith   |
| 101.PR<br>E | Inline XBRL Taxonomy Extension Presentation Linkbase Document  | Filed herewith   |
| 101.DE<br>F | Inline XBRL Taxonomy Extension Definition Linkbase Document  | Filed herewith   |
| 104         | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   | Filed herewith   |

<sup>\*</sup> Confidential treatment has been granted as to certain portions of this exhibit.

<sup>†</sup> Management contract or compensatory plan or arrangement.

Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022, (ii) Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the years ended December 31, 2023 and December 31, 2022, (iii) Consolidated Statements of Cash Flows for the years ended December 31, 2023 and December 31, 2022, (iv) Consolidated Statements of Changes in Stockholders' Equity for the years ended December 31, 2023 and December 31, 2022, and (v) Notes to Consolidated Financial Statements.

## **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## **ULTRALIFE CORPORATION**

Date: March 21, 2024 /s/ Michael E. Manna

Michael E. Manna

President, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

| Date: March 21, 2024 | /s/ Michael E. Manna Michael E. Manna President, Chief Executive Officer and Director (Principal Executive Officer)                    |
|----------------------|--|
| Date: March 21, 2024 | /s/ Philip A. Fain Philip A. Fain Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer) |
| Date: March 21, 2024 | /s/ Janie Goddard Janie Goddard (Director)   |
| Date: March 21, 2024 | /s/ Thomas L. Saeli Thomas L. Saeli (Director)   |
| Date: March 21, 2024 | /s/ Robert W. Shaw II Robert W. Shaw II (Director)   |
| Date: March 21, 2024 | /s/ Bradford T. Whitmore Bradford T. Whitmore (Director)   |

#### **SUBSIDIARIES**

We have a 100% ownership interest in ABLE New Energy Co., Limited, incorporated in Hong Kong, which has a 100% ownership interest in ABLE New Energy Co., Ltd, incorporated in the People's Republic of China.

Through our ownership interest in Ultralife UK LTD, we have a 100% controlling interest in Accutronics, Ltd., also incorporated in the United Kingdom.

We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom.

We have 100% ownership interest in Southwest Electronic Energy Corporation and its wholly owned subsidiary, CLB, Inc. (collectively "SWE"), both incorporated in Texas.

We have 100% ownership interest in Ultralife Excell Holding Corp., a Delaware corporation, which has 100% ownership interest in Excell Battery Corporation USA, a Texas corporation, and 100% ownership interest in Ultralife Canada Holding Corp., a Delaware corporation, which has 100% ownership interest in Excell Battery Canada ULC, a British Columbia unlimited liability corporation.

We have a 51% ownership interest in Ultralife Batteries India Private Limited, incorporated in India.

We have a 100% ownership interest in Ultralife Energy Services Corporation, incorporated in Florida.

## CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-203037, 333-258107) and Form S-3 (Registration No. 333-254846) of our report dated March 21, 2024, relating to the consolidated financial statements of Ultralife Corporation appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.

/s/ Freed Maxick CPAs, P.C.

Rochester, New York March 21, 2024

## I, Michael E. Manna, certify that:

- 1. I have reviewed this annual report on Form 10-K of Ultralife Corporation;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 21, 2024

/s/ Michael E. Manna

Michael E. Manna

President and Chief Executive Officer

#### I, Philip A. Fain, certify that:

- 1. I have reviewed this annual report on Form 10-K of Ultralife Corporation;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 21, 2024

/s/ Philip A. Fain
Philip A. Fain
Chief Financial Officer and Treasurer

#### Section 1350 Certification

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ("Section 906"), Michael E. Manna and Philip A. Fain, the President and Chief Executive Officer and Chief Financial Officer and Treasurer, respectively, of Ultralife Corporation, certify that (i) the Annual Report on Form 10-K for the year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Ultralife Corporation.

A signed original of this written statement required by Section 906 has been provided to Ultralife Corporation and will be retained by Ultralife Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

Date: March 21, 2024 /s/ Michael E. Manna

Michael E. Manna

President and Chief Executive Officer

Date: March 21, 2024 /s/ Philip A. Fain

Philip A. Fain

Chief Financial Officer and Treasurer

This certification is being furnished as required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that we specifically incorporate this certification by reference.

## ULTRALIFE CORPORATION

# POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

#### **BACKGROUND**

NASDAQ's new rule, "NASDAQ Listing Rule 5608", requires all listed U.S. companies to adopt clawback policies. A company's clawback policy must require it to recover, reasonably promptly, erroneously awarded incentive based compensation to a Section 16 reporting officer during the performance period for incentive-based compensation related to the three fiscal years preceding the date on which the company is required to prepare an accounting restatement. The company needs to recover the amount over what would have been paid had the stated results been accurate, calculated on a gross basis without regard to any taxes paid. The amount of the recovery must be the amount received by the executive officer in excess of the amount that would have been received if the calculation was based on the restated financial statements.

All incentive-based compensation "received" on and after October 2, 2023 is subject to clawback; and Issuers must make compensation clawback disclosures (as required) in annual reports and proxy and information statements filed on or after October 2, 2023.

In addition, listed companies must file the clawback policy as an exhibit to its annual report and disclose the company's actions to enforce the clawback policy, including information regarding completed, ongoing and forgone recoveries, such as the names of involved executive officers and amounts of excess incentive-based compensation attributable to an accounting restatement.

## A. OVERVIEW

In accordance with the applicable rules of The Nasdaq Stock Market (the "Nasdaq Rules"), Section 10D and Rule 10D-1 ("Rule 10D-1"), of the Securities Exchange Act of 1934, as amended (the "Exchange Act") the Board of Directors (the "Board")¹ of Ultralife Corporation (the "Company") has adopted this Policy (the "Policy") to provide for the recovery of erroneously awarded Incentive-based Compensation from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H. below.

#### B. RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

- (1) In the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with Nasdaq Rules and Rule 10D-1 as follows:
  - (i) After an Accounting Restatement, the Compensation and Management Committee (if composed entirely of independent directors, or in the absence of such a committee, a majority of independent directors serving on the Board) (the "Committee") shall determine the amount of any Erroneously Awarded Compensation Received by each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.
    - (a) For Incentive-based Compensation based on (or derived from) the Company's stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:
      - i. The amount to be repaid or returned shall be determined by the Committee

based on a reasonable estimate of the effect of the Accounting Restatement on the Company's stock price or total stockholder return upon which the Incentive-based Compensation was Received; and

- The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to the Nasdaq.
- (ii) The Committee shall have discretion to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. Notwithstanding the foregoing, except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer's obligations hereunder.
- (iii) To the extent that the Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.
- (iv) To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.
- (2) Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee (which, as specified above, is composed entirely of independent directors or in the absence of such a committee, a majority of the independent directors serving on the Board) determines that recovery would be impracticable and any of the following two conditions are met:
  - (i) The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation to the Nasdaq; or
  - (ii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.

#### C. DISCLOSURE REQUIREMENTS

The Company shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission ("**SEC**") filings and rules.

## D. PROHIBITION OF INDEMNIFICATION

The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company's enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company's right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date

of this Policy).

#### E. ADMINISTRATION AND INTERPRETATION

This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.

The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company's compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.

#### F. AMENDMENT; TERMINATION

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Nasdaq rule.

## **G. OTHER RECOVERY RIGHTS**

This Policy shall be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.

## H. DEFINITIONS

For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.

- (1) "Accounting Restatement" means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a "Big R" restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a "little r" restatement).
- (2) "Clawback Eligible Incentive Compensation" means all Incentive-based Compensation Received by an Executive Officer or former Executive Officer (i) on or after October 2, 2023 (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).
- (3) "Clawback Period" means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.
- (4) "Erroneously Awarded Compensation" means, with respect to each Executive Officer in

connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.

- (5) "Executive Officer" means each individual who is currently or was previously designated as an "officer" of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).
- (6) "Financial Reporting Measures" means measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total stockholder return (and any measures that are derived wholly or in part from stock price or total stockholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company's financial statements or included in a filing with the SEC.
- (7) "*Incentive-based Compensation*" means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
- (8) "Nasdag" means The Nasdag Stock Market.
- (9) "Received" means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.
- (10) "Restatement Date" means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

Effective as of October 2, 2023.

# ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

By my signature below, I acknowledge and agree that:

- I have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation (this "*Policy*").
- I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.

| Signature:    |  |
|---------------|--|
|               |  |
|               |  |
| Drinted News  |  |
| Printed Name: |  |
|               |  |
|               |  |
| Date:         |  |

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **FORM 10-K/A**

(Amendment No. 1)

| (Mark       | One)   |                               |  |
|-------------|--|-------------------------------|--|
| $\boxtimes$ | ANNUAL REPORT PURSUANT   | TO SECTION 13 OR 15(d)        | OF THE SECURITIES EXCHANGE ACT OF  |
|             | 1934   |                               |  |
|             | For th   | e fiscal year ended Decem     | ber 31, 2023   |
|             |  | OR                            |  |
|             | TRANSITION REPORT PURSUA   | NT TO SECTION 13 OR           | 15(d) OF THE SECURITIES EXCHANGE ACT   |
|             | OF 1934  |                               |  |
|             | For the transition   | on period from                | to   |
|             | (  | Commission file number 0      | -20852   |
|             |  | RALIFE CORPO                  |  |
| (S          | <b>Delaware</b> tate or other jurisdiction of incorporati              | on of organization)           | 16-1387013<br>(I.R.S. Employer Identification No.)   |
| 2           | 2000 Technology Parkway Newark, (Address of principal executive office |                               | (315) 332-7100<br>strant's telephone number, including area code:)   |
|             | Securities re  | egistered pursuant to Sectio  | n 12(b) of the Act:  |
| Comi        | non Stock, \$0.10 par value per  |                               |  |
|             | share (Title of each class)  | ULBI<br>(Trading Symbol)      | NASDAQ<br>(Name of each exchange on which<br>registered)   |
|             | Securities regis   | tered pursuant to Section 1   | 2(g) of the Act: <b>None</b>   |
|             | te by check mark whether the registran  ] No     ■                     | t is a well-known seasoned    | issuer, as defined in Rule 405 of the Securities Act.  |
|             | te by check mark if the registrant is n  3 No ☑                        | ot required to file reports p | oursuant to Section 13 or Section 15(d) of the Act.  |
| Securi      |  | preceding 12 months (or for   | required to be filed by Section 13 or 15(d) of the such shorter period that the registrant was required s for the past 90 days. Yes ⊠ No □ |
| submi       |  | n S-T (§ 232.405 of this ch   | nically every Interactive Data File required to be apter) during the preceding 12 months (or for such   No □                               |
| Indica      | te by check mark whether the registra                                  | ant is a large accelerated f  | iler, an accelerated filer, a non-accelerated filer, a   |

smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated

filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

| Large accelerated filer □                        | Accelerated filer □  |
|--|--|
| Non-accelerated filer                            | Smaller reporting company  |
| Emerging growth company □                        |  |
|  | check mark if the registrant has elected not to use the extended transitioned financial accounting standards provided pursuant to Section 13(a) of the   |
| effectiveness of its internal control over finan | t has filed a report on and attestation to its management's assessment of the noial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. firm that prepared or issued its audit report. $\square$ |
| Indicate by check mark whether the registrant    | is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes $\Box$  |

On June 30, 2023, the aggregate market value of the common stock held by non-affiliates as defined in Rule 405 under the Securities Act of 1933) of the registrant was approximately \$46,718,255 (in whole dollars) based upon the closing price for such common stock as reported on the NASDAQ Global Market on June 30, 2023.

As of April 22, 2024, the registrant had 16,466,594 shares of common stock outstanding.

## DOCUMENTS INCORPORATED BY REFERENCE

None.

#### **EXPLANATORY NOTE**

This Amendment No. 1 to the Annual Report on Form 10-K of Ultralife Corporation (the "Company") for the year ended December 31, 2023 as originally filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024 (the "Original Form 10-K"), is being filed solely to include the information required by Items 10 through 14 of Part III and to amend Item 15 of Part IV and the Index of Exhibits of Original Form 10-K. This information from Part III of Form 10-K was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such proxy statement is filed no later than 120 days after our fiscal year-end. We are including this Part III information in this Amendment No. 1 to the Original Form 10-K because we will not file a definitive proxy statement containing such information within 120 days after the end of the fiscal year covered by the Original Form 10-K. We plan on filing our definitive proxy statement on or about May 28, 2024 as we are holding our 2024 Annual Stockholders' Meeting (the "Meeting") on July 16, 2024.

In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended ("the Exchange Act"), Part III, Items 10 through 14, and Part IV, Item 15 of the Original Form 10-K are hereby amended and restated in their entirety. The reference on the cover page of the Original Form 10-K to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted. Pursuant to Rule 12b-15 and Rule 13a-14(a) under the Exchange Act, this Amendment No. 1 contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto.

Except as set forth in the first paragraph of this Explanatory Note, this Amendment No. 1 does not amend, modify, or otherwise update any financial or other information in or on exhibits filed with the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and our other filings with the SEC. In addition, this Amendment No. 1 does not change any financial information in the Original Form 10-K or reflect events that may have occurred subsequent to the filing date of the Original Form 10-K.

Unless expressly indicated or the context requires otherwise, the terms "Company," "we," "our," and "us" in this document refer to Ultralife Corporation ("Ultralife"), a Delaware corporation, and, where appropriate, its subsidiaries.

## TABLE OF CONTENTS

## **PART III**

| Item 10.      | Directors, Executive Officers and Corporate Governance   | 1  |
|---------------|--|----|
| Item 11.      | Executive Compensation   | 6  |
| Item 12.      | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 14 |
| Item 13.      | Certain Relationships and Related Transactions, and Director Independence                      | 16 |
| Item 14.      | Principal Accountant Fees and Services   | 17 |
| PART IV       |  |    |
| Item 15.      | Exhibits, Financial Statement Schedules  | 18 |
| Exhibit Index |  | 19 |
| Signatures    |  | 22 |

#### **PART III**

#### ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

#### **Directors**

The following sets forth certain information concerning our directors as of April 24, 2023.

53

67

#### Name Age Present Principal Occupation, Employment History and Expertise

Michael E. Manna 54

Mr. Manna has served as our President and Chief Executive Officer and as a director of the Company since November 22, 2022. Mr. Manna has almost thirty years' experience in the battery industry, all with Ultralife Corporation. He joined the Company in 1993 and held numerous leadership positions of increasing responsibility in engineering, operations, product management, research & development and sales. Most recently, Mr. Manna served as President, Battery & Energy Products and continues in his leadership of this business segment. Mr. Manna is a well-recognized expert in rechargeable and primary battery cell design across multiple chemistries in both commercial and government/defense markets. He has been awarded several patents for the Company and was a key member of the team that delivered the first Lithium-Ion Polymer Cell to the market. Mr. Manna has a BS degree in Computer Science from Rochester Institute of Technology. Mr. Manna has been nominated for election to our Board of Directors because of his battery industry expertise and his demonstrated leadership as President and Chief Executive Officer of the Company.

Janie Goddard

Ms. Goddard has been a director of the Company since February 21, 2023. Since October 2023, Janie has served as the CEO of ICM Controls Corporation, an advanced manufacturing company. ICM provides electronic controls, components, and sub-systems for industrial applications. Prior to ICM, Ms. Goddard served as a Divisional Chief Executive for the Environmental and Analysis Sector at Halma plc, a global group of technology companies and as a Divisional Chief Executive of Halma's Medical and Environmental Sector from 2019 - 2023. Prior to Halma, Ms. Goddard served in leadership roles at Novanta, Covidien (acquired by Medtronic), and Johnson & Johnson. Ms. Goddard also serves on the board of directors of Methode Electronics, Inc., a public company (NYSE: MEI) that develops and manufactures custom solutions for automotive and industrial markets. She received a B.S. in Business Administration from Washington University in St. Louis and an M.B.A. from Harvard Business School. Ms. Goddard has been nominated for election to our Board of Directors because of her strong track record of profit and loss leadership within global companies, her background in commercial execution, strategic marketing, product development and in mergers and acquisitions.

Thomas L. Saeli

Mr. Saeli has been a director of the Company since March 2010. In March 2024, Mr. Saeli retired from JRB Enterprises / Duro-Last Inc, where since 2011, he had served in the positions of Chief Executive Officer, President and a director. JRB Enterprises / Duro-Last Inc is a diversified manufacturer of primarily low slope commercial roofing systems and the business was sold to Holcim Inc one year prior to his retirement. From 2009 to 2011, Mr. Saeli was a consultant to international corporate clients on matters involving business development strategies, acquisitions and operations. He previously served as Chief Executive Officer and a director of Noble International, Ltd., an international automotive supplier. Prior to that, Mr. Saeli was Vice President of Corporate Development for Lear Corporation, an international automotive supplier. Mr. Saeli has served on boards of various privately held businesses and nonprofit organizations. Mr. Saeli has a BA in Economics from Hamilton

College, and an MBA in Finance and Accounting from Columbia University's Graduate School of Business. Mr. Saeli has been nominated for re-election to our Board of Directors because of his manufacturing, corporate development, mergers and acquisitions and finance experience. Mr. Saeli qualifies as an audit committee financial expert under applicable SEC rules.

Robert W. Shaw II

Mr. Shaw has been a director of the Company since June 2010. Since 2015 he has been a consultant for Pratt Miller, Inc., a large engineering company for automotive racing and defense businesses. Mr. Shaw has served as President of the largest dining and excursion boat operator in the United States, with over 100 vessels. He has been President of a large mechanical contracting company specializing in the federal government and healthcare markets. Mr. Shaw served in the US Marine Corps as an infantry Captain, has an MBA degree from Harvard University and a BS degree in engineering from Cornell University. Mr. Shaw has been nominated for re-election to our Board of Directors because of his management expertise and experience as an executive officer.

**Bradford T. Whitmore** 

Mr. Whitmore has been a director of the Company since June 2007 and Chair of our Board of Directors since March 2010. Since 1985, he has been the Managing Partner of Grace Brothers LP, an investment firm that holds approximately 3% of the outstanding shares of our common stock. Mr. Whitmore and Grace Brothers LP collectively hold or claim beneficial ownership of 37.6% of the outstanding shares of our common stock. Mr. Whitmore has a BS in Mechanical Engineering from Purdue University and an MBA from Northwestern University's J.L. Kellogg Graduate School of Management. Over the past several years, Mr. Whitmore has served as a director of several privately held companies in which Grace Brothers LP and its affiliates held investments as well as not-for-profit organizations. Mr. Whitmore has been nominated for re-election to our Board of Directors because of his corporate development expertise and significant expertise in corporate financial matters.

#### **Executive Officers**

Our named executive officers are appointed annually by our Board of Directors. Our named executive officers for the year ended December 31, 2023 were:

Michael E. Manna, President and Chief Executive Officer

69

67

67

• Philip A. Fain, Chief Financial Officer, Treasurer and Secretary

There were no other individuals who meet the definition of Named Executive Officer.

Mr. Manna's information is set forth above with the other directors. Certain information with respect to our other named executive officer for fiscal 2023 is presented below.

## Name Age Present Principal Occupation and Employment History

Philip A. Fain

Mr. Fain was named our Chief Financial Officer in November 2009, Treasurer in December 2009 and Corporate Secretary in April 2013. He previously served as Vice President of Business Development, having joined us in February 2008. Prior to joining us, he was Managing Partner of CXO on the GO, LLC, a management-consulting firm, which he co-founded in November 2003 and which we retained in connection with our acquisition activity. Prior to founding CXO on the GO, LLC, Mr. Fain served as Vice President of Finance - RayBan Sunoptics for Luxottica, SpA. Prior to the acquisition of Bausch & Lomb's global eyewear business by Luxottica, Mr. Fain served as Bausch & Lomb's

Senior Vice President Finance - Global Eyewear from 1997 to 1999 and as Vice President and Controller for the US Sunglass business from 1993 to 1996. In these roles, he led the process to acquire some of the world's most sought-after sunglass companies and brands for Bausch & Lomb. From 1983 to 1993, Mr. Fain served in various positions with Bausch & Lomb including executive positions in corporate accounting, finance and audit. Mr. Fain began his career as a CPA and consultant with Arthur Andersen & Co. in 1977. He received his BA in Economics from the University of Rochester and an MBA from the William E. Simon Graduate School of Business Administration of the University of Rochester.

#### **Corporate Governance**

#### General

Pursuant to the General Corporation Law of the State of Delaware and our By-laws, our business, property and affairs are managed under the direction of our Board of Directors. Members of our Board of Directors are kept informed of Company business through regular discussions with our President and Chief Executive Officer and our Chief Financial Officer, Treasurer and Secretary, by reviewing materials provided to them by the Company's management and by participating in meetings of the Board and its committees.

Our Board of Directors has determined that, except for Michael E. Manna, our President and Chief Executive Officer, all directors are "independent" for purposes of listing standards of The NASDAQ Global Market ("NASDAQ") applicable to the Corporate Development and Governance Committee and the Compensation and Management Committee. In addition, our Board of Directors has determined that, except for Michael E. Manna and Bradford T. Whitmore, our Board Chair, all directors are "independent" for purposes of NASDAQ listing standards applicable to the Audit and Finance Committee. We believe that the segregation of the roles of Board Chair from that of the President and Chief Executive Officer ensures better overall governance of our Company and provides meaningful checks and balances regarding our overall performance. This structure allows our President and Chief Executive Officer to focus on our business while the Board Chair leads our Board of Directors in establishing corporate policy and enhancing our governance structure and practices. We believe this structure is appropriate for a company with our varied product portfolio addressing both commercial and defense markets.

Our Board of Directors has three standing committees: an Audit and Finance Committee, a Corporate Development and Governance Committee, and a Compensation and Management Committee. During 2023, our Board of Directors held four meetings and the committees of our Board of Directors held a total of thirteen meetings. During 2023, Bradford T. Whitmore served as our Board Chair. As Board Chair, Mr. Whitmore served as a non-voting ex-officio member of all our Board committees. Each director attended, in person or virtually, at least 75% of the aggregate of: 1) the total number of meetings of the Board; and 2) the total number of meetings held by all committees of the Board on which he or she served.

Our Board of Directors has adopted a charter for each of the three standing committees that addresses the composition and function of each committee and has also adopted Corporate Governance Principles that address the composition and function of the Board of Directors. These charters and Corporate Governance Principles are available on our website at <a href="http://investor.ultralifecorporation.com">http://investor.ultralifecorporation.com</a> under the subheading "Corporate Governance." Pursuant to our Corporate Governance Principles, it is our policy that directors retire from service at the annual meeting following their 70<sup>th</sup> birthday.

Our Board of Directors has determined that all directors who serve on these committees are "independent" for purposes of the listing standards of NASDAQ, and that the members of the Audit and Finance Committee are also "independent" for purposes of Section 10A(m)(3) of the Securities Exchange Act of 1934, as amended. Our Board of Directors based these determinations primarily on a review of the responses of the directors to questions regarding employment, compensation history, affiliations and family and other relationships, and on follow-up discussions with directors.

Our Board of Directors, consisting of five members, has one director who identifies as "Female" and "African American or Black" in accordance with NASDAQ's listing standards.

#### Committees of the Board of Directors

The composition and the functions of our three standing committees of our Board of Directors are set forth below. Our Board of Directors appoints members of the committees and designates chairs of those committees from among those individuals elected at our annual meetings of stockholders.

#### Audit and Finance Committee

The current members of the Audit and Finance Committee are Thomas L. Saeli (Chair), Janie Goddard and Robert W. Shaw II. This committee selects our independent registered public accounting firm and has oversight responsibility for reviewing the scope and results of the independent registered public accounting firm's annual audit of our financial statements and the quality and integrity of those financial statements. Further, the Audit and Finance Committee reviews the qualifications and independence of the independent registered public accounting firm. The Audit and Finance Committee meets with our Chief Financial Officer and Treasurer, our Corporate Controller and the independent registered public accounting firm to review matters relating to internal accounting controls, our accounting practices and procedures and other matters relating to our financial condition and has the power to engage outside counsel and other outside experts. The Audit and Finance Committee also reviews and monitors areas of financial and cybersecurity risk that could have a material impact on our Company. The Audit and Finance Committee met four times during 2023.

Our Board of Directors has determined that each of the members of the Audit and Finance Committee is "financially literate" in accordance with NASDAQ's listing standards. In addition, our Board of Directors has determined that Mr. Saeli qualifies as an "audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K.

#### Corporate Development and Governance Committee

The current members of the Corporate Development and Governance Committee are Janie Goddard (Chair), Thomas L. Saeli and Robert W. Shaw II. This committee works with management to develop corporate strategy and to identify and evaluate acquisition opportunities, reviews the performance and compensation of our directors annually, makes annual recommendations to our Board of Directors for nominations for election to the Board of Directors and committee assignments and for the compensation of our directors, and manages the annual evaluation of the performance of our President and Chief Executive Officer and our Board Chair. The Corporate Development and Governance Committee met five times during 2023.

The Corporate Development and Governance Committee identifies potential nominees for director based on its own research for appropriate candidates as well as on recommendations received by directors or from stockholders as described below. The Corporate Development and Governance Committee has the authority to retain an executive search firm to assist in the identification of potential director nominees. The evaluation process and the factors considered in undertaking that evaluation are set forth under the caption "Stockholder Recommendations and Standards for Director Nominations" below.

The Corporate Development and Governance Committee also has overall responsibility for assessing and managing our exposure to risks associated with the conduct of our business.

#### Compensation and Management Committee

The current members of the Compensation and Management Committee are Robert W. Shaw II (Chair), Janie Goddard and Thomas L. Saeli. The Compensation and Management Committee has ultimate responsibility for determining the compensation of officers appointed by our Board of Directors, granting stock options and other equity awards and otherwise administering our equity compensation plans, and approving and administering any other compensation plans or agreements. The Compensation and Management Committee has the authority to retain outside experts in making compensation determinations. The Ultralife Corporation 2014 Long-Term Incentive Plan ("2014 LTIP") is administered by the Compensation and Management Committee. In addition, if approved by the Company's stockholders, the proposed Ultralife Corporation Long-Term Incentive Plan (the "New LTIP") will be administered by the Compensation and Management Committee. The Compensation and Management Committee met four times during 2023.

#### Stockholder Recommendations and Standards for Director Nominations

As noted above, the Corporate Development and Governance Committee considers and establishes procedures regarding recommendations for nomination to our Board of Directors, including nominations submitted by stockholders. Such recommendations, if any, should be sent to our Corporate Secretary, Attn: Philip A. Fain, Ultralife Corporation, 2000 Technology Parkway, Newark, New York 14513. Any recommendations submitted to the Corporate Secretary should be in

writing and should include any material the stockholder considers appropriate in support of that recommendation but must include the information that would be required under the rules of the SEC in a proxy statement soliciting proxies for the election of such candidate and a signed consent of the candidate to serve as a director, should he or she be elected. The Corporate Development and Governance Committee evaluates all potential candidates in the same manner, regardless of the source of the recommendation.

The Corporate Development and Governance Committee reviews the credentials of potential director candidates, including those recommended by stockholders, in making a determination whether to conduct a full evaluation of a candidate. The Corporate Development and Governance Committee considers the composition, size and diversity of the existing Board of Directors, along with other factors such as any anticipated vacancies due to retirement or other reasons and the Company's need for a person with specific skills, experiences or attributes, in making its determination to conduct a full evaluation of a candidate. As part of the full evaluation process, the Corporate Development and Governance Committee may conduct interviews, obtain additional background information and conduct reference checks of candidates. The Corporate Development and Governance Committee may also ask the candidate to meet with management and other members of our Board of Directors.

In evaluating a director candidate, our Board of Directors, with the assistance of the Corporate Development and Governance Committee, considers a variety of factors that would qualify the candidate to serve as a director. The criteria for selection to our Board of Directors, as described in our Corporate Governance Principles, include character and leadership skills; general business acumen and executive experience; knowledge of strategy, finance and relations between business and government; and internal business operations – all to ensure an active and diverse Board of Directors whose members work well together and possess the collective knowledge and expertise required to meaningfully contribute as directors. Our Corporate Development and Governance Committee reviews the qualifications of director candidates with those of our current directors to augment and complement the skills, experiences and attributes of our current Board members. The Company is committed to a Board of Directors comprised of individuals with diverse backgrounds, skills and experiences.

#### Annual Meeting Attendance

Our policy is that all our directors, absent special circumstances, should participate in our Annual Meetings of Stockholders, either in person or telephonically. All directors participated in last year's Annual Meeting of Stockholders.

#### **Executive Sessions**

Our Corporate Governance Principles require our independent directors to meet in executive session regularly by requiring them to have at least four regularly scheduled meetings per year without management present. Our independent directors met in executive session four times during 2023. In addition, our standing committees meet in executive session on a regular basis.

## Communicating with the Board of Directors

Stockholders interested in communicating directly with our Board of Directors as a group or individually must request the opportunity to do so in writing to our Corporate Secretary, Attn. Philip A. Fain, Ultralife Corporation, 2000 Technology Parkway, Newark, New York 14513. The Corporate Secretary will review all such correspondence and forward to our Board of Directors a summary of that correspondence and copies of any correspondence that, in his opinion, deals with the functions of the Board of Directors or that he otherwise determines requires their attention. Directors may at any time review a log of all correspondence received by us that are addressed to members of the Board of Directors and request copies of any such correspondence. Any concerns relating to accounting, internal controls or auditing matters will be brought to the attention of the Audit and Finance Committee and handled in accordance with the procedures established by the Audit and Finance Committee with respect to such matters.

## Risk Management

Our management team is responsible for assisting the Corporate Development and Governance Committee in its assessment of our exposure to risks associated with the conduct of business. We have an enterprise risk management process to identify, assess and manage the most significant risks facing our Company. Our Corporate Development and Governance Committee has overall responsibility to regularly review management's risk management process, including the policies and guidelines used by management to identify, assess and manage our exposure to risk on an on-going basis. Our Audit and Finance Committee has oversight responsibility for financial risks and other risks that could have a material impact on our Company. Our management reviews these financial risks with our Audit and Finance Committee regularly and reviews the risk management process, as it affects financial risks, with our Audit and Finance Committee on an on-going basis. Based upon

this risk assessment and management process, the Board may recommend changes to the operations of the Company to reduce risk.

#### **Code of Ethics**

We have a Code of Ethics applicable to all employees, including our named executive officers and all members of our Board of Directors. Our Code of Ethics includes the elements of a code of ethics specified in Item 406 of Regulation S-K and also complies with NASDAQ's requirements for a code of conduct. Stockholders can find a link to this Code of Ethics on our website at <a href="http://investor.ultralifecorporation.com">http://investor.ultralifecorporation.com</a> under the subheading "Corporate Governance."

Our Code of Ethics emphasizes our commitment to conducting business in a legal and ethical manner and encourages prompt and confidential reporting of any suspected violations of law or the Code of Ethics. As part of our Code of Ethics, directors and employees are expected to make business decisions and to take actions based upon the best interests of our Company and not based upon personal relationships or benefits. In conjunction with our Code of Ethics, our General Counsel conducts an annual training session with our Board of Directors with emphasis on all facets of compliance with new and existing regulations and best practices. Any potential conflict of interest, and any transaction or relationship involving our officers or directors that could give rise to a conflict of interest, must be reviewed and resolved by our Corporate Development and Governance Committee.

#### **Employee, Officer and Director Hedging**

Pursuant to our Insider Trading Compliance Policy, the Company's directors, officers and employees are prohibited from engaging in short sales of Ultralife securities or from buying or selling put options, call options or other derivatives of Ultralife securities.

#### ITEM 11. EXECUTIVE COMPENSATION

#### **Director Compensation**

Our Corporate Development and Governance Committee presently uses cash compensation to attract and retain qualified candidates to serve on our Board of Directors. Our practice is to survey our peer group companies, generally consisting of like-sized micro-cap companies and/or public companies in our industry, periodically to ascertain whether our overall director compensation is appropriate and balanced. If we perceive that there has been a major change in our Company or the market, we may survey more frequently as directed by the Corporate Development and Governance Committee. In setting director compensation, our Corporate Development and Governance Committee considers the amount of time that directors spend fulfilling their duties to us, the skill-level required by members of our Board of Directors, and based on publicly available data, the compensation paid to directors in similar-sized organizations in our industry. Our program is designed to deliver annual director compensation at the median levels of director compensation for companies in similar industries and of similar size. Our annual director compensation period runs from July 1 to June 30.

#### **Annual Retainers**

Each non-employee director will receive an annual cash retainer of \$70,040, except for the Board Chair, who will receive an annual cash retainer of \$103,000, for the period July 1, 2023 through June 30, 2024, the same as the amounts paid to our non-employee directors for the period July 1, 2022 through June 30, 2023. These retainers are paid quarterly in cash. In addition, each director who is a member of a Board committee receives an additional cash retainer for such committee service.

Annual retainers for Board committee service for the period July 1, 2023 to June 30, 2024 were as follows:

|                                       | Annual Retainer for | Annual Retainer for |
|---------------------------------------|---------------------|---------------------|
|                                       | Committee Members   | Committee Chair     |
| Audit and Finance Committee           | \$6,950             | \$17,250            |
| Compensation and Management Committee | \$6,950             | \$17,250            |
| Corporate Development and Governance  |                     |                     |
| Committee                             | \$6,950             | \$17,250            |
|                                       |                     |                     |

Annual retainers for Board committee service for the period July 1, 2022 to June 30, 2023 were as follows:

|                                       | Annual Retainer for | Annual Retainer for |
|---------------------------------------|---------------------|---------------------|
|                                       | Committee Members   | Committee Chair     |
| Audit and Finance Committee           | \$6,950             | \$17,250            |
| Compensation and Management Committee | \$5,410             | \$13,650            |
| Corporate Development and Governance  |                     |                     |
| Committee                             | \$6,950             | \$17,250            |

Annual retainers for both committee members and committee chairs are paid quarterly in cash. For Board and committee service during the fiscal year ended December 31, 2023, we paid our non-employee directors an aggregate \$435,427.

Our non-employee directors have stock ownership guidelines that require them to maintain ownership of at least \$40,000 of our common stock. Newly elected directors have two years from their election to the Board to achieve the stock ownership requirement. Currently, all our non-employee directors, except for Ms. Goddard who joined the Board on February 21, 2023 and has two years from that date to achieve the stock ownership requirement, meet the stock ownership guidelines. Refer to the Executive Officer Compensation section contained herein for stock ownership guidelines for our named executive officers.

#### **Director Compensation Table**

The table below summarizes the compensation paid by us to our non-employee directors for their service for the fiscal year ended December 31, 2023. Pursuant to our Corporate Governance Principles, it is our policy that directors retire from service at the annual meeting following their 70<sup>th</sup> birthday. Accordingly, Ranjit C. Singh retired at our 2023 Annual Meeting of Stockholders. Janie Goddard joined our Board on February 21, 2023 and was subsequently elected a director at our 2023 Annual Meeting of Stockholders

| Fees Paid<br>in Cash (\$) | Stock<br>Awards (\$)                                    | Option<br>Awards (\$)   | Non- Equity<br>Incentive Plan<br>Compensation   | Nonqualified<br>Deferred<br>Compensation<br>Earnings  | All Other<br>Compensation (\$)  | Total (\$)   |
|---------------------------|---|---|---|---|---|--|
| (1)                       | (2)   | (3)   | (4)   | (5)   | (6)   |  |
| 82,792                    | -   | -   | -   | -   | -   | 82,792   |
| 100,420                   | -   | -   | -   | -   | -   | 100,420  |
| 99,390                    | -   | -   | -   | -   | -   | 99,390   |
| 49,825                    | -   | -   | -   | -   | -   | 49,825   |
| 103,000                   |   |   |   |   |   | 103,000  |
| 435,427                   | -   |   |   |   | -   | 435,427  |
|                           | (1)<br>82,792<br>100,420<br>99,390<br>49,825<br>103,000 | in Cash (S)         Awards (S)           (1)         (2)           82,792         -           100,420         -           99,390         -           49,825         -           103,000         - | in Cash (\$)         Awards (\$)         Awards (\$)           (1)         (2)         (3)           82,792         -         -           100,420         -         -           99,390         -         -           49,825         -         -           103,000         -         - | Fees Paid in Cash (S)         Stock Awards (S)         Option Awards (S)         Incentive Plan Compensation           (1)         (2)         (3)         (4)           82,792         -         -         -           100,420         -         -         -           99,390         -         -         -           49,825         -         -         -           103,000         -         -         - | Fees Paid in Cash (\$)         Stock Awards (\$)         Option Awards (\$)         Non- Equity Incentive Plan Compensation         Deferred Compensation Earnings           (1)         (2)         (3)         (4)         (5)           82,792         -         -         -           100,420         -         -         -           99,390         -         -         -           49,825         -         -         -           103,000         -         -         - | Fees Paid in Cash (S)         Stock Awards (S)         Option Awards (S)         Non- Equity Incentive Plan (Compensation Plan (Compensation Plan (Plan (P |

- (1) Amounts shown represent cash compensation earned during 2023. Amounts may differ from amounts paid in 2023 due to timing of payments.
- (2) There were no stock awards granted to our non-employee directors during 2023 or outstanding at December 31, 2023.
- (3) There were no option awards granted to our non-employee directors during 2023 or outstanding at December 31, 2023.
- (4) There was no non-equity incentive plan compensation paid to our non-employee directors for the fiscal year ended December 31, 2023.
- (5) No non-qualified deferred compensation earnings were accrued for our non-employee directors for the fiscal year ended December 31, 2023.
- (6) There was no other compensation paid to our non-employee directors for the fiscal year ended December 31, 2023.

Michael E. Manna, our current President and Chief Executive Officer, was ineligible to receive compensation for his service as a director because he is also an employee. Refer to the Summary Compensation Table for the compensation of our named executive officers.

#### **Executive Officer Compensation**

We have determined that Mr. Manna and Mr. Fain were our named executive officers for 2023 and that Mr. Popielec, the Company's former CEO and President, from January 1, 2022 to November 22, 2022, Mr. Manna commencing November 22, 2022, and Mr. Fain were our named executive officers for 2022.

As a smaller reporting company under the Securities Exchange Act of 1934, as amended, we are providing executive compensation information in accordance with the scaled disclosure requirements of Regulation S-K. As a result, a Compensation Disclosure and Analysis and certain other disclosures are not included.

### **Summary Compensation Table**

The following table sets forth information concerning the compensation earned by or awarded to our named executive officers for their services in all capacities to us during 2023 and 2022:

|  |      | Salary (\$) | Bonus (\$) | Stock<br>Awards (\$) | Option Awards (\$) | All Other<br>Compensation (\$) | Total (\$) |
|--|------|-------------|------------|----------------------|--------------------|--------------------------------|------------|
| Name and Principal Position (1)                    | Year | (2)         | (3)        | (4)                  | (5)                | (6)                            |            |
| Michael E. Manna, President and Chief              | 2023 | 376,923     | 278,214    | -                    | 106,004            | 17,902                         | 779,043    |
| Executive Officer (Current)                        | 2022 | 241,422     | 31,283     | -                    | 32,087             | 12,561                         | 317,353    |
| Philip A. Fain, Chief Financial Officer, Treasurer | 2023 | 350,667     | 215,694    | -                    | 65,628             | 21,463                         | 653,452    |
| and Secretary                                      | 2022 | 340,414     | 36,363     | -                    | 51,339             | 20,150                         | 448,266    |
| Michael D. Popielec, President and Chief           | 2023 | -           | -          | -                    | -                  | -                              | -          |
| Executive Officer (Former)                         | 2022 | 534,400     | 85,631     | -                    | 102,678            | 24,252                         | 746,961    |

- (1) The 2022 amounts presented in the Compensation Table above for Mr. Popielec represent his compensation for the full year, although he served as a named executive officer from January 1, 2022 to November 22, 2022. Similarly, the 2022 amounts presented for Mr. Manna represent his compensation for the full year, although he served as a named executive officer commencing on November 22, 2022.
- (2) Amounts shown represent base salary cash compensation paid during the respective years. Amounts may differ from amounts earned due to timing of payroll periods. Refer to the "Narrative to Summary Compensation Table" below for further information.
- (3) Amounts shown represent short-term incentive plan cash awards earned during the respective years and paid in the subsequent year. Refer to the "Narrative to Summary Compensation Table" for further information.
- (4) There were no stock awards other than stock options granted during fiscal years 2023 and 2022 shown under the column above titled Option Awards.
- (5) Amounts shown represent the aggregate grant date fair value of stock options awarded during the respective years computed in accordance with Accounting Standards Codification Topic 718, Compensation Stock Compensation ("ASC 718"). See the notes to our audited consolidated financial statements included in our Annual Reports on Form 10-K for the fiscal years ended December 31, 2023 and December 31, 2022, respectively, for the assumptions used in valuing these stock option awards in accordance with ASC 718. Refer to the "Narrative to Summary Compensation Table" below for further information.
- (6) Amounts shown as "All Other Compensation" consist of the following:

|      | 401(k) Plan<br>Employer Match<br>(\$) | Other<br>Benefits <sup>(a)</sup><br>(\$)                    | Total<br>(\$)   |
|------|---------------------------------------|---|---|
| 2023 | 12,879                                | 5,023   | 17,902  |
| 2022 | 9,656                                 | 2,905   | 12,561  |
| 2023 | 13,200                                | 8,263   | 21,463  |
| 2022 | 12,200                                | 7,950   | 20,150  |
| 2023 | -                                     | -   | -   |
| 2022 | 9,206                                 | 15,046  | 24,252  |
|      | 2022<br>2023<br>2022<br>2023          | (\$) 2023 12,879 2022 9,656  2023 13,200 2022 12,200 2023 - | (\$)         (\$)           2023         12,879         5,023           2022         9,656         2,905           2023         13,200         8,263           2022         12,200         7,950           2023         -         - |

(a) The "Other Benefits" column of the above table includes premiums paid for group medical and dental coverage and long-term care insurance, reimbursement for tax preparation and certain financial planning expenses.

## Narrative to Summary Compensation Table

#### Compensation Overview

Our executive compensation program is evaluated and approved each year by our Compensation and Management Committee. Annual total compensation for our named executive officers is comprised of the following key components:

- Base salary;
- A short-term incentive plan ("STIP");
- A long-term incentive plan; and
- Perquisites and other benefits.

Our executive compensation program is structured to align the interests of our named executive officers with those of our stockholders by rewarding performance that achieves successful execution of our business strategy, grows our business and increases stockholder value. Our executive compensation program is designed to incentivize our named executive officers to achieve strong financial, operational and strategic performance and to provide a link between the compensation earned by our executives and the creation of long-term sustainable value. The Compensation and Management Committee establishes specific annual, long-term and strategic goals and seeks to reward our named executive officers for performance that meets or exceeds those goals. In addition, we expect our named executive officers to work toward achievement of these goals while maintaining the highest ethical standards.

#### Base Salary

The Corporate Development and Governance Committee evaluates the performance of the President and Chief Executive Officer and presents its evaluation annually to the Compensation and Management Committee for recommendation annually for base salary adjustment, if any, to the Board of Directors for approval. The President and Chief Executive Officer evaluates the performance of Mr. Fain, our Chief Financial Officer, Treasurer and Secretary, and presents his evaluation and recommendation annually for a base salary adjustment, if any, to the Compensation and Management Committee, which, in turn, may recommend acceptance of or adjustment to such base salary recommendation to the Board of Directors. If adjustments to base salaries are recommended and approved, the adjustments are made to be effective for a period ranging from twelve months from the date of the last salary adjustment.

In October 2022, the Board of Directors, at the recommendation of the Compensation and Management Committee, approved a base salary increase of 3.0% for Mr. Popielec (\$531,761 to \$547,715) and 3.0% for Mr. Fain (\$338,713 to \$348,875). On November 22, 2022, upon his appointment as President and Chief Executive Officer, the Board of Directors upon recommendation of the Compensation and Management Committee, approved a base salary of \$375,000 for Mr. Manna. His salary as President, Battery & Energy Products prior to his appointment as President and Chief Executive Officer had been \$253,000. In October 2023, the Board of Directors, at the recommendation of the Compensation and Management Committee, approved a base salary increase of 3.0% for Mr. Manna (\$375,000 to \$386,249) and 3.0% for Mr. Fain (\$348,875 to \$359,341). The salary increases were approved by the Compensation and Management Committee based on a number of factors including individual and Company performance.

#### Short-Term Incentive Plan

Our Compensation and Management Committee establishes a STIP each fiscal year to provide our named executive officers an opportunity to earn an annual cash award in addition to their base salaries. The STIP is designed to place "at risk" a significant portion of the annual total cash compensation of our named executive officers to incentivize them to achieve our short-term financial objectives while making progress toward our longer-term goals. Generally, the STIP target levels are set such that, assuming achievement of pre-established performance metrics, the combined annual base salary and STIP award for our named executive officers will be at or near the 50<sup>th</sup> percentile for named executive officers at the companies in our peer group.

For 2023, the STIP target bonus levels for Messrs. Manna and Fain were 60% and 50% of their respective base salaries. For Messrs. Manna and Fain, the performance goals to be achieved to be awarded the STIP targeted bonus for 2023 were

consolidated operating profit and consolidated revenue goals of \$7.7 million and \$156.5 million, respectively, as measured pursuant to generally accepted accounting principles. The STIP award was structured with a 70% weighting on the consolidated operating profit goal and a 30% weighting on the respective revenue goal. Achievement of less than 75% of the consolidated operating profit and less than 90% of the revenue goals would result in no award being earned with respect to that metric. Achievement of the target goals would result in an 90% payment of the target bonus levels with respect to that metric. Achievement of over 100% to 111% of the consolidated operating profit goal and achievement of over 100% to 111% of the revenue goal would result in an award ranging from 90% to 100% of the target award with respect to the metric for which such performance levels had been achieved. Achievement of over 111% to 125% of the consolidated operating profit goal and over 111% to 125% of the revenue goal would result in an award ranging from 101% to 135% of the target award with respect to the metric for which such performance levels had been achieved. Our named executive officers were eligible for a partial award if one of the two metrics was achieved.

Based on our 2023 financial performance, Messrs. Manna and Fain earned STIP awards for 2023 of \$278,214 and \$215,694, respectively, which were paid in March 2024.

For 2022, the STIP target bonus levels for Messrs. Popielec, Fain and Manna were 75%, 50% and 50% of their respective base salaries. For Messrs. Popielec and Fain, the performance goals to be achieved to receive the STIP targeted bonus for 2022 were consolidated operating profit and consolidated revenue goals of \$7.3 million and \$139.2 million, respectively, as measured pursuant to generally accepted accounting principles. For Mr. Manna, the performance goals to be achieved to receive the STIP target bonus were consolidated operating profit and Battery & Energy Products revenue goals of \$7.3 million and \$118.2 million, respectively, as measured pursuant to generally accepted accounting principles. The STIP award was structured with a 70% weighting on the consolidated operating profit goal and a 30% weighting on the respective revenue goal. Achievement of less than 75% of the consolidated operating profit and less than 90% of the revenue goals would result in no award being earned with respect to that metric. Achievement of the target goals would result in an 80% payment of the target bonus levels with respect to that metric. Achievement of over 100% to 112.5% of the consolidated operating profit goal and achievement of over 100% to 112.5% of the revenue goal would result in an award ranging from 81% to 100% of the target award with respect to the metric for which such performance levels had been achieved. Achievement of over 112.5% to 150% of the consolidated operating profit goal and over 112.5% to 125% of the revenue goal would result in an award ranging from 101% to 120% of the target award with respect to the metric for which such performance levels had been achieved. Our named executive officers were eligible for a partial award if one of the two metrics was achieved.

Based on our 2022 financial performance, Messrs. Popielec, Fain and Manna earned STIP awards for 2022 of \$85,631, \$36,362, and \$31,283, respectively, which were paid in April 2023. In addition, at the recommendation of the Compensation and Management Committee, the Board of Directors approved discretionary bonuses of \$30,000 and \$20,000 for Mr. Popielec and Mr. Fain, respectively, which were paid in February 2022 for their roles in the 2021 acquisition and integration of Excell Battery Group.

#### Long-Term Incentive Plan

Stock options and other equity awards are used to align the interests of our named executive officers with those of our stockholders by incentivizing our named executive officers to achieve long-term growth and sustainable stockholder value.

Refer to "Outstanding Equity Awards" below for stock options granted during 2023 and 2022. There were no other equity-based awards granted to our named executive officers during 2023 and 2022.

## Retirement Benefits

We provide a tax-qualified 401(k) plan to all active employees that provides for both employer and employee contributions. Under this plan, employees may contribute a portion of their eligible cash compensation to the plan. For 2023 and 2022, the Company matched 100% on the first 3% and 50% on the next 2% of an employee's eligible contributions.

## Perquisites and Other Personal Benefits

We provide our named executive officers with certain perquisites and other personal benefits which are consistent with the objectives of our overall compensation program to better enable us to attract and retain superior employees for key positions. The Compensation and Management Committee periodically reviews the levels of such perquisites and other personal benefits to ensure they remain at appropriate levels. The aggregate incremental costs of the perquisites and other personal benefits provided to our named executive officers are included in the "All Other Compensation" column of the Summary Compensation Table above with components detailed in an accompanying note.

#### **Outstanding Equity Awards**

The following table sets forth information concerning the number of shares underlying exercisable and non-exercisable stock option awards outstanding at December 31, 2023 for our named executive officers.

|                  | Equity Incentive        |                         |                         |            |            |
|------------------|-------------------------|-------------------------|-------------------------|------------|------------|
|                  |                         |                         | Plan Awards:            |            |            |
|                  | Number of<br>Securities | Number of<br>Securities | Number of<br>Securities |            |            |
|                  | Underlying              | Underlying              | Underlying              |            |            |
|                  | Unexercised             | Unexercised             | Unexercised             | Option     | Option     |
|                  | Options (#)             | Options (#)             | Options (#)             | Exercise   | Expiration |
| Name             | Exercisable             | Unexercisable           | Unearned                | Price (\$) | Date       |
| Michael E. Manna | 8,500                   | -                       | -                       | 9.8514     | 4/18/2025  |
|                  | 10,000                  | -                       | -                       | 8.2523     | 7/23/2026  |
|                  | 10,000                  | -                       | -                       | 8.4476     | 9/6/2026   |
|                  | 11,000                  | -                       | -                       | 6.5062     | 4/22/2027  |
|                  | 8,334                   | 4,166 (1)               | -                       | 6.9694     | 10/20/2028 |
|                  | 4,167                   | 8,333 (2)               | -                       | 5.4533     | 10/19/2029 |
|                  | -                       | 12,500 (3)              |                         | 4.0737     | 2/21/2030  |
|                  | -                       | 23,000 (4)              |                         | 6.8354     | 12/7/2030  |
| Philip A. Fain   | 20,000                  | -                       | -                       | 5.7075     | 4/19/2024  |
|                  | 20,000                  | -                       | -                       | 9.8514     | 4/18/2025  |
|                  | 25,000                  | -                       | -                       | 8.2523     | 7/23/2026  |
|                  | 20,000                  | -                       | -                       | 6.5062     | 4/22/2027  |
|                  | 13,334                  | 6,666 (5)               | -                       | 6.9694     | 10/20/2028 |
|                  | 6,667                   | 13,333 (6)              | -                       | 5.4533     | 10/19/2029 |
|                  | -                       | 18,400 (7)              |                         | 6.8354     | 12/7/2030  |
|                  |                         |                         |                         |            |            |

- (1) On October 20, 2021, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Manna the option to purchase 12,500 shares of our common stock. This option vested with respect to 4,167 shares on October 20, 2022, 4,167 shares on October 20, 2023 and will vest with respect to 4,166 shares on October 20, 2024.
- (2) On October 19, 2022, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Manna the option to purchase 12,500 shares of our common stock. This option vested with respect to 4,167 shares on October 19, 2023, and will vest with respect to 4,167 shares on October 19, 2024 and 4,166 shares on October 19, 2025.
- (3) On February 21, 2023, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Manna the option to purchase 12,500 shares of our common stock. This option vested with respect to 4,167 shares on February 21, 2024, and will vest with respect to 4,167 shares on February 21, 2025 and 4,166 shares on February 21, 2026.
- (4) On December 7, 2023, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Manna the option to purchase 23,000 shares of our common stock. This option will vest with respect to 7,667 shares on December 7, 2024, 7,667 shares on December 7, 2025 and 7,666 shares on December 7, 2026.
- (5) On October 20, 2021, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Fain the option to purchase 20,000 shares of our common stock. This option vested with respect to 6,667 shares on October 20, 2022 and 6,667 shares on October 20, 2023, and will vest with respect to 6,666 shares on October 20, 2024.

- (6) On October 19, 2022, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Fain the option to purchase 20,000 shares of our common stock. This option vested with respect to 6,667 shares on October 19, 2023, and will vest with respect to 6,667 shares on October 19, 2024 and 6,666 shares on October 19, 2025.
- (7) On December 7, 2023, our Board of Directors, on recommendation of the Compensation and Management Committee, granted to Mr. Fain the option to purchase 18,400 shares of our common stock. This option will vest with respect to 6,134 shares on December 7, 2024, 6,133 shares on December 7, 2025 and 6,133 shares on December 7, 2026.

There were no other equity awards outstanding at December 31, 2023 for our named executive officers.

#### **Option Exercises**

The following table sets forth information concerning the exercise of stock option awards for the year ended December 31, 2023 for our named executive officers.

| Number of Shares Acquired on Value Realized on |              |                  |  |  |
|--|--------------|------------------|--|--|
| Name   | Exercise (#) | Exercise (\$)(1) |  |  |
| Philip A. Fain                                 | 630 (2)      | 2,791            |  |  |
| Michael E. Manna                               | 315 (3)      | 1,395            |  |  |
| Michael E. Manna                               | 5,059 (4)    | 35,931           |  |  |

- (1) Represents the aggregate fair market value of the net shares of the Company's common stock acquired pursuant to the Company's 2014 LTIP.
- (2) Represents shares of the Company's common stock acquired on May 19, 2023 upon the exercise of options for 20,000 shares of common stock otherwise expiring on June 1, 2023, net of shares of common stock having a fair value equal to the aggregate exercise price of the shares of common stock for which the options were exercised together with the amount of minimum statutory tax withholdings.
- (3) Represents shares of the Company's common stock acquired on May 19, 2023 upon the exercise of options for 10,000 shares of common stock otherwise expiring on June 1, 2023, net of shares of common stock having a fair value equal to the aggregate exercise price of the shares of common stock for which the options were exercised together with the amount of minimum statutory tax withholdings.
- (4) Represents shares of the Company's common stock acquired on December 27, 2023 upon the exercise of options for 20,000 shares of common stock otherwise expiring on January 18, 2024, net of shares of common stock having a fair value equal to the aggregate exercise price of the shares of common stock for which the options were exercised together with the amount of minimum statutory tax withholdings.

#### **Employment Arrangements**

As of December 31, 2022, we had an Employment Agreement dated December 6, 2010 with Michael D. Popielec (the "Employment Agreement"), our former President and Chief Executive Officer. Under the terms of the Employment Agreement, Mr. Popielec was given sixty days advance notice of his involuntary termination by the Company's Board of Directors on November 22, 2022, at which time he relinquished his position as President and Chief Executive Officer and as a member of the Board of Directors, with his employment ending on January 20, 2023.

In connection with the termination of his employment, Mr. Popielec was entitled to receive the following severance benefits under the terms of the Employment Agreement with the total cost of approximately \$779,000 comprising a one-time charge reflected in the Company's 2022 fourth quarter results:

 Salary, any unpaid bonus from the prior year, and the cash value of any accrued Paid Time Off through January 20, 2023 plus continued salary for a period of twelve months thereafter in accordance with the Company's regular payroll schedule;

- A pro-rata amount (calculated on a per-diem basis) of the full year bonus which Mr. Popielec would have earned for the 2023 calendar year;
- Acceleration of vesting of all outstanding stock options held by Mr. Popielec; provided that the acceleration shall not cover more than eighteen months from January 20, 2023, and all such options shall remain exercisable for one year from January 20, 2023; and
- Continuation of health benefits for Mr. Popielec, his spouse and any dependent children for a period of twelve months following January 20, 2023.

The foregoing description of the termination benefits provided by Mr. Popielec's Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.40 to the Company's Form 10-K filed with the Securities and Exchange Commission on March 15, 2011

There are no employment agreements in place for Mr. Manna or for Mr. Fain. Mr. Manna and Mr. Fain have executed Employee Confidentiality Non-Disclosure, Non-Compete, Non-Disparagement and Assignment Agreement in our standard form.

#### Retirement Benefits and Potential Payments upon Termination, Change in Control or Retirement

The only arrangement that we maintain that provides for retirement benefits is our tax-qualified defined contribution 401(k) plan. The material terms of our tax-qualified defined contribution 401(k) plan are summarized above under the heading "Retirement Benefits."

All potential payments and benefits payable by us to our named executive officers in the event of various circumstances involving either a termination of employment or change in control are determined pursuant to the 2014 LTIP. On June 18, 2018, the Compensation and Management Committee unanimously approved a resolution for full vesting of all outstanding unvested stock options and other equity awards upon the occurrence of a "Change in Control" (as defined by the 2014 LTIP). On October 18, 2018, the Compensation and Management Committee unanimously approved a modification to the retirement policy whereby a named executive officer upon retirement and signing the Company's non-compete agreement and fully complying with the same will retain any and all unexpired stock options until the relevant option term has expired.

#### **Stock Ownership Guidelines**

To better align the interests of our named executive officers and stockholders, the Compensation and Management Committee implemented stock ownership requirements for our named executive officers. The stock ownership requirements for our named executive officers are as follows:

| President & CEO         | 1.00 times salary |
|-------------------------|-------------------|
| Chief Financial Officer | 0.50 times salary |

For 2023, the Compensation and Management Committee established the presumed share price to be used for purposes of determining the minimum number of shares to be owned by the named executive officers. This presumed price was \$7.32 per share, which was based on the volume weighted average price ("VWAP"), calculated as an amount equal to the sum of the dollar value of every transaction in our common stock for the two-year period ended December 31, 2023, divided by the total shares traded for such two-year period. Each year the Compensation and Management Committee will establish a new price per share to be used to determine the minimum number of shares required to be held which will be based on the VWAP of our common stock for the preceding two-year period. Named executive officers have three years from the date of hire or appointment as a named executive officer to achieve the required holdings, which are based on the price per share as calculated above. Additionally, our stock ownership policy requires that until the share ownership guidelines are met, named executive officers are prohibited from disposing of more than 50% of vested shares received from restricted share grants (on an after-tax basis) and 50% of shares received on exercise of stock options. Shares owned by an executive, as well as shares underlying awards of stock options and restricted stock are treated as owned by the executive for purposes of determining whether required ownership has been achieved. Mr. Fain is in compliance with the stock ownership requirement, and Mr. Manna has until November 21, 2024 to meet the share ownership guidelines.

## ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

#### **Security Ownership of Certain Beneficial Owners**

The table below shows certain information regarding the beneficial ownership of shares of our common stock by each person known by us to beneficially own more than five percent of the outstanding shares of our common stock, with percentages based on 16,466,594 shares issued and outstanding as of April 22, 2024.

| Name and Address of Beneficial Owner   | Number of Shares Beneficially Owned | Percent of Class Beneficially Owned |
|--|-------------------------------------|-------------------------------------|
| Bradford T. Whitmore (1)<br>5215 Old Orchard Road, Suite 620<br>Skokie, IL 60077             | 6,201,013                           | 37.7%                               |
| Visionary Wealth Advisors (2)<br>1405 North Green Mount Rd., Suite 500<br>O'Fallon, IL 62208 | 1,082,246                           | 6.6%                                |
| Dimensional Fund Advisors LP (3)<br>6300 Bee Cave Road<br>Building One<br>Austin, TX 78746   | 931,030                             | 5.7%                                |

- (1) Based on information contained in a Form 4 dated December 6, 2023 as filed by Bradford T. Whitmore with the SEC on December 8, 2023, Mr. Whitmore individually and as sole manager and sole voting member of SUNRAY I, LLC, a Delaware limited liability company and as General Partner of Grace Brothers LP, a Delaware limited partnership, beneficially owns 6,201,013 shares of our common stock. Mr. Whitmore has sole voting and dispositive power with respect to 5,682,397 of such shares, of which 4,452,283 are held in the name in SUNRAY I, LLC, and shared voting and dispositive power (with Grace Brothers, LP) with respect to 518,616 of such shares.
- (2) Based on information contained in a Schedule 13G dated February 14, 2024 as filed by Visionary Wealth Advisors, a registered investment adviser, with the SEC on that same date to report beneficial ownership of shares of the Company's common stock as of December 31, 2023, and, consequently, the beneficial ownership of Visionary Wealth Advisors may have subsequently changed. The Schedule 13G reported that Visionary Wealth Advisors had sole voting power as to 9,000 shares of common stock and shared dispositive power as to 1,082,246 shares of common stock.
- (3) Based on information contained in a Schedule 13G dated February 9, 2024 as filed by Dimensional Fund Advisors LP, a registered investment adviser, with the SEC on that same date to report beneficial ownership of shares of the Company's common stock as of December 29, 2023, and, consequently, the beneficial ownership of Dimensional Fund Advisors LP may have subsequently changed. The Schedule 13G reported that Dimensional Fund Advisors LP had sole voting power as to 911,335 shares of common stock and sole dispositive power as to 931,030 shares of common stock, all of which shares of common stock were held in portfolios of four registered investment companies to which Dimensional Fund Advisors LP or one of its subsidiaries furnishes investment advice and of certain other commingled funds, group trusts and separate accounts for which Dimensional Fund Advisors LP or one of its subsidiaries serves as investment manager or sub-adviser. The shares of common stock reported were owned by the investment companies, commingled funds, group trusts, and separate accounts and Dimensional Fund Advisors LP disclaimed beneficial ownership of the reported shares of common stock.

#### **Security Ownership of Management**

The table below shows certain information regarding the beneficial ownership of shares of our common stock as of April 22, 2024 by (1) each of our directors, (2) each of our executive officers, and (3) all of our directors and executive officers as a group.

| Name of Beneficial Owner (1)                                   | Number of Shares<br>Beneficially Owned (1) | Percent of Class<br>Beneficially Owned (1)(2) |
|--|--|---|
| Michael E. Manna   | 74,542 (3)                                 | * (4)   |
| Janie Goddard  | 1,500                                      | *   |
| Thomas L. Saeli  | 80,000                                     | *   |
| Robert W. Shaw II  | 62,750                                     | *   |
| Bradford T. Whitmore   | 6,201,013 (5)                              | 37.7%   |
| Philip A. Fain   | 222,810 (6)                                | 1.3% (7)                                      |
| All Directors and Executive<br>Officers as a group (6 persons) | 6,642,615 (8)                              | 40.0% (9)                                     |

<sup>\*</sup>Less than 1%

- (1) Except as otherwise indicated, the stockholders named in this table have sole voting and investment power with respect to the shares of our common stock beneficially owned by them. The information provided in this table is based upon information provided to us by such stockholders. The table reports beneficial ownership for our directors and executive officers in accordance with Rule 13d-3 under the Exchange Act. This means all our securities over which directors and executive officers directly or indirectly have or share voting or investment power are included as beneficially owned. The amounts also include shares that may be acquired by exercise of stock options within 60 days, which shares are referred to in the footnotes to this table as "shares of common stock subject to options that may be exercised."
- (2) Except as otherwise indicated, computations are based on 16,466,594 shares outstanding as of April 22, 2024.
- (3) The number of shares deemed to be beneficially owned consists of 18,374 shares of common stock held by Mr. Manna as of April 22, 2024, or less than 1% of common stock outstanding as of that date, and 56,168 shares of common stock subject to options that may be exercised within 60 days by Mr. Manna.
- (4) Computed based on 16,522,762 shares of common stock deemed outstanding, which consists of 16,466,594 shares of common stock outstanding as of April 22, 2024 and 56,168 shares of common stock subject to options that may be exercised within 60 days by Mr. Manna.
- (5) See "Security Ownership of Certain Beneficial Owners" above.
- (6) The number of shares deemed to be beneficially owned consists of 137,809 shares of common stock held by Mr. Fain as of April 22, 2024, or less than 1% of common stock outstanding as of that date, and 85,001 shares of common stock subject to options that may be exercised within 60 days by Mr. Fain.
- (7) Computed based on 16,551,595 shares of common stock deemed outstanding, which consists of 16,466,594 shares of common stock outstanding as of April 22, 2024 and 85,001 shares of common stock subject to options that may be exercised within 60 days by Mr. Fain.
- (8) The number of shares deemed to be beneficially owned consists of 6,501,446 shares of common stock held by all directors and executive officers as a group as of April 22, 2024, or 39.5% of common stock outstanding as of that date, and 141,169 shares of common stock subject to options that may be exercised within 60 days.
- (9) Computed based on 16,607,763 shares of common stock deemed outstanding, which consists of 16,466,594 shares of common stock outstanding as of April 22, 2024 and 141,169 shares of common stock subject to options that may be exercised within 60 days.

## Securities Authorized for Issuance Under Equity Compensation Plans

The following table summarizes compensation plans under which our equity securities are authorized for issuance as of December 31, 2023.

| Plan Category  | Number of securities to<br>be issued upon exercise<br>of outstanding options,<br>warrants and rights<br>(a) | Weighted-average<br>exercise price of<br>outstanding options,<br>warrants and rights<br>(b) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))  (c) |
|--|---|---|--|
| Equity compensation plans approved by security holders     | 1,250,595   | \$7.10  | 632,593  |
| Equity compensation plans not approved by security holders |   |   | <u> </u>   |
| Total  | 1,250,595   | \$7.10  | 632,593  |

# ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

## **Related Party Transactions**

We have adopted written policies and procedures for the review and approval or ratification of any "related party transaction," as defined by Regulation S-K, Item 404. The policy provides that each related party transaction must be reviewed by our Audit and Finance Committee. The Audit and Finance Committee reviews the relevant facts and circumstances of the transaction, including if the transaction is on terms comparable to those that could be obtained in arms-length dealings with an unrelated third party and the extent of the related party's interest in the transaction, taking into account the conflicts of interest and corporate opportunity provisions of our Code of Ethics, and either recommends that the Board of Directors approve or disapprove the related party transaction. We will disclose all related party transactions, as required, in our filings with the SEC. No reportable transactions occurred during 2023 and 2022, and there are currently no such proposed transactions.

## **Director Independence**

Refer to the Corporate Governance section of Part III, Item 10 of this Amendment No. 1.

#### ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The firm of Freed Maxick CPAs P.C. served as our independent registered public accounting firm for the years ended December 31, 2023 and 2022.

#### Principal Accountant Fees and Services

Aggregate fees for professional services rendered for us for 2023 and 2022 were:

|                      | 2023      | 2022      |
|----------------------|-----------|-----------|
| Audit Fees           | \$565,700 | \$575,057 |
| Audit - Related Fees | 13,125    | 18,500    |
| Tax Fees             |           | 5,891     |
| Total Fees           | \$578,825 | \$599,448 |

#### Audit Fees

Audit fees were for professional services rendered for the audits of our consolidated financial statements and reviews of our quarterly consolidated financial statements.

#### Audit-Related Fees

Audit-related fees were for the annual audits of our 401(k) defined contribution plan.

#### Tax Fees

Tax fees were attributable to the amalgamation/restructuring of our legal entity structure for Excell Battery Group in 2022.

Our Audit and Finance Committee has not adopted pre-approval policies and procedures for audit and non-audit services. Nevertheless, all audit, audit-related and permitted non-audit services for which our independent registered public accounting firm was engaged were reviewed and approved prior to the commencement of the services by our Audit and Finance Committee in compliance with applicable SEC requirements.

## All Other Fees

There were no other services rendered to us by Freed Maxick for 2023 and 2022 and accordingly no other fees were incurred.

## **PART IV**

## ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

- (a) The following documents are filed as part of this report:
  - 1. Consolidated Financial Statements:

No financial statements or supplemental data are filed with this Amendment No. 1 to our Form 10-K filed for the year ended December 31, 2023 on March 21, 2024 ("2023 Form 10-K"). All such financial statements and supplemental data were previously filed with the 2023 Form 10-K.

Auditor information: Freed Maxick CPAs, P.C. Rochester, New York PCAOB ID 317

## 3. Exhibits:

See the Exhibit Index below.

## EXHIBIT INDEX

| Exhibit<br>Index | Description of Document  | Filed Herewith or Incorporated by Reference from:  |
|------------------|--|--|
| 2.1              | Share Purchase Agreement, dated December 13, 2021, by and among 1336889 B.C. Unlimited Liability Company, Mark Kroeker, Randolph Peters, Brian Larsen, M. & W. Holdings Ltd., Karen Kroeker, Heather Peterson, Michael Kroeker, Nicholas Kroeker, Brentley Peters, Craig Peters, Kurtis Peters, Heather Larsen, Ian Kane, Carol Peters, 0835205 B.C. LTD, and Excell Battery Canada Inc. | Exhibit 2.1 of the Form 8-K filed on December 16, 2021   |
| 2.2              | Share Purchase Agreement, dated December 13, 2021, by and among 1336902 B.C. Unlimited Liability Company, M. & W. Holdings Ltd., Ian Kane, Sanford Capital Ltd., Arcee Enterprises Inc., 0835205 B.C. Ltd., and 656700 B.C. LTD  | Exhibit 2.2 of the Form 8-K filed on December 16, 2021   |
| 2.3              | Stock Purchase Agreement, dated May 1, 2019, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, Southwest Electronic Energy Medical Research Institute, and Claude Leonard Benckenstein  | Exhibit 2.1 of the Form 8-K filed on May 2, 2019   |
| 2.4              | Stock Purchase Agreement Relating to<br>Accutronics Limited by and between Robert<br>Andrew Phillips and Others and Ultralife<br>Corporation   | Exhibit 2.2 of the Form 10-K for the year ended December 31, 2015, filed March 2, 2016                                     |
| 3.1              | Restated Certificate of Incorporation  | Exhibit 3.1 of the Form 10-K for the year ended December 31, 2008, filed March 13, 2009                                    |
| 3.2              | Amended and Restated By-laws   | Exhibit 3.2 of the Form 8-K filed December 9, 2011   |
| 4.1              | Specimen Stock Certificate   | Exhibit 4.1 of the Form 10-K for the year ended December 31, 2008, filed March 13, 2009                                    |
| 4.2              | Description of Registrant's Securities   | Exhibit 4.2 of the Form 10-K/A for the year ended December 31, 2019, filed April 28, 2020                                  |
| 10.1*            | Amendment to the Agreement relating to rechargeable batteries  | Exhibit 10.24 of our Form 10-K for the fiscal year ended June 30, 1996 (this Exhibit may be found in SEC File No. 0-20852) |
| 10.2†            | Employment Agreement between the Registrant and Michael D. Popielec dated December 6, 2010   | Exhibit 10.40 of the Form 10-K for the year ended December 31, 2010, filed March 15, 2011                                  |
| 10.3†            | Ultralife Corporation Amended 2014 Long-<br>Term Incentive Plan  | Appendix B of Form DEF 14A filed on  |
| 10.4             | Credit and Security Agreement between Ultralife Corporation and KeyBank National Association dated May 31, 2017  | June 1, 2021<br>Exhibit 10.1 of the Form 8-K filed on<br>June 6, 2017  |
| 10.5             | First Amendment Agreement, dated May 1, 2019, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, INC., and KeyBank National Association   | Exhibit 10.1 of the Form 8-K filed on May 2, 2019  |

| 10.6†       | Amendment No. 1 to Ultralife Corporation<br>Amended 2014 Long-Term Incentive Plan  | Appendix A of Form DEF 14A filed on June 1, 2021   |
|-------------|--|--|
| 10.7        | Second Amendment Agreement, dated December 13, 2021, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, INC., Ultralife Excell Holding Corp., Ultralife Canada Holding Corp., Excell Battery Corporation USA, and KeyBank National Association                          | Exhibit 10.1 of the Form 8-K filed on December 16, 2021                                  |
| 10.8        | Third Amendment Agreement, dated November 28, 2022, by and among Ultralife Corporation, Southwest Electronic Energy Corporation, CLB, Inc., Ultralife Excell Holding Corp., Ultralife Canada Holding Corp., Excell Battery Corporation USA, Excell Battery Canada ULC and KeyBank National Association | Exhibit 10.8 of the Form 10-K for the year ended December 31, 2022, filed March 31, 2023 |
| 21          | Subsidiaries   | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 23.1        | Consent of Freed Maxick CPAs, P.C.   | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 31.1        | Rule 13a-14(a) CEO Certification   | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 31.2        | Rule 13a-14(a) CFO Certification   | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 31.3        | Rule 13a-14(a) CEO Certification   | Filed herewith   |
| 31.4        | Rule 13a-14(a) CFO Certification   | Filed herewith   |
| 32          | Section 1350 Certifications  | Furnished with Form 10-K for the year ended December 31, 2023, filed March 21, 2024      |
| 97.1        | Ultralife Corporation Policy for the Recovery of Erroneously Awarded Compensation  | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 101.IN<br>S | Inline XBRL Instance Document  | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 101.SC<br>H | Inline XBRL Taxonomy Extension Schema<br>Document  | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 101.CA<br>L | Inline XBRL Taxonomy Extension Calculation Linkbase Document   | Filed with Form 10-K for the year ended December 31, 2023, filed March                   |
|             |  | 21, 2024   |
| 101.LA<br>B | Inline XBRL Taxonomy Extension Label<br>Linkbase Document  | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 101.PR<br>E | Inline XBRL Taxonomy Extension<br>Presentation Linkbase Document   | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 101.DE<br>F | Inline XBRL Taxonomy Extension Definition Linkbase Document  | Filed with Form 10-K for the year ended December 31, 2023, filed March 21, 2024          |
| 104         | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   | Filed herewith   |

<sup>\*</sup> Confidential treatment has been granted as to certain portions of this exhibit.

| † | † Management contract or compensatory plan or arrangen | nent. |
|---|--|-------|
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |
|   |  |       |

## **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## **ULTRALIFE CORPORATION**

Date: April 26, 2024 /s/ Michael E. Manna

Michael E. Manna

President, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

| Date: April 26, 2024 | /s/ Michael E. Manna Michael E. Manna President, Chief Executive Officer and Director (Principal Executive Officer)                    |
|----------------------|--|
| Date: April 26, 2024 | /s/ Philip A. Fain Philip A. Fain Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer) |
| Date: April 26, 2024 | /s/ Janie Goddard<br>Janie Goddard (Director)  |
| Date: April 26, 2024 | /s/ Thomas L. Saeli<br>Thomas L. Saeli (Director)  |
| Date: April 26, 2024 | /s/ Robert W. Shaw II Robert W. Shaw II (Director)   |
| Date: April 26, 2024 | /s/ Bradford T. Whitmore Bradford T. Whitmore (Director)   |

## I, Michael E. Manna, certify that:

- 1. I have reviewed this Amendment No. 1 to annual report on Form 10-K of Ultralife Corporation; and
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 26, 2024 /s/ Michael E. Manna

Michael E. Manna

President and Chief Executive Officer

## I, Philip A. Fain, certify that:

- 1. I have reviewed this Amendment No. 1 to annual report on Form 10-K of Ultralife Corporation; and
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 26, 2024 /s/ Philip A. Fain

Philip A. Fain

Chief Financial Officer and Treasurer

## **CORPORATE & SHAREHOLDER INFORMATION**

#### **Board of Directors**

Bradford T. Whitmore Board Chair; Managing Partner, Grace Brothers LP

Michael E. Manna President and Chief Executive Officer, Ultralife Corporation

Janie Goddard Chief Executive Officer, ICM Controls Corporation

Thomas L. Saeli Retired Chief Executive Officer, Duro-Last

Robert W. Shaw II Consultant for Domestic Defense Vehicle Companies

## **Corporate Officers**

Michael E. Manna President and Chief Executive Officer

Philip A. Fain Chief Financial Officer, Treasurer and Secretary

## **Stock Exchange Listing**

**NASDAQ** 

#### Stock Symbol

ULBI

#### Stock Transfer Agent

Equiniti 6201 15<sup>th</sup> Avenue Brooklyn, NY 11219

#### **Annual Meeting**

July 16, 2024 9:00 AM Eastern Time Sheraton Charlotte Airport Hotel 3315 Scott Futrell Drive Charlotte, NC 28202

#### Form 10-K

Shareholders may obtain a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 by going to the Investor Info page at <a href="https://www.ultralifecorporation.com">www.ultralifecorporation.com</a> or by calling us at 1-315-210-6110. This information is also available at no charge by sending a request to Shareholder Services at the following address:

Ultralife Corporation Attn: Philip A. Fain 2000 Technology Parkway Newark, NY 14513



Ultralife Corporation• 2000 Technology Parkway• Newark, NY 14513 • 315-332-7100 www.ultralifecorp.com

©2024 Ultralife Corporation. All rights reserved.